MXPA02007058A - Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation. - Google Patents
Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation.Info
- Publication number
- MXPA02007058A MXPA02007058A MXPA02007058A MXPA02007058A MXPA02007058A MX PA02007058 A MXPA02007058 A MX PA02007058A MX PA02007058 A MXPA02007058 A MX PA02007058A MX PA02007058 A MXPA02007058 A MX PA02007058A MX PA02007058 A MXPA02007058 A MX PA02007058A
- Authority
- MX
- Mexico
- Prior art keywords
- mmol
- compound
- nmr
- pharmaceutically acceptable
- prodrug
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 209
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 24
- 108060006633 protein kinase Proteins 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 167
- -1 carbocycle Chemical group 0.000 claims description 91
- 150000003839 salts Chemical class 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 239000000651 prodrug Substances 0.000 claims description 43
- 229940002612 prodrug Drugs 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 239000002207 metabolite Substances 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 230000022983 regulation of cell cycle Effects 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 52
- 201000011510 cancer Diseases 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 22
- 230000033115 angiogenesis Effects 0.000 abstract description 16
- 201000004681 Psoriasis Diseases 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract description 2
- 208000010412 Glaucoma Diseases 0.000 abstract description 2
- 201000003142 neovascular glaucoma Diseases 0.000 abstract description 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 531
- 239000000543 intermediate Substances 0.000 description 398
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 218
- 238000005481 NMR spectroscopy Methods 0.000 description 198
- 239000000126 substance Substances 0.000 description 178
- 229940093499 ethyl acetate Drugs 0.000 description 177
- 235000019439 ethyl acetate Nutrition 0.000 description 176
- 229910052799 carbon Inorganic materials 0.000 description 160
- 238000004458 analytical method Methods 0.000 description 156
- 229910052757 nitrogen Inorganic materials 0.000 description 156
- 239000000243 solution Substances 0.000 description 130
- 229910001868 water Inorganic materials 0.000 description 108
- 239000000203 mixture Substances 0.000 description 104
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 103
- 239000007787 solid Substances 0.000 description 95
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 77
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 74
- 101150041968 CDC13 gene Proteins 0.000 description 72
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 72
- 238000004587 chromatography analysis Methods 0.000 description 70
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 68
- 238000006243 chemical reaction Methods 0.000 description 68
- 239000000741 silica gel Substances 0.000 description 68
- 229910002027 silica gel Inorganic materials 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- 235000002639 sodium chloride Nutrition 0.000 description 55
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 52
- 239000003921 oil Substances 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 238000010511 deprotection reaction Methods 0.000 description 39
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 37
- 235000019341 magnesium sulphate Nutrition 0.000 description 37
- 229920006395 saturated elastomer Polymers 0.000 description 36
- 238000000746 purification Methods 0.000 description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 34
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 32
- 238000010992 reflux Methods 0.000 description 31
- 238000003756 stirring Methods 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 29
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 28
- 239000011734 sodium Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 28
- 239000000843 powder Substances 0.000 description 26
- 150000002148 esters Chemical class 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 230000022131 cell cycle Effects 0.000 description 22
- 239000000284 extract Substances 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- 108091007914 CDKs Proteins 0.000 description 21
- 239000003054 catalyst Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 239000006260 foam Substances 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 238000001816 cooling Methods 0.000 description 20
- 229910052717 sulfur Chemical group 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 18
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- 108091000080 Phosphotransferase Proteins 0.000 description 18
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 18
- 102000020233 phosphotransferase Human genes 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- 238000006317 isomerization reaction Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 15
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 15
- 235000017557 sodium bicarbonate Nutrition 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 14
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 14
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 13
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 13
- 230000001575 pathological effect Effects 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 239000011593 sulfur Chemical group 0.000 description 13
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 12
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 12
- 150000002894 organic compounds Chemical class 0.000 description 12
- 229910052763 palladium Inorganic materials 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 102000016736 Cyclin Human genes 0.000 description 11
- 108050006400 Cyclin Proteins 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 125000000532 dioxanyl group Chemical group 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- 238000010189 synthetic method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108090000257 Cyclin E Proteins 0.000 description 9
- 102000003909 Cyclin E Human genes 0.000 description 9
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 230000005778 DNA damage Effects 0.000 description 8
- 231100000277 DNA damage Toxicity 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 229910052796 boron Inorganic materials 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 102000003910 Cyclin D Human genes 0.000 description 6
- 108090000259 Cyclin D Proteins 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 108091008794 FGF receptors Proteins 0.000 description 6
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000012954 diazonium Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229910017974 NH40H Inorganic materials 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- 101150050673 CHK1 gene Proteins 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical group NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 150000001543 aryl boronic acids Chemical class 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000003944 tolyl group Chemical group 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 3
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 3
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 238000005361 D2 NMR spectroscopy Methods 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102400001093 PAK-2p27 Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229950010817 alvocidib Drugs 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 150000001503 aryl iodides Chemical class 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004127 vitreous body Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- BIKQXDIDVOSHHU-UHFFFAOYSA-N 4-bromo-5-fluoroisoquinoline Chemical compound N1=CC(Br)=C2C(F)=CC=CC2=C1 BIKQXDIDVOSHHU-UHFFFAOYSA-N 0.000 description 2
- SCRBSGZBTHKAHU-UHFFFAOYSA-N 4-bromoisoquinoline Chemical compound C1=CC=C2C(Br)=CN=CC2=C1 SCRBSGZBTHKAHU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150012716 CDK1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 241000405886 Diamma Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000417893 Kania Species 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 201000000497 familial melanoma Diseases 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- NDUWNWVXAYLZSO-UHFFFAOYSA-N pyrrolidin-2-ol Chemical compound OC1CCCN1 NDUWNWVXAYLZSO-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000005504 styryl group Chemical group 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- AIGICAJERYBZNA-UHFFFAOYSA-N (2-acetyloxy-3-iodosylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC(I=O)=C1OC(C)=O AIGICAJERYBZNA-UHFFFAOYSA-N 0.000 description 1
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- MQDTXDVZHGTKQS-UUBZBTQISA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxy-1-morpholin-4-ylhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)N1CCOCC1 MQDTXDVZHGTKQS-UUBZBTQISA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- PTMRDOLOEDPHLB-UHFFFAOYSA-N 2,3-dipentylphenol Chemical compound CCCCCC1=CC=CC(O)=C1CCCCC PTMRDOLOEDPHLB-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- PCZVZFBNBDNNBN-UHFFFAOYSA-N 2,5,7-triphenylpyrazolo[1,5-a]pyrimidine Chemical compound N=1C2=CC(C=3C=CC=CC=3)=NN2C(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 PCZVZFBNBDNNBN-UHFFFAOYSA-N 0.000 description 1
- MDKWXZDIFPHNPS-UHFFFAOYSA-N 2-(2,3-diaminophenyl)ethanol Chemical compound NC1=CC=CC(CCO)=C1N MDKWXZDIFPHNPS-UHFFFAOYSA-N 0.000 description 1
- OENQGPIPDICILU-UHFFFAOYSA-N 2-(2-amino-3-nitrophenyl)ethanol Chemical compound NC1=C(CCO)C=CC=C1[N+]([O-])=O OENQGPIPDICILU-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- YNTJKQDWYXUTLZ-UHFFFAOYSA-N 2-(3-chlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(Cl)=C1 YNTJKQDWYXUTLZ-UHFFFAOYSA-N 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RILZRCJGXSFXNE-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]ethanol Chemical compound OCCC1=CC=C(OC(F)(F)F)C=C1 RILZRCJGXSFXNE-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical class CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- SXJNRYPVXFTJOU-UHFFFAOYSA-N 2-fluoro-5-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(F)C(C(Cl)=O)=C1 SXJNRYPVXFTJOU-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical class CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- YAWVPJHNPTVUBN-UHFFFAOYSA-N 3,5-diiodo-2h-indazole Chemical compound C1=C(I)C=C2C(I)=NNC2=C1 YAWVPJHNPTVUBN-UHFFFAOYSA-N 0.000 description 1
- OFMXMHIJYYVGBD-UHFFFAOYSA-N 3-(1H-benzimidazol-2-yl)-5-(2-fluorophenyl)-1H-indazole Chemical compound FC1=CC=CC=C1C1=CC=C(NN=C2C=3NC4=CC=CC=C4N=3)C2=C1 OFMXMHIJYYVGBD-UHFFFAOYSA-N 0.000 description 1
- FLROJJGKUKLCAE-UHFFFAOYSA-N 3-amino-2-methylphenol Chemical compound CC1=C(N)C=CC=C1O FLROJJGKUKLCAE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- PLLSYRBSJINNID-UHFFFAOYSA-N 4-chloro-3-iodo-1h-pyridin-2-one Chemical compound OC1=NC=CC(Cl)=C1I PLLSYRBSJINNID-UHFFFAOYSA-N 0.000 description 1
- GPFGRYFMMHDHGA-UHFFFAOYSA-N 4-chloro-3-iodopyridine Chemical compound ClC1=CC=NC=C1I GPFGRYFMMHDHGA-UHFFFAOYSA-N 0.000 description 1
- RYIHZFZTDJNDGM-UHFFFAOYSA-N 4-ethenyl-3,5-dimethyl-1,2-oxazole Chemical compound CC1=NOC(C)=C1C=C RYIHZFZTDJNDGM-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- DZEPQPIZSRYBPQ-UHFFFAOYSA-N 5-(2-methylphenyl)-3-phenyl-1h-indazole Chemical compound CC1=CC=CC=C1C1=CC=C(NN=C2C=3C=CC=CC=3)C2=C1 DZEPQPIZSRYBPQ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- CGCHCLICSHIAAM-UHFFFAOYSA-N 5-iodo-1h-indazole Chemical compound IC1=CC=C2NN=CC2=C1 CGCHCLICSHIAAM-UHFFFAOYSA-N 0.000 description 1
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000012746 DNA damage checkpoint Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- 101710178747 Phosphatidate cytidylyltransferase 1 Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091006627 SLC12A9 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 1
- YYYVIMJBNDEUCB-UHFFFAOYSA-N [S].C1COCCO1 Chemical group [S].C1COCCO1 YYYVIMJBNDEUCB-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LGMSNQNWOCSPIK-LWHGMNCYSA-N alvocidib hydrochloride Chemical compound Cl.O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O LGMSNQNWOCSPIK-LWHGMNCYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GRSTVVGJSKHCCS-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanone Chemical compound N=1C=CNC=1C(=O)C1=NC=CN1 GRSTVVGJSKHCCS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- VXOSGHMXAYBBBB-UHFFFAOYSA-N indazole-3-carbaldehyde Natural products C1=CC=C2C(C=O)=NNC2=C1 VXOSGHMXAYBBBB-UHFFFAOYSA-N 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-BJUDXGSMSA-N iodoethane Chemical class [11CH3]CI HVTICUPFWKNHNG-BJUDXGSMSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- FXBYOMANNHFNQV-UHFFFAOYSA-L magnesium;hydrogen sulfate Chemical compound [Mg+2].OS([O-])(=O)=O.OS([O-])(=O)=O FXBYOMANNHFNQV-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- YNLFEVAOQLXINF-UHFFFAOYSA-N methylsulfanylmethane;tribromoborane Chemical compound CSC.BrB(Br)Br YNLFEVAOQLXINF-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical class CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- YNZAFFFENDLJQG-UHFFFAOYSA-N pyrrol-1-amine Chemical compound NN1C=CC=C1 YNZAFFFENDLJQG-UHFFFAOYSA-N 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000022161 regulation of S phase Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- QJEXFQIDEHSWNM-UHFFFAOYSA-N sulfonylmethane hydrochloride Chemical compound Cl.C=S(=O)=O QJEXFQIDEHSWNM-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- RXMRGBVLCSYIBO-UHFFFAOYSA-M tetramethylazanium;iodide Chemical compound [I-].C[N+](C)(C)C RXMRGBVLCSYIBO-UHFFFAOYSA-M 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000005000 thioaryl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
- B22D41/00—Casting melt-holding vessels, e.g. ladles, tundishes, cups or the like
- B22D41/50—Pouring-nozzles
- B22D41/56—Means for supporting, manipulating or changing a pouring-nozzle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Indazole compounds that modulate andor inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating , e.g., kinasesdependent diseases to modulate andor inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis andor cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Description
INDA ^ OL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE MEDIATION OR INHIBITION OF CELL PROLIFERATION
Field of the invention
This invention is directed to indazole compounds that mediate or inhibit cell proliferation, for example, through the inhibition of the activity of protein kinases, such as VEGF, CHK-1, and cyclin-dependent kinases (CDK). , such as CDK1, CDK2, CDK4, and CDKß. The invention extends to pharmaceutical compounds containing such compounds and compositions, and to cancer treatment methods as well as other pathological conditions associated with undesired angiogenesis and / or cell proliferation, by administration of sufficient amounts of such compounds.
BACKGROUND OF THE INVENTION
Uncontrolled cell proliferation is the hallmark of cancer. Cell proliferation in response to various stimuli is manifested by the deregulation of the cell division cycle, the process
Ref: 138171
by which the cells multiply and divide. Tumor cells typically have a lesion of genes that directly or indirectly regulate progression throughout the cell division cycle.
Hyperproliferative disease states, including cancer, are characterized by unbridled circulation through the cell cycle with uncontrolled vigor due to, for example, injury to genes that directly or indirectly regulate progression through the cycle. Therefore, agents that modulate the cell cycle, and therefore hyperproliferation, could be used to treat various pathological conditions associated with uncontrolled or unwanted cell proliferation. In addition to cancer chemotherapeutic agents, cell cycle inhibitors are postulated as antiparasitic (See, Gray et al., Curr. Med. Chem. 6, 859-875 (1999)) and have recently been demonstrated as antiviral potentials (See , Schang et al., J. Virol. 74, 2107-2120 (2000)). Moreover, the utility of antiproliferative agents can be extended to the treatment of cardiovascular disorders such as atherosclerosis or restenosis (See Braun-Dullaeus et al., Circul a ti on, 98, 82-89 (1998)), and
inflammatories such as arthritis (See, Taniguchi et al., Na ture Med., 5, 760-767 (1999)) or psoriasis.
The mechanisms of cell proliferation are being actively investigated at the cellular and molecular level. At the cellular level, deregulation of the pathways, loss of control of the cell cycle, unrestrained angiogenesis or stimulation of inflammatory pathways are under scrutiny, while at the molecular level, these processes are modulated by various proteins, among which the Protein kinases are prominently suspected. The overall decrease in proliferation can also be a consequence of programmed cell death, or apoptosis, which is also regulated by multiple pathways, some of which involve proteolytic enzyme proteins.
Among the regulatory proteins postulated, protein kinases are a family of enzymes that catalyze the phosphorylation of the hydroxyl group of specific tyrosine, serine or threonine residues in proteins. Typically, said phosphorylation drastically disrupts protein function, and therefore protein kinases are the main axis of regulation of a wide variety of cellular processes, including metabolism, cell proliferation, differentiation
cellular, and cell survival. Of the numerous different cellular functions in which it is known that the activity of protein-qumasa is necessary, some processes represent attractive targets for therapeutic intervention for certain pathological states. Two examples are cell cycle control and angiogenesis, in which protein kinases play a central role; Both processes are essential for the growth of solid tumors and also in other diseases.
CDKs constitute a class of enzymes with a critical role in regulating the transition between different phases of the cell cycle, such as the progression of a quiescent Gi state (the lapse between mitosis and the start of DNA replication for a new beginning of cell division) to the S state (the period of active synthesis of DNA), or the progression of the G2 phase to the M phase, in which active mitosis and cell division occur. See, for example, the articles compiled in Sci ence, vol. 274 (1996), pp. 1643-1677; and Ann. Rev. Cel l Dev. Bi ol. , vol. 13 (1997), pp. 261-291. CDK complexes are formed by the association of a regulatory cyclin subunit (eg, cichna A, Bl, B2, DI, D2, D3, and E) and a catalytic qumase subunit (eg, cdc2
(CDK1), CDK2, CDK4, CDK5 and CDK6). As the name implies, CDKs have a total dependence on the cyclin subunit to phosphorylate their specific substrates, and different pairs of kinases and cyclins function in the regulation of progression through the different phases of the cell cycle.
Cyclins D are sensitive to extracellular growth signals and become activated in response to mitogens during the Gi phase of the cell cycle. CDK4 / cyclin D plays an important role in the progression of the cell cycle by phosphorylating, and therefore inactivating, the retinoblastoma (Rb) protein. The hypophosphorylated Rb binds to a family of transcriptional regulators, but as Rb is hyperphosphorylated by CDK4 / cyclin D, these transcription factors are released and activate genes whose products are responsible for the progression of the S phase. Phosphorylation of the Rb and the inactivation by CDK4 / cyclin D allows the passage of the cell beyond the restriction point of the Gi phase, after which the sensitivity to extracellular growth or inhibitory signals is lost, and the cell is dedicated only to the division. During the late Gi phase, Rb is also phosphorylated and inactivated by CDK2 / cyclin E, and recent evidence indicates that CDK2 / cyclin E can
also regulate the progression towards the S phase through a parallel pathway that is independent of the phosphorylation of Rb (see Lukas et al., "Cyclin E-induced S Phase Without Activation of the pRb / E2F Pathway", Genes and Dev. , Vol 11 (1997), pp. 1479-1492).
The progression of the Gi phase to the S phase, achieved by the action of CDK4 / cyclin D and CDK2 / cyclin E, is subject to a variety of growth regulating mechanisms, both negative and
10 positives Stimuli for growth, such as mitogens, cause an increase in cyclin DI synthesis and thus an increase in functioning CDK4. In contrast, cell growth can be "restrained" in response to DNA damage or negative stimuli
15 for growth, by induction of endogenous inhibitory proteins. These natural inhibitory proteins include the families p21WAF 1 / CIP1, P27KIP and pl6INK4, the latter of which exclusively inhibits CDK4 (see Harper, "Cyclin Dependent Kinase Inhibitors",
20 Cancer Surv. , vol. 29 (1997), pp.91-107). The aberrations in this control system, particularly those that affect the function of CDK4 and CDK2, are involved in the advance of the cells towards the highly proliferative state characteristic of the cells.
25 neoplasms, such as familial melanomas, carcinomas
"SBÉSSEBS: X.
of esophagus, and pancreatic cancer (see, for example, Hall and Peters, "Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and CDK Inhibitors in Human Cancer," Adv. Cancer Res., vol 68 (1996), pp.67-108; and Ka by col., "A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types," Sci ence, vol 264 (1994), pp. 436-440). Overexpression of cyclin DI is linked to esophageal, breast and epidermoid carcinomas (see, for example, DelSal et al., "Cell Cycle and Cancer: Critical Events at the Gi Restriction Point", Cri ti cal Rev. Oncogenesi s, vol. 71 (1996), pp. 127-142). The genes encoding the specific inhibitors of CDK4 of the plß family frequently have deletions and mutations in familial melanoma, gliomas, leukemias, sarcomas, pancreatic carcinoma, non-small cell lung carcinoma, and carcinomas of the head and neck (see Nobori et al., "Deletions of the Cyclin-Dependent Kinase-4 Inhibitor Gene in Multiple Human Cancers," Na ture, vol 368 (1994), pp. 753-756). The amplification and / or overexpression of cyclin E has also been observed in a wide variety of solid tumors, and high levels of cyclin E have been correlated with unfavorable prognoses. In addition, cellular levels of the p27 inhibitor of CDK, which acts as a substrate and inhibitor of CDK2 / cyclin E, are
abnormally low in breast, colon and prostate carcinomas, and the expression levels of p27 correlate inversely with the stage of the disease (see Loda et al., "Increased Protease Dependent Degradation of the Cyclin-Dependent Kinase Inhibitor p27 in Aggressive Colorectal Carcinomas, "Na t ure Medi cine, vol 3 (1997), pp. 231-234). There is recent evidence that CDK4 / cyclin D could abduct p27, as reviewed by Sherr, et al., Genes Dev., Vol. 13 (1999), p. 1501-1512. The p21 proteins also appear to transmit the tumor suppression signal p53 to the CDK; thus, mutations in p53 in approximately 50% of all human cancers can indirectly result in deregulation of CDK activity.
Emerging reports provide strong validation for the use of compounds that inhibit CDK, and CDK4 and CDK2 in particular, as anti-proliferative therapeutics. Certain biomolecules have been proposed for this purpose. For example, U.S. Pat. No. 5,621,082 to Xiong et al. discloses the nucleic acid coding of the CDK6 inhibitors, and WO 99/06540 of the CDKs. Peptides and peptidomimetic inhibitors are described in European Patent Publication No. 0 666 270 A2, Bandara, et al., Na t uie
Bi otechnol ogy, Vol. 15 (1997), pp. 896-901 and Chen, et al., Proceedings of the Na tional Academy of Sci ence, USA, Vol. 96 (1999), p. 4325-4329. Peptide aptagen were identified by screening in Cohen et al., Proc. Na ti. Acad. Sci. U. S TO . , Vol. 95 (1998), pp.14272-14277. Several small molecules have been identified as CDK inhibitors (for recent reviews, see Webster, "The Terapeutic Potential of Targeting the Cell Cycle," Exp. Opin., Investigations, Vol. 7 (1998), pp. 865-887 , and Stover, et al., "Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis", Curren t Opinion in Drug Di verse and Devel opmen t, Vol.2 (1999), pp. 274-285 ). The flavopiridol exerts modest selectivity for the inhibition of CDKs and other kinases, but inhibits CDK4, CDK2 and CDK1 equipotentially, with IC5o ranging from 0.1-0.3 μM. Flavopiridol is currently in Phase II clinical trials as a cancer chemotherapeutic (Sedlacek et al., "Flavopiridol (L86-8275; NSC 649890), A New Kinase Inhibitor for Tumor Therapy", Int. J. Oncol., Vol.9 (1996), pp. 1143-1168). Flavopiridol analogs are subject to other publications, for example, U.S. Pat. No. 5,733,920 of Mansuri et al. (International Publication No. WO 97/16447) e
International Publication No. WO 97/42949 and WO 98/17662. The results with purine base derivatives are described in Schow et al., Bioorg. Med. Chem. Lett. , Vol. 7 (1997), pp. 2697-2702; Grant et al., Proc. Amer. Assoc. Cancer. Res., Vol. 39 (1998), Abst. 120 ?; Legravend et al., Bioorg. Med. Chem. Lett., Vol.8 (1998), pp. 793-798; Gray et al., Science, Vol. 281 (1998), pp. 533-538; Chang, et al., Chemistry & Biology, Vol. 6 (1999), pp. 361-375, WO 99/02162, WO 99/43675 and WO 99/43676. Additionally, the following publications disclose certain pyrimidines that inhibit cyclin-dependent kinases and kinases mediated by growth factors: International Publication No. WO 98/33798; Ruetz et al., Proc. Amer. Assoc. Cancer Res., Vol. 39 (1998), Abst. 3796; and Meyer et al., Proc, Amer. Assoc. Cancer. Res., Vol. 39 (1998), Abst. 3794
Benzenesulfonamides which block cells in Gl phase are under development by Eisai, see Owa, et al., J. Med. Chem., Vol. 42 (1999), pp. 3789-3799. An oxindolic inhibitor of CDKs is under development by Glaxo-Wellcome, see Luzzio, et al., Proc. Amer. Assoc. Cancer Res., Vol. (1999), Abst. 4102 and WO99 / 15500. The paullones were found in collaboration with the NCI, Schultz, et al., J. Med. Chem., Vol. (1999), pp. 2909-2919. The indenopyrazones are
described in W099 / 17769 and by Seltz, et al, 218. tLha ACS Na ti. Mtg. (August 22-26, 1999, New Orleans), Abst MEDI 316. Aminothiazoles are used in W099 / 24416 and W099 / 21845.
CHK1 is another protein kinase. CHK1 plays an important role as a checkpoint in the progression of the cell cycle. These control points coordinate the progression of the cell cycle by influencing the formation, activation and subsequent inactivation of the cyclin-dependent kinases. The control points prevent the progression of the cell cycle at inappropriate times, maintain the metabolic balance of the cells while they are stopped and, in some cases, can induce apoptosis (programmed cell death) when the requirements of the control point are not met. See, for example, O'Connor, Cancer Surveys, 29, 151-182 (1997); Nurse, Cell, 91, 865-867 (1997); Hartwell et al., Sci ence, 266, 1821-1828 (1994); Hartwell et al., Sci ence, 246, 629-634 (1989).
A series of control points monitor the integrity of the genome and, by sensing DNA damage, these "DNA damage control points" block the progression of the cell cycle in the Gi and G2 phases, and slow down the progression through the phase S.
O'Connor, Cancer Surveys, 29, 151-182 (1997); Hartwell et al., Sci ence, 266, 1821-1828 (1994). This action allows DNA repair processes to complete their tasks before genome replication occurs and the subsequent separation of their genetic material into new daughter cells. Importantly, the gene most commonly mutated in human cancer, the p53 tumor suppressor gene, produces a DNA damage control protein that blocks the progression of the cell cycle in the Gi phase and / or induces apoptosis (programmed cell death) after DNA damage. Hartwell et al., Sci ence, 266, 1821-1828 (1994). It has also been shown that the p53 tumor suppressor strengthens the action of a DNA damage checkpoint in the G2 phase of the cell cycle. See, for example, Bunz et al., Sci ence, 28, 1497-1501 (1998); Wmters et al., Oncogene, 17, 673-684 (1998); Thompson, Oncogene, 15, 3025-3035 (1997).
Given the importance of p53 as the natural axis of the tumor suppression pathway in human cancer, therapeutic interventions that exploit vulnerabilities in cancer with defective p53 have been intensively sought. An emerging vulnerability lies in the operation of the G2 control point in neoplastic cells with defective p53. The cancer cells,
»4? F *
lacking control point Gi, they are particularly vulnerable to the lack of the last remaining barrier of protection against the effects of DNA damage caused by cancer: the G2 checkpoint. The control point G2 is regulated by a control system that has been preserved from yeasts to humans. In this conserved system, a chemase, CHK1, is important, which transduces signals from the DNA damage sensor complex to inhibit the activation of cyclin B / Cdc2 kinase, which promotes entry into the mitosis phase. See, for example, Peng et al., Sci ence, 277, 1501-1505 (1997); Sánchez et al., Sci ence, 277, 1497-1501 (1997). Inactivation of CHK1 has been shown to abrogate G2 arrest induced by DNA damage both endogenous and caused by both anticancer agents, as well as result in preferential death of the resulting defective cells at the control point. See, for example., Nurse, Cell, 91, 865-867 (1997); Welnert, Sci ence, 277, 1450-1451 (1997); Walworth et al., Na t ure, 363, 368-371 (1993); and Al-Khodairy et al., Mol eq. Bi ol. . Cell, 5, 147-160 (1994).
Selective manipulation of the checkpoint in cancer cells could provide extensive use of chemotherapeutic and antieoplastic radiotherapeutic regimens and could, in addition, provide
a common hallmark of the "genomic instability" of human cancer to be exploited as a selective basis for the destruction of cancer cells. A number of factors place CHKl as the central target at the point of control of DNA damage. Elucidation of inhibitors of this and other functionally related kinases such as CDS1 / CHK2, a kinase that was recently discovered to be a cooperator with CHK1 in the regulation of S-phase progression (see Zeng et al., Na t ure, 395, 507-510 (1998); Matsuoka, Sci ence, 282, 1893-1897 (1998)), could lead to new therapeutic modalities in the treatment of cancer.
Another group of chemists are tyrosine kinases. The tyrosmo-kinases can be of the receptor type (having extracellular, transmembrane and intracellular domains) or of the non-receptor type (being totally intracellular). At least one of the non-receptor protein tyrosmaqumases, LCK, is supposed to mediate the transduction in T cells of a cross-interaction signal between a cell surface protein (Cd4) and an anti-Cd4 antibody. A more detailed discussion of non-receptor tyrosine kinases is provided by Bolen, Oncogene,
8, 2025-2031 (1993), which is incorporated herein by reference.
In addition to their role in controlling the cell cycle, protein kinases play a crucial role in angiogenesis, which is the mechanism by which new capillaries are formed from pre-existing vessels. When required, the vascular system has the potential to generate new capillary networks to maintain the proper functioning of tissues and organs. In the adult, however, angiogenesis is quite limited, occurring only in the process of wound repair and neovascularization of the endometrium during menstruation. See Merenmies, J., Parada, L.F., Henkemeyer, M., CeJJ Growth & Differenti a ti on, 8, 3-10 (1997). On the other hand, unwanted angiogenesis is the pathognomonic sign of several diseases, such as retinopathies, psoriasis, rheumatoid arthritis, macular degeneration related to age and cancer (solid tumors). Folkman, Na t ure Med., 1, 27-31 (1995). Protein kinases that are proven to be involved in the angiogenic process include three members of the tyrosine kinase growth factor receptor family: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR (receptor)
• li1 'of the kinase insertion domain) and as FLK-1); FGF-R (fibroblast growth factor receptor); and TEK (also known as Tie-2).
VEGF-R2, which is expressed only in endothelial cells, binds to the potent angiogenic growth factor VEGF and mediates the subsequent transduction of the signal through the activation of its action as an intracellular kinase. Therefore, it is expected that direct inhibition of VEGF-R2 kinase activity will result in the reduction of angiogenesis even in the presence of exogenous VEGF (see Strawn et al., Cancer Research, 56, 3540-3545 (1996 )), as has been observed with VEGF-R2 mutants that fail to mediate signal transduction. Millauer et al., Cancer Research, 56, 1615-1620 (1996). Moreover, VEGF-R2 seems to have no other function in the adult beyond that of mediating the angiogenic activity of VEGF. Therefore, it would be expected that a selective inhibition of the kinase activity of VEGF-R2 would cause little toxicity.
Similarly, FGF-R binds to the angiogenic growth factors aFGF and bFGF and mediates the subsequent intracellular signal transduction. Recently, it has been suggested that factors of
Growth such as bFGF can play a critical role in the induction of angiogenesis in solid tumors that have reached a certain size. Yoshiji et al., Cancer Research, 57, 3924-3928 (1997). Unlike VEGF-R2, however, FGF-R is expressed in a number of different cell types throughout the body and may or may not play important roles in other normal physiological processes in the adult. However, it has been reported that systemic administration of a small molecule inhibiting the kinase activity of FGF-R blocks angiogenesis induced by bFGF in mice without apparent toxicity. Mohammad et al., EMBO Journal, 17, 5996-5904 (1998).
The TEK (also known as Tie-2) is another receptor tyrosine kinase expressed only in endothelial cells that have been shown to play a role in angiogenesis. The ligation of the angiopoietin-1 factor results in the autophosphorylation of the kinase domain of the TEK and results in a signal transduction process that seems to mediate the interaction of the endothelial cells with the supporting peri-endothelial cells, facilitating the maturation of the blood vessels recently formed. The angiopoietin-2 factor, on the other hand, seems to antagonize the action of ang? Opoyetma-1 on the TEK and interrupts the
angiogenesis Maisonpierre et al., Sci ence, 277, 55-60 (1997).
As a result of the aforementioned advances, it has been proposed to treat angiogenesis by the use of compounds that inhibit the kinase activity of VEGF-R2, FGF-R and / or TEK. For example, in WIPO International Publication No. WO 97/34876 it is disclosed that certain cinnoline derivatives which are inhibitors of VEGF-R2, can be used for the treatment of pathological conditions associated with abnormal angiogenesis and / or increased vascular permeability such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheromas, arterial restenosis, autoimmune diseases, acute inflammation and eye diseases with proliferation of retinal vessels.
In addition to the above identified protein kinases, many other protein kinases have been considered as therapeutic targets, and numerous publications disclose inhibitors of kinase activity, such as the following reviews: McMahon et al., Current Opinion in Drug Di scovery and Development,
1, 131-146 (1998); Strawn et al., Exp. Opi n. Inves t. Drugs, 7, 553-573 (1998).
There is still a need, however, for other small molecule compounds that can be synthesized and are potent inhibitors of cell proliferation, for example, inhibitors of one or more protein kinases, such as CHK1, VEGF, CDK or CDK / cyclin complexes. Since CD4 can serve as a general activator of cell division in most cells, and since the complexes of CDK4 / cyclin D and CDK2 / cyclin E dominate the early phase of the Gi stage of the cell cycle, effective inhibitors are necessary and specific for CDK4 and / or CDK2 for the treatment of one or more types of tumors.
BRIEF DESCRIPTION OF THE INVENTION
An object of the invention is to provide potent anti-proliferative agents.
Accordingly, an object of the invention is to achieve compounds and drug compounds that inhibit the activity of one or more kinases, such as CDK, VEGF, and CHK-1, or cyclin complexes thereof. A further objective is to provide a method
effective treatment of cancer in indicated cases, through the inhibition of kinases, such as VEGF, CHK-1, CDK4 or CDK4 / cyclin complexes type D and / or CDK2 or CDK2 / Cyclin E type complexes. Another objective is to achieve pharmaceutical compositions containing compounds effective to block the transition of cancer cells towards their proliferative phase. These and other objects and benefits of the invention, which will become apparent below in the light of the detailed description, are achieved through the use of agents that control the cell cycle of the invention which will be described below.
In accordance with these objectives, Formula I represents a compound provided in accordance with the present invention.
I)
where
R1 is a substituted or unsubstituted alkyl, aryl, heteroaryl, carbocycle or heterocycle, or
where R 4 is H or a lower alkyl, and X is an alkyl, aryl, heteroaryl, carbocycle, a substituted or unsubstituted heterocycle; and R2 is an unsubstituted or substituted alkyl, aryl, heteroapl, carbocycle, or heterocycle group, or
where R 4 is H or a lower alkyl, and X is an aryl, heteroaryl, carbocycle, or substituted or unsubstituted heterocycle; or a pharmaceutically acceptable salt of a compound of Formula I; or a pharmaceutically active prodrug or metabolite of a compound of Formula I, or a pharmaceutically acceptable salt of the prodrug or metabolite.
In accordance with these objects, a compound represented in Formula II is also provided:
where R '^ is an alkyl, apl, heteroa il, carbocycle, or substituted or unsubstituted heterocycle group,
wherein each R4 is individually H or a lower alkyl, and X is a substituted or unsubstituted alkyl, apl, heteroapl, carbocycle, or heterocycle group; and R 'is an amino, nitro, alkenyl, alkyl, aryl, heteroaryl, carbocycle, or substituted or unsubstituted heterocycle group,
where R 4 is independently H or a lower alkyl, and X is a substituted or unsubstituted apl, heteroapl, carbocycle or heterocycle group; or a pharmaceutically acceptable salt of a compound of Formula II; or a pharmaceutically active prodrug or metabolite of
a compound of Formula II, or a pharmaceutically acceptable salt of the prodrug or metabolite.
Also provided in accordance with the invention is a pharmaceutical composition which includes:
(a) a cell cycle control agent selected from:
(i) a compound of Formula I or II,
(11) a pharmaceutically acceptable salt of a compound of Formula I or II; or
(m) a pharmaceutically active prodrug or metabolite of a compound of Formula I or II, or a pharmaceutically acceptable salt of the prodrug or metabolite; Y
(b) a pharmaceutically acceptable carrier.
The invention also provides methods for obtaining the compounds of Formula I and II.
In addition, according to the invention, the method of using a compound as a cell cycle control agent for the treatment of diseases or disorders mediated by the inhibition of quasis, by administration to the patient who requires it, is provided composed of Formula I or II, or a
salt of a pharmaceutically acceptable compound of Formula I or II; or a pharmaceutically active prodrug or metabolite of a compound of Formula I t or II, or a pharmaceutically acceptable salt of the prodrug or metabolite.
Additionally, the invention provides a method for treating fungal infections, neoplasia, or cancer, as well as other pathological conditions associated with unwanted angiogenesis and / or cell proliferation, including the administration, to a patient in need of such treatment, of effective amounts of a compound of Formula I or II or a pharmaceutically acceptable salt of a compound of Formula I or II; or a pharmaceutically active prodrug or metabolite of a compound of Formula I or II, or a pharmaceutically acceptable salt of the prodrug or metabolite.
The invention also provides a method for modulating and / or inhibiting the activity of kinases by means of administration to the patient that requires it, of a compound of Formula I or II or a salt of a compound of Formula I or II pharmaceutically acceptable; or a pharmaceutically active prodrug or metabolite of a compound of Formula I or II, or a pharmaceutically acceptable salt of the prodrug or metabolite.
25
Also provided according to the invention is a pharmaceutical composition containing a compound of Formula I or II or a pharmaceutically acceptable salt of a compound of Formula I or II; or a pharmaceutically active prodrug or metabolite of a compound of Formula I or II, or a pharmaceutically acceptable salt of the prodrug or metabolite, and the therapeutic use of the composition in the treatment of diseases mediated by the activity of kinases, such as cancer , as well as other pathological conditions associated with undesired angiogenesis and / or cell proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis and psoriasis.
For the pharmaceutical composition and methodological aspects of the invention, Ri may also be, hydrogen, in Formula I and II.
The agents of the invention and the compositions containing said agents may be useful in the treatment of various disorders or pathological conditions associated with uncontrolled or undesired cell proliferation, such as cancer, autoimmune disorders, viral diseases, fungal diseases, neurodegenerative disorders, and diseases. cardiovascular Therefore, the invention is also oriented to methods for
the treatment of such diseases by administration of an effective amount of the agent of the invention.
Other aspects, benefits, and characteristics of the invention will become apparent from the detailed description presented below.
DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS OF THE INVENTION
The compounds and compositions of the present invention are useful as antiproliferative agents and as inhibitors of kinase complexes of mammals, insects and fungi. For example, the VEGF, CHK-1 and / or CDK complexes can be inhibited. Such compounds and compositions are also useful for controlling proliferation, differentiation and / or apoptosis.
Preferred Ri, R2, R'i and R'2 are exemplified below in the compounds of the groups of Formula I or 11:
Preferably, Ri and R'i are
Li ?? ¿IÉ¿ ^
where Y is CH or N or CR3, X is as defined above and R3 is H, or one or more substitutes located on the ring, such as an alkyl, alkenyl, aryl, heteroaryl, carbocycle, heterocycle, hydroxy, halogen, alkoxy group , aryloxy, heteroaryloxy, thioalkyl, thioaryl, thioacyl, thioheteroap or substituted or unsubstituted amino; or
where the two Y can be the same or different. In these implementations, in which Ri or R 'i is
there are one or more substitutes of R3 in the phenyl ring
Preferably, Ri and R'i are substituted or unsubstituted
where the R3 groups are as described above. In addition, two R3 together with an adjacent nitrogen can form a heteroaryl ring or heterocycle.
Preferably, R2 are substituted or unsubstituted phenyls or
where R is H or a lower alkyl, and X is a substituted or unsubstituted alkyl, aryl, heteroaryl, carbocycle or heterocycle selected group.
Other preferred R2 and R 'groups are substituted or unsubstituted heteroaryls such as
Other preferred groups R2 and R'2 are
where R3 is as defined above
Preferred substituent groups for the phenyl of R 2 include fluorine, chlorine, hydroxyl, or an alkoxy group, such as methoxy. Examples of the preferred R, X, and Y groups are found in the following exemplified compounds.
And it is preferably nitrogen.
X is preferably aryl, heteroaryl * carbocycle, or heterocycle, more preferably phenyl.
R2 and R'2 can also be an amino (-NR'R ") wherein R 'and R" are independently defined as R3 above, and together with an adjacent nitrogen can form a ring.
R 4 is preferably a hydrogen, or it may be a lower alkyl containing 1 to 6 carbon atoms, which may be substituted or unsubstituted. The two R4 can be the same or different.
Other preferred Ri, R2, R'i and R'2 groups are found in the following exemplified compounds.
Any desired alkyl group can be used, for example, as Rx or R2 or R 'i or R' 2 or R3 or X. The alkyl group can be a straight or branched chain alkyl group having one to twelve carbon atoms. Exemplified alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like. The alkyl can be substituted or unsubstituted. Preferred substituted alkyls include fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-h? droxipropil, and the like.
Any desired aryl, heteroaryl, carbocycle, or heterocycle group can be used as, for example, R%
R; or R 'R-. X, Groups can be fused or non-fused, monocyclic or polycyclic.
Preferred aryl and heteroaryl groups include unsaturated or aromatic ring structures,
* «*" 32
monocyclic and polycyclic, referring as "aril" to those who are carbocycles and as "heteroaryl" to those who are heterocycles. Examples of ring structures include phenyl, naphthyl, 1,2,3-tetrahydronaphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyridinyl, pyrazolyl, imidazolyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1, 2, 4-Oxadiazolyl, 1,3,4-oxadiazolyl, lH-tetrazol-5-yl, indolyl, quinolinyl, benzothiophenyl (tylphthanyl), furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, isoquinolinyl, acridinyl, pyrimidinyl , benzimidazolyl, benzofuranyl, and the like.
Preferred carbocyclic groups include those having from three to twelve carbon atoms, including bicyclic and tricyclic cycloalkyl structures. Preferred carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
Preferred heterocyclic groups include saturated rings containing carbon atoms, for example rings of 4 or 5 carbon atoms and at least one heteroatom selected from nitrogen, oxygen and sulfur, and without unsaturation. Heterocyclic groups include pyrrolidinyl, piperidinyl, thiazinyl, and morpholinyl.
Ri / R2, R3 / X and other R groups can be unsubstituted or substituted with any desired substituents or substituents that do not adversely affect the desired activity of the compound. Examples of preferred substituents are those found in the following exemplified compounds, as well as halogens (chlorine, iodine, bromine, or fluorine); C? -6-alkyl; Ci-e-alkenyl; Ci- '6-alkinil; hydroxyl; C? -6-alkoxyl; Not me; nitro; thiol; thioether; imina; cyano; amido; phosphonate; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen (= 0); haloalkyl (for example trifluoro et al); carbocyclic cycloalkyl, which may be monocyclic or polycyclic non-fused or fused (eg, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (eg, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiaziml); carbocyclic or heterocyclic, monocyclic or polycyclic aryl not fused or fused (for example, phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinil, pyrazinyl, pyridazmyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); ammo (primary, secondary or tertiary); nitro; thiol; thioether; O-lower alkyl, Q-
apl, aril; aryl-lower alkyl; C02CH3, CONH2; OCH2CONH :; NH2; S02NH2; OCHF2; CF3; 0CF3; and similar. Such molecules can also be optimally substituted by a fused or bridged ring structure, for example OCH2-0. These substituents can in turn be optimally substituted with a substituent selected from such groups. Preferred compounds are shown in the following examples, and also:
The present invention also relates to intermediates useful in the preparation of compounds of Formula I or II. A particularly preferred intermediary has the structure
Another preferred intermediary has the structure
Another preferred intermediary has the structure
X = halogen, N02
[X = Halogen, N02J
In place of SEM, in the above-mentioned three intermediates, other known protecting groups can be used, such as benzyloxycarbonyl (CBZ), tertiary-bicarbomethyl (BOC), tetrahydropyranyl (THP), and fluoro-9-methyloxycarbonyl (FMOC) . I b
Other preferred intermediaries include
twenty
5
19C The abbreviations "SEM" and "PMB" refer to (trimethylsilyl) ethoxymethyl and p-methoxybenzyl, respectively. A preferred intermediary has the structure
where PG is a protecting group, T is a reactive group such as boron, halogen, N02, or unsubstituted or substituted NH2, and T 'is a reactive group such as CHO, C02H, CO2R3 * CONR3R3, where the R3 groups are as define above. The pharmaceutical compositions according to the invention can comprise, as an active component, alternatively or additionally to a compound of formula I or II, a pharmaceutically acceptable salt of a compound of formula I or II, or a pharmaceutically active prodrug or metabolite of such compound or salt or a salt of the prodrug or metabolite. Such compounds, salts, prodrugs and metabolites are sometimes referred to herein together as "cell cycle control agents". The term "prodrug" refers to the metabolic precursor of a compound of Formula I or II (or a salt thereof) that is pharmaceutically acceptable. A prodrug can be inactive when it is administered to a subject, but it has not been converted into an active compound of Formula I or II. The term "active metabolite" refers to a metabolic product of a compound of Formula I or II that is pharmaceutically acceptable and effective. The prodrugs and active metabolites of compounds of Formula I and II can be determined using known techniques. The active metabolites and prodrugs of a compound can be identified using routine techniques
known. See, for example, Bertolini et al., J. Med. Chem. , 40, 2011-2016 (1997); Shan, et al., J. Pharm. Sci. , 86 (7), 765-767; Bagshawe, Drug Dev. Res. , 34, 220-230 (1995); Bodor, Advances m Drug Res. , 13, 224-331 (1984); Bundgaard, Design of Prodrugs (Elsevier Press 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Har ood Academic Publishers, 1991). It is understood that within the invention a compound of Formula I or II can exhibit the phenomenon of tautomerism and that the figures of the formula with their corresponding specifications represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form that modulates and / or inhibits the activity of quasars and should not be limited merely to a single tautomeric form used within the figures of the formula. Some of the compounds of the invention may exist as simple stereoisomers (e.g., essentially free of other stereoisomers), racemates, and / or mixtures of enantiomers and / or diastereomers. It is intended that all of these simple stereoisomers, racemates and mixtures thereof be encompassed in the present invention. Preferably, the optically active compounds of the invention are used in an optically pure form.
As generally understood by those skilled in the art, an optically pure compound containing a chiral center (e.g., an asymmetric carbon atom), is one that consists essentially of one of the two possible enantiomers (ie, is enantiomerically pure). ), and an optically pure compound containing more than one chiral center is one that is both enantiomerically and diasterically pure. Preferably, the compounds of the present invention are used in a form that is at least 90% optically pure, ie, a form that contains at least 90% of a simple isomer (80% enantiomeric excess ("ee") or excess diastereomer ("de")), more preferably at least 95% (90% ee or de), better yet at, minus 97.5% (95% ee or de), and most preferred is at least 99% (98% ee or of). Additionally, Formulas I and II are intended to cover both the solvated and unsolvated forms of the identified structures. For example, Formulas I and II include compounds of the structure indicated in both their hydrated and non-hydrated forms. Other examples of solvates include the structures in combination with isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid or ethanolamine. "A pharmaceutically acceptable salt" is intended to mean a salt that retains the biological effectiveness of
'** < ** »*, # *.
the free acids and bases of the specific compound and which is not biologically or in any other undesirable form. A compound of the invention may contain sufficient acidic, basic functional groups, or both, and react with any of a number of organic or inorganic bases, and organic or inorganic acids, to form a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts are those prepared by reacting the compounds of the present invention with a mineral or organic acid or an inorganic base, such as salts including sulfates, pyrosulfates, bisulfates, sulphites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formats, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butin-1,4- dioates, hexin-1, 6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, ethoxybenzoates, phthalates, sulfonates, xylene sulphonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates,? -hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, fift naphthalene-2-sulfonates and mandelates.
If the compound of the invention is a desirable pharmaceutically acceptable salt base, it can be prepared with any suitable method available in the industry, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, acid sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyrovic acid, oxalic acid, glycolic acid, acidole? salicylic acid, a pyranosidic acid, such as glucuronic or galacturonic acid, an alphahydroxide acid, such as citric or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as -toluenesulfonic or
15 ethanesulfonic acid, or the like. If the compound of the invention is an acid, the desirable pharmaceutically acceptable salt can be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, tt, secondary or tertiary), an alkali metal hydroxide or metal hydroxide of alkali earth or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonium, primary, secondary and tertiary amines, and cyclic amines, such as piperidma, morpholine and piperacma, and salts
• *. • ^ 42
inorganic derivatives of sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium. In the case of solid agents, those skilled in the art understand that the compounds and salts of the invention exist in different cpstallic or polymorphic forms, it being intended that all of them be within the scope of the present invention and specified formulas. The cell cycle control agents according to the l? invention, are useful as pharmaceuticals for the treatment of proliferative disorders in mammals, especially humans, characterized by undesired proliferation of endogenous tissues. The compounds of Formula I or II can be used for the treatment of individuals with
15 disorders associated with excessive cell proliferation, for example, cancers, psoriasis, immune disorders involving an undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders. Moreover, said compounds can be used to prevent
20 de-differentiation of tissues and / or postmitotic cells. Diseases or disorders associated with abnormal or uncontrolled cell proliferation include, but are not limited to, the following: a variety of cancers, including, but not limited to, carcinoma, hematopoietic tumors of
lymphoid strain, hematopoietic tumors of myeloid origin, tumors of mesenchymal origin, tumors of the central and peripheral nervous system and other tumors including melanomas, seminomas, Kaposi's sarcoma and the like.
-pathological processes with characteristics of abnormal cell proliferation, for example, benign prostatic hyperplasia, familial adenomatosis, polyp, neurofibromatosis, arteriosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis after angioplasty or vascular surgery, hypertrophic scar formation, inflammatory disease intestinal, rejection of transplant, endotoxic shock, and fungal infections.
- conditions associated with defective apoptosis, such as cancers (including but not limited to the types mentioned above), viral infections (including, but not limited to, herpes viruses, poxviruses, Epstein-Barr virus, Sindbís virus and adenovirus) , prevention of the development of AIDS in HIV-infected individuals, autoimmune diseases (including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, psoriasis,
*
autoimmune-mediated glomerulonephritis, inflammatory bowel disease and autoimmune diabetes mellitus), neurodegenerative disorders (which "include, but are not limited to, Alzheimer's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, Parkinson's disease, AIDS-related dementia, spinal muscular atrophy , atrophy and cerebellar degeneration), myelodysplastic syndrome, aplastic anemia, ischemic insult associated with myocardial infarction, cerebrovascular accident and reperfusion injury, arrhythmia, arteriosclerosis, hepatic diseases induced by toxins or alcohol, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including without being limited to them, osteroporosis and arthritis), aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney disease and pain from cancer. The active agents of the invention can also be useful in the inhibition of the development of invasive cancer, tumor angigogenesis and metastasis. Moreover, the active agents of the invention, for example, as inhibitors of CDKs, can modulate cellular RNA level and DNA synthesis and therefore
it is expected to be useful in the treatment of viral infections such as HIV, human papilloma virus, herpes virus, Epstein-Barr virus, adenovirus, Sindbis virus, poxvirus and the like. The compounds and compositions of the invention inhibit the activity of kinases of, for example, the CDK / cyclin complexes, such as those active in the Go or Gi stage of the cell cycle, for example, CDK2, CDK4, and / or CDK6 complexes. The specific dose of a cell cycle control agent to be administered to obtain a therapeutic or inhibitory effect can be determined in a manner known in the art according to the particular circumstances of the case, including, for example, the specific agent to be administered, the route of administration, the condition that is being treated, and the individual or guest that is being treated. An example of a total daily dose of a cell cycle control agent, which can be administered in single or multiple doses, contains a dosage level of about 0.01 mg / kg of body weight to about 50 mg / kg of body weight . The cell cycle control agents of the invention can be administered by a variety of appropriate routes, such as oral, rectal,
46
Transdermal, Subcutaneous, Intravenous, Intramuscular or Transnasal "" The cell cycle control agents are preferably formulated into compositions appropriate for the desired routes of administration before being administered A pharmaceutical composition or preparation according to the invention includes an effective amount of a cell cycle control agent, optionally one or more other active agents, and a pharmaceutically acceptable carrier, such as a diluent or excipient for the agent, when the carrier serves as a diluent, it can be a solid, semi-solid, or liquid material acting as vehicle, excipient, or medium for the active ingredient (s) The compositions according to the invention can be made by mixing the active ingredient (s) with the carrier, or by dilution with the carrier, or by inclusion or encapsulation of the ingredient. active within the transporter, which can be fo capsule, sachet, paper container, or similar. Exemplary ingredients, in addition to one or more cell cycle control agents and any other active ingredient, include Avicel (microcpstamma cellulose), starch, lactose, calcium sulfate dihydrate, alba earth, sucrose, talc, gelatin, agar, pectin , acacia, magnesium stearate, stearic acid, peanut oil, olive oil, glyceryl **
monostearate, Tween 80 (polysorbate 80), 1, 3-butanediol, cocoa butter, beeswax, polyethylene glycol / propylene glycol, sorbitan monostearate, polysorbate 60, 2-octyldodecanol, benzyl alcohol, glycine, sorbic acid, potassium sorbate, disodium hydrogen phosphate, sodium chloride and water. The compositions can be prepared in any variety of forms suitable for the desired mode of administration. For example, the pharmaceutical compositions can be prepared in the form of tablets, tablets, powders, lozenges, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid medium), ointments (for example, containing up to 10% of its weight in the form of a cell cycle control agent), soft gel and hard gel capsules, suppositories, sterile injectable solutions, sterile packaging powders, and the like. In similar fashion, the carrier or diluent may contain retarding or releasing materials known in the art, such as glycerol monostearate or glycerol distearate alone or with wax, ethylcellulose, hydroxypropylmethylcellulose, methyl merylate and the like. A variety of pharmaceutical forms can be used. Therefore, if a
solid carrier, the preparation can be in the form of tablets, placed in hard gelatin capsules in the form of powder or in the form of pills or in the form of a troche or lozenge. The amount of solid carrier may vary, but will generally be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation can be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in a vial or vial or non-aqueous liquid suspension. To obtain a stable water-soluble dosage form, a pharmaceutically stable salt of an agent of the invention is dissolved in an aqueous solution of an organic or inorganic acid such as the 0.3M solution of succinic acid or citric acid. If a soluble salt is not available, the agent can be dissolved in a suitable solvent or combinations of cosolvents. Examples of suitable co-solvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0-60% of the total volume. A compound of Formula I or II can be dissolved in DMSO and diluted with water. The composition can also be in the form of a solution of a salt of the active ingredient in a
suitable aqueous vehicle such as water or isotonic solutions of saline or dextrose. The compositions of the invention can be manufactured in commonly known forms for the preparation of pharmaceutical compositions, for example, using conventional techniques such as mixing, dissolving, granulating, drageeing, polishing, emulsifying, encapsulating, compressing or lyophilizing. The pharmaceutical compositions can be formulated in a conventional manner using one or more physiologically acceptable carriers, which can be selected from excipients and auxiliaries that facilitate the processing of the active compounds into preparations that can be used pharmaceutically. The proper formulation depends on the chosen route of administration. To be injected, the agents of the invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, suitable penetrants are used in the formulation for the barrier to be penetrated. Such penetrants are generally known in the art. For oral administration, the compounds can be formulated simply by the combination
of active compounds with pharmaceutically acceptable carriers known in the art. Such transporters allow the compounds of the invention to be formulated as tablets, tablets, dragees, capsules, liquids, gels, syrups, watered pastes, suspensions and the like, for oral ingestion by the patient to be treated. Pharmaceutical preparations for oral use can be obtained by using a solid excipient in admixture with * the active ingredient (agent), optionally grinding the resulting mixture, and processing the mixture of granules after the addition of suitable auxiliaries, if desired, to obtain tablets or dragees Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol and cellulose preparations, eg, corn starch, wheat starch, rice starch, potato starch, gelatin, gum, hydroxypropyl ethyl -cellulose, sodium carboxymethylcellulose, methyl cellulose, or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as, linked polyvinyl pyrrolidone, agar, or alginic acid or salts thereof such as sodium alginate. Dragee centers are provided with * appropriate wraps. For this purpose, they can be
use sugar solutions, which can optionally ^ >; contain gum arabic, polyvinyl pyrrolidone, g l? * Carbopol, polyethylene glycol, and / or titanium dioxide, •. 'Lacquer and organic solvents or mixture of suitable solvents. *,' * Can you add tinctures or pigments to tablets or dragee wraps for the identification or characterization of the different combinations of active agent J. The pharmaceutical preparations that can be used orally include gelatin "push-fit" capsules, as well as sealed soft capsules, made of gelatin and a plasticizer, such as glycerol or sorbitol.The "push-fit" capsules can contain the active ingredients attached by mixing to fillings such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate, and, optionally, stabilizers In soft capsules, the active agents can be dissolved or suspended in suitable liquids, such as fatty oils , liquid paraffin, or liquid polyethylene glycol Additionally, stabilizers can be added All formulations for oral administration they should be in appropriate doses for such administration. For oral administration, the compositions can take the form of tablets or lozenges formulated in conventional manner.
For nasal or inhalation administration, the compounds for use according to the present invention are conveniently administered in an aerosol presentation form presented in pressurized or nebulized containers, by the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluororaethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosing unit can be determined by the provision of a valve that manages an established amount. Capsules and gelatin cartridges for use in an inhaler or insufflator or the like can be formulated containing a powder mixture of the compound and a suitable powder base such as lactose or starch. The compounds can be formulated for injectable parenteral administration, for example, by bolus injection or continuous infusion. The injectable formulations can be presented in the form of metered units, for example in ampoules or multi-dose containers, with the addition of a preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulated agents such as stabilizing and / or dispersing suspensors.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in a water-soluble form. Additionally, suspensions of the active agents can be suitably prepared in the form of oily suspension injections. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic esters of fatty acids, such as ethyl oleate or triglycerides or liposomes. Aqueous injectable suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain appropriate stabilizers or agents that increase the solubility of the compounds to allow the preparation of highly concentrated solutions. For ocular administration, the active agent is presented in an acceptable pharmaceutically acceptable ophthalmic vehicle, so that the compound is kept in contact with the ocular surface for a sufficient period of time to allow the compound to penetrate the cornea and inner regions of the eye. , including / for example, the anterior chamber, the posterior chamber, the vitreous body, the aqueous humor, the vitreous humor, the cornea, the iris / ciliary body, the lens, the choroid / retina and the sclera.
The pharmaceutically suitable ophthalmic vehicle may be an ointment, vegetable oil or encapsulating material. The compound of the invention can also be injected directly into the vitreous and aqueous humor. Alternatively, the active ingredient may be in powder form to be reconstituted prior to use with an appropriate vehicle, eg, sterile, pyrogen-free water. The compounds can also be administered rectally in compositions such as suppositories or retention enemas, for example, containing conventional suppository bases such as cocoa oil or other glycerides. The compounds can also be formulated in depot preparations. Such long-acting formulations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. For this reason, the compounds can be formulated, for example, with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil) or with ion exchange resins, or as sparingly soluble derivatives, for example, a sparingly soluble salt. A pharmaceutical carrier for hydrophobic compounds is a solvent system containing benzyl alcohol, a non-polar surfactant, an organic polymer
miscible with water and an aqueous phase. The soldering system can be a VPD co-solvent system. VPD is a solution of 3% w / v of benzyl alcohol, 8% w / v of non polar polyester surfactant 80 and 65% w / v of polyethylene glycol 300, brought to volume in absolute ethanol. The VPD co-solvent system (VPD: 5W) contains VPD diluted 1: 1 with a dextrose solution in 5% water. This cosolvent system dissolves hydrophobic compounds well, and by itself produces little toxicity when administered systemically. Naturally, the proportions of a system
The dissolvent can be varied considerably without destroying its solubility and toxicity characteristics. Moreover, the identity of the components of the cosolvent can be varied. For example, other non-polar low-toxicity surfactants may be used instead of polysorbate 80; the fractional size of polyethylene glycol can be varied; polyethylene glycol can be replaced by other polymers
• biocompatible, for example, dextrose can be replaced by polyvinylpyrrolidone and other sugars or polysaccharides. Alternatively, other hydrophobic pharmaceutical compound delivery systems may be used. Liposomes and emulsions are examples, known from release vehicles or transporters for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide can also be used, although usually with the
i.
'* * and * X - 56
cost of greater toxicity. Additionally, the compounds can be administered using a sustained release system, in the form of semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. 5 Various sustained release materials have been established and are known to those skilled in the art. Sustained-release capsules can, depending on their chemical nature, release the compounds for a few weeks and up to more than 100 days. According to the
In the chemical nature and biological stability of the therapeutic reagent, additional strategies can be employed for protein stabilization. The pharmaceutical compositions may also include suitable carriers or excipients with base
15 solid or gelled. Examples of such carriers are calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycol. Some of the compounds of the invention can be provided in the form of salts with pharmaceutically compatible counter ions. The pharmaceutically compatible salts can be formed with many acids, including hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. The salts tend to be
• $ & ** & ? 57
more soluble in aqueous solvents or other protonic solvents than the corresponding free base forms. A pharmaceutical composition according to the invention includes a cell cycle control agent and, optionally, one or more other active ingredients, as a known antiproliferative agent that is compatible with the cell cycle control agent and suitable for the indication to be treated. The compounds are useful as agents
10 antiangiogenic and as modulating agents and / or inhibitors of the activity of protein kinases, therefore provide treatment for cancer or other diseases associated with cell proliferation mediated by protein kinases. Therapeutically effective amounts of the agents of the invention can be used to treat diseases mediated by the modulation or regulation of protein kinases. An "effective amount" means the amount of an agent that, when administered to a mammal
20, which requires such treatment, is sufficient to effect the treatment of a disease mediated by the activity of one or more kinases. Thus, for example, a therapeutically effective amount of a compound of Formula I or II, salt, active metabolite or derivative prodrug is a
25 enough to modulate, regulate, or inhibit the
activity of one or more kinases in such a way that a pathological condition that is mediated by that activity s, * • * reduces or is alleviated. i "Treat" means at least the mitigation of 5, a pathological condition in a mammal, such as a human, that is affected at least in part, by the activity of one or more qumases, and includes: preventing the occurrence of the pathological condition in a mammal, particularly when the mammal is predisposed to have the pathological condition but has not yet been diagnosed; modulate and / or inhibit the pathological condition; and / or alleviate the pathological condition. The agents of the invention can be prepared using the reaction routes and synthetic schemes described below, employing the techniques available in the art and using materials that are readily available. The general schemes exemplified 1 to 6, shown below, can be used to make the compounds of the invention.
Track 1
X = CI I
C D E F [Pd catalyst = Pd Catalyst] The halogenated intermediate A can be obtained by standard 5-amino nomdazole diathozation and treatment of the resulting diazonium salt with an appropriate halide salt, such as CuCl or Kl. Subsequent halogenation to obtain 3-halomdazole B is achieved by treatment with a suitable base such as sodium or potassium mdroxide and an elemental halogen such as iodide. The intermediate B is protected using any number of suitable protecting groups and is treated with an alkyl or aryl boronic acid (preferably stoichiometric) or ester and a suitable Pd catalyst, for example, Pd (PPh3), to affect the selective reaction in the C-3 position. A subsequent reaction with a second alkyl or aryl boronic acid or ester and a suitable Pd catalyst makes it possible to obtain the desired intermediate substance 3, 5-d? Sust? E?, Which is then deprotected to obtain the final compound F.
The conditions of deprotection are consistent with Q * -specific protective group used, for example-acid conditions for the removal of a protective group, **
THP. R; and R2 are as defined above and can be R ',, and
R'2. Variation of track 1
[Pd catalyst = Pd Catalyst] The alternative synthetic variation to lane 1 presented above requires the treatment of intermediate C, where X is Cl with alkyl dithm species, such as hexamethyl dithm, and an appropriate Pd catalyst, to obtain the intermediate substance G. The reaction of intermediate G with an alkyl or aryl halide and an appropriate Pd catalyst provides the desired intermediate D which may continue to be worked up as described above.
Via 2 *.
[Pd catalyst = Catalyst, Pd Diammoethane = Diaminoethane] Alternatively, as shown in lane 2 above, a 5-n? Tromdazole can be halogenated as described above for intermediate A, to obtain a nitro compound H, by treatment with a b ^ se suitable as sodium hydroxide or potassium hydroxide and an elemental halogen as the iodide to obtain an intermediate substance I after the standard protection cbn a suitable protective group. With the treatment of intermediate I with alkyl dithm species, such as
ditin hexamethyl and a suitable Pd catalyst, intermediate substance J can be obtained. A further reaction of the nitro compound J with an alkyl or aryl boronic acid or ester and a suitable Pd catalyst makes it possible to obtain the 3-substituted-K mdazole. The amine is obtained by reducing K with a suitable reducing agent, such as hydrogen with palladium catalyst or SnCl2. The diazotization of the resulting 5-amino indazole and the treatment of the resulting diazonium salt with a salt of
Suitable halide, such as CuCl or Kl, produces the intermediate substance with halo L. The reaction of L with an alkyl or aryl boronic acid or ester and a suitable Pd catalyst produces the intermediate M which is deprotected as before to give the final compound F. Rx, and R are those defined above $ and can be R 'i and R'2. ID "
5
: > ^, - 63"'PA [Acid activation« = Acid activation / Protécti n - r * Protection, Reduction = Reduction] In lane 3 shown above, a B - carboxy - indazole is activated to provide an active acyltin species, such as carbonyl di-imidazole, which is treated with a suitable alkoxy alkyl amine, such as N, N-dimethylhydroxylamine, resulting in amide A 'The selective halogenation of intermediate A' j with an elemental halogen such as bromine or iodine, and preferably with a catalyst such as bis (trifluoroacetoxy) yodosobenzene or bis (acetoxy) iodosobenzene produces indazole B ', of 5 halos Protection of intermediate B' under standard conditions with an appropriate protecting group as PMB or THP provides a protected C-amide.The reduction of C with an appropriate reductant such as lithium aluminum hydride or an equivalent hydride reducing agent provides the key intermediate aldehyde D '. The R3 is corao defined above, pref. preferably an alkyl, substituted or unsubstituted, preferably a lower alkyl.
Track 4
; Deprotect? On = Deprotection]
In path 4 shown above, intermediate D 'reacts with a substituted "B" diamine and a suitable oxidizing agent such as sulfur to provide benzimidazole C ". The conversion of compound C "to the corresponding borated ester D" is achieved by reacting with a suitable diboro species, such as dipychocholate or other boron electrophilic source, with a suitable palladium catalyst. Intermediate D "then reacts, under a palladium catalyst, with a halogenated alkyl or aryl halide to give substituted 5-indazole, intermediate E", which after an appropriate deprotection provides the final compound H. "Alternatively, the initial compound D 'is reacted with a suitable diboro species, such as the bis (pinacolato) diboro or another suitable electrophilic boron source and a palladium catalyst suitable for giving the boron ester F ". The preparation of compound F "to intermediate D" is achieved as described above for intermediate D '. Another alternative conversion can be achieved by the reaction of the intermediate aldehyde F "with an alkyl or substituted aryl halide to provide R2 with a palladium catalyst for
provide G "which then further reacts with a substituted" B "diamine and a suitable oxidizing agent, such as sulfur, to provide the benzimidazole E." As before, deprotection allows to obtain the final compound H ". R2 is as defined above and can be R'2. R3 is as defined above. A further preparation of the intermediate E "can be achieved by acid or alkyl borinic ester in a suitable palladium catalysis." Other electrophilic boron species that can be used in the structure:
R3 R3 B-B where R3 is as defined above and R3 groups can form a ring R3? ' OR3
[Where R3 as defined above and two R3 groups can form a ring. = Where R3 is as defined above and two R3 groups can form a ring.] Specific examples include:
Track 5
[Deprotection = Deprotection] In lane 5 above, the intermediate alcohol X: can be activated, for example, by reaction with a sulfonyl halide, such as methanesulfonyl chloride and a suitable base such as triethylamine, and this electrophilic species then it reacts with a nucleophile, such as a substituted amine, to provide the intermediate substance X2 which is then deprotected under the appropriate conditions. R2 is as defined above, and may be R'2. R3 is as defined above.
\ '
'4 69
final products. 'Ri and R2 are as defined above and can be R'i and R'2. The preparation of the specific preferred compounds of the invention is described in detail in the following examples. The artisan will recognize that the described chemical reactions can readily be adapted to prepare a number of other inhibitors of kinases of the invention. For example, the synthesis of compounds not exemplified according to the invention can be carried out
I0 .1t- successfully through modifications known to those who are experts in the art, for example, by means of the appropriate protection of interfering groups, the exchange for other suitable reactants known in the art or the modification in the routine conditions of the reaction. As an alternative, other reactions disclosed herein or known in the art will be recognized that are applicable for the preparation of other compounds of the invention. In the examples described below, except where indicated, all temperatures are presented at 0 degrees Celsius and all parts and percentages are by weight. The reactants were purchased from commercial suppliers such as Aldrich Chemical Company or Lancaster Synthesis Ltd. and were used without further purification unless otherwise indicated. Tetrahydrofuran (THF) 5 distilled from calcium hydride and N, N-dimethylformamide (DMF)
were purchased from Aldrich in sealed "Sure seal" bottles and used in the way they were received. All solvents were purified using standard methods known to those skilled in the art, unless otherwise indicated. The reactions indicated below were generally made under a positive argon pressure or with a drying tube, at room temperature (unless otherwise clarified), in anhydrous solvents, and the reaction vessels were provided with rubber holes for the introduction of substrates and reagents with a syringe. The glass elements were dried in the oven and / or by heat. Analytical thin-layer chromatography (TLC) was performed on Analtech 60 F 254 glass-silica gel plates (0.25 mm), extracted with solvents in appropriate proportions (v / v) and denoted where appropriate. The reactions were tested by TLC and finished judging by the consumption of the initial material. The visualization of the TLC plates was carried out with a p-anisaldehyde reagent spray or a phosphomolybdic acid reagent (Aldrích Chemical 20% by weight in ethanol) and activated with heat. The procedures were typically done by doubling the reaction volume with the reaction or extraction solvent and then washing with the indicated aqueous solutions using 25%
by volume of extraction volume unless otherwise indicated. The product solutions were dried over Na2SO4 or anhydrous MgSO4 prior to filtration and evaporation of the solvents under reduced pressure in a
* x Rotary evaporator and annotated as solvents removed in vacuo. 3te performed flash column chromatography (Still et al., J. Org. Chem., 43, 2923 (1978)) using flash silica gel with Baker graduation (47-61 μm) and a silica gel: material ratio crude from approximately 20: 1 to 0 50: 1, unless otherwise indicated. The hydrogenation was carried out at the pressure indicated in the examples or at ambient pressure. The 1 H-NMR spectra were recorded on a Bruker instrument operating at 300 or 500 MHz and the 5 13 C-NMR spectra were recorded operating at 75 MHz. The NMR spectra were obtained as CDC 13 solutions (reported in ppm), with chloroform as reference standard (7.25 ppm and 77.00 ppm), CD3OD (3.4 ppm and 4.8 ppm and 49.3 ppm) or internal tetramethylsilane (0.00 ppm) when appropriate. Other NMR solvents were used as needed. When the maximum multiplicities are reported, the following abbreviations are used: s (smgleta), d (doublet), t (triplet), m (multiplet), br (extended), dd (doublet of doublets), dt (doublet of triplets ). When they occur
coupling constants, they are expressed as hertz (Hz). The infrared (IR) spectra were recorded 'in. . * pg ..; í an Perkin-Elmer FT IR spectrometer as clean oils or KBr pellets, and are reported in wave numbers (c "1) .. Mass spectra were obtained using LSIMS or electrospray. All melting points (mp) are uncorrected The starting materials used in the examples are commercially available and / or can be prepared with techniques known in the art.
Example 1: 5-Phenyl-3-Est r? L-lfí-Indazol
[dioxane = dioxane, Toluene = Toluene, reflux = reflux] (a) Intermediate substance la-5-Chloro-3-yada-lH-mdazole: 5-Am? no-lH-mdazole (15.41 g, 116 mmol) 4 se suspended in a mixture of water (250 ml), ice (250 ml), and concentrated HCl (100 ml). The mixture was cooled in an ice bath and salt to an internal temperature of -5 ° C. S. added to this mixture a solution of sodium nitrite (8.78 g, 127 mmol) in water (75 ml), which had been cooled to 0 ° C. The resulting diazomo solution was stirred for 15 minutes at -5 ° C. copper chloride solution (I) { 14 .9
"'vtti g, 151 mmol) in concentrated HCl (150 ml) was cooled to 0 ° C and then added dropwise to the diazonium solution," - causing the formation of an orange precipitate.The cold bath was then removed To allow the reaction to warm to room temperature, the evolution of the gas started at an internal temperature of 10 ° C. After stirring at room temperature for 1.5 hours, the evolution of the gas gave way, then the flask was heated to 60 ° C for 30 ,.
\ 6 minutes and then cooled to ~ 15 ° C. A brown precipitate formed. The precipitate was collected by suction filtration and dried in a tumble dryer over NaOH for 16 hours to give crude 5-chloro-1-indazole (25.6 g) as a tan powder. 15 This crude intermediate was dissolved in 1,4-dioxane (400 ml). Aqueous 3 M NaOH (400 mL) and iodide flakes (35.3 g, 139 mmol) were added to the solution. After stirring at room temperature for 2 hours, the reaction mixture was neutralized to pH = 6 with 20% aqueous citric acid, causing the change from dark to light green * Saturated aqueous sodium thiosulfate was added (~ 400 ml) to the solution, causing the color change from green to yellow, and the solution was extracted with ethyl acetate (3 x 1000 ml). The combined organic extracts were dried over sodium sulfate, filtered by suction through coarse frit.
** t! i? £: *? .. "ß * i: ffi? £ i! üíJ2ia
and concentrated to a green slurry which was then dissolved in ethyl acetate (500 ml), filtered through a pad of Celite and concentrated to a green solid. Purification by chromatography on silica gel (25% ethyl acetate in hexanes) provided 5-chloro-3-iodo-lH-mdazole (14.18 g, 44% of 5-amino-1H-mdazole) in the form of a whitish solid: mp * 198-199 ° C; Rf = 0.53 (50% ethyl acetate / hexanes); XH NMR- (DMSO-de) 6 7.44 (m, 2H), 7.60 (d, ÍH, J = 8.7 Hz), 13.68 (á, ÍH). Analysis (C7H4C1IN2) C, H, N. (b) Intermediate Ib-5-Chloro-3-? Odo-l- (2- (trimethylsilyl) -ethoxymethyl] -lH-indazole: 5-Chloro-3- was dissolved iodide-liya-indazole (8.86 g, 31.8 mmol) in THF (100 ml) and cooled in a water bath and salt at 0 ° C. Solid sodium t-butoxide (3.67 g, 38.2 mmol) was added and The mixture was stirred at 0 ° C for 1 hour, then 2- (trimethylsilyl) ethoxymethyl chloride (7.96 g, 38.2 mmol) was added, and stirring was continued at 0 ° C for an additional 1 hour. ethyl acetate (200 ml) and washed with water (100 ml) and brine (100 ml) The organic layer was dried over magnesium sulfate, filtered and concentrated chromatography on silica gel (5 to 20% acetate ethyl acetate in hexanes) gave Ib (9.75 g, 75%) as a yellow oil: Rf = 0.39 (5% ethyl acetate / hexanes); XH NMR (CDC13) d -0.06 (s, 9H ), 0.87 (t,
f 1 »* * '. 76
2H, J = 8.1 Hz), 3 # 55 (t, 2H, J = 8.1 Hz), s5.70 (s, 2H), 7.43 (dd, ÍH, J = 8.9, 1.7 Hz), 7.49 (m, 2H ). Analysis > (C? 3H? 8ClIN2OSÍ) C, H, N. (c) Intermediate le-5-Chloro-3-styryl-l- [2- (trimethylsilanyl) -ethoxymethyl-1H-indazole: 5-Chloro-3 was dissolved -Iodo-2-SEM-indazole Ib (553 mg, 1.35 mmol), styrylboronic acid (300 g, 2.03 mmol) and tetrakis (triphenylphosphino) palladium (78.2 mg, 0.068 mmol) nf toluene (10 ml) and methanol (1.4 ml) ). A saturated aqueous solution of sodium bicarbonate (1.7 ml) was added and the mixture i was heated in an oil bath at 90 ° C for 3 hours. A slight reflux was observed. After cooling to room temperature, the solution was diluted with water (15 ml) and extracted with ethyl acetate (4 x 50 ml). The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated. Purification by chromatography on silica gel (toluene) provided pure lc (350.7 mg, 67%) as a yellow-colored oil: Rf = 0.20 (toluene); XH NMR (CDC13) d -0.09 (s, 9H), 0.86 (t, 2H, J = 8.1 Hz), 3.55 (t, 2H, J = 8.3 Bz), '> 5.65 (s, 2H), 7.2-7.4 (m, 7H), 7.54 (d, 2H, J = 7.6.H2), and 7.93 (d, ÍH, J = 1.6 Hz). 13C NMR (CDC13) d -1.5, 17.7, 66.5, 77.9, 111.0, 119.2, 120.3, 123.6, 126.5, 127.3, 127.4, '128.0, 128.7, 131.6, 136.9, 139.4, 142.5. Analysis (C2? H2SClN2OS? »0.02 CHC13) C, H, N, Cl.
(d) Intermediate substance Id-5-Phenyl-3-styryl-l- [2- (triraethylsilanyl) -ethoxymethyl] -lfi-indazole: To a solution of 5-chloro-3-styryl-2-SEM-in? jtezbl _ lc (209.4 mg, 0.544 mmol) in dry 1,4-dioxan (0.5 ml) Be added phenylboronic acid (69.6 mg, 0.571 mmol), cesium carbonate (213 mg, 0.653 mmol), and tris (dibenzylidinacetone) dipalladium ( 10.0 mg, 0.0108 mmol). A solution of tri-tert-butyl phosphino in 1,4-dioxane (0.1 M, 0.217 ml) was added and the mixture was heated at 80 ° C for 6 hours. After cooling to room temperature, the solution was diluted with ethyl ether (20 ml), and filtered through a pad of Celite to remove the black precipitate of palladium. The filtrate was dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (toluene) to give ld (77.2 mg, 33%) as a colorless oil: Rf = 0.09 (toluene); XH NMR * (CDC13) d -0.04 (s, 9H), 0.93 (t, 2H, J = 8.1 Hz), 3.62 (t, 2H, J = 8.1 Hz), 5.76 (s, 2H, J), 7.3- 7.7 (m, 14H) 8.17 (s, ÍH). Analysis (C27H3oN2OSi «0.2 H20) C, H, N. (e) Example 1 - 5-Phenyl-3-Styryl-lH-Indazole: Intermediate ld (68.1 mg, 0.16 mmol) was dissolved in absolute ethanol (2.0 ml ) and 3 M HCl (2.0 ml). The solution was heated to reflux for 20 hours, cooled to room temperature, and extracted with ethyl acetate (3 x 30 ml). The organic extracts
The combined extracts were dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (25 to 50% ethyl acetate in hexanes), which yielded the title compound (19.2 mg, 40%) in the form of a white solid: R: - = 0.14 (25% ethyl acetate / hexanes); XH NMR (CDC13) d 6.92 (d, 1H, J = 6.3 Hz), 7.3-7.7 (m, 13H), 8.20 (s, ÍH), 10.3 (br S, ÍH). HRMS calculated for C2: HnN2 297.1392 (MH +), found 297.1398. Analysis (C2? H? 6N2-0.7 H20) C, H, N.
Example 2: 3,5-D st r? L-lH-Indazol
i.
(a) Intermediate 2a-5-iodo-lfí-indaz © l: 5-Amino-lf-indazole (10.21 g, 76.7 mmol) was suspended in a mixture of water (100 ml), ice (100 ml), and Concentrated HCl (35 ml). The mixture was cooled in an ice bath and salt to an internal temperature of -5 ° C. To this mixture was added a solution of sodium nitrite (5.82 g, 84.4 mmol) in water (30 ml), which had been cooled to 0 ° C. The resulting diazonium solution was stirred for 10 minutes at -5 ° C, then a solution of potassium iodide (15.3 g, 92 mmol) in water was slowly added dropwise (50 ml). foam with the first drops of the Kl solution, and then a black, tarred gum was formed.After the addition was completed, the mixture was heated at 90 ° C for 1 hour.The tarry precipitate dissolved and a purple vapor evolved during heating, then the reaction was cooled to room temperature, causing the
"formation of a fine brown precipitate." This precipitate was collected by suction filtration, and dried under vacuum to provide 5-iodoindazole 2a (14.12 g, 15%.) as a brown powder: Rf = 0.28 (50%). ethyl acetate / hexanes); XH NMR (DMSO-d6) d 7.40 (d, 1H, J = 9.0 Hz), 7.56 (dd, ÍH, J = 8.5, 1.5 Hz), 8.01 (s, ÍH) 8.16 (s , 1H), 13.23 (s, ÍH) Analysis (C7H5IN2) C, H, I, N.
(b) Intermediate 2b-3,5-Diiodes-lf-indazole: Intermediate 2b was prepared by a synthetic method analogous to that of the synthesis of the intermediate substance la. The treatment of intermediate 2a with iodide and sodium hydroxide afforded 3,5-diiodo-lH-mdazole 2b (84%) in the form of a yellow solid: Rf = 0.39 (30% ethyl acetate / hexanes); XH NMR (DMSO-d6) d > < 7.41 (d, ÍH, J = 8.7 Hz), 7.66 (dd, ÍH, J = 8.7, 1.5 Hz), 7.77 (d, ÍH, J = 0.9 Hz) 13.65 (s, ÍH). (c) Intermediate 2c-3,5-Diiodo-l- [2- (trimethylsilanyl) -ethoxymethyl] -lfi-indazole: By a synthetic method similar to that of intermediate Ib, the treatment of 3,5-diiodoindazole 2b with sodium t-butoxide and 2- (trimethylsilyl) ethoxymethyl chloride gave 2c (64%) as a yellow oil: Rf = 0.53 (30% ethyl acetate / hexanes); 1H NMR (CDC13) d -0.05 (s, 9H), 0.86 (t, 2H, J = 8.1 Hz), 3.54 (t, 2H, J = 8.1 Hz), 5.69 (s, 2H), 7.34 (d, HI) , J = 8.7 Hz), 7.69 (dd, ÍH, J = 8.7, 1.5 Hz), 7.87 (d, ÍH, J = 1.5 Hz). (d) Intermediate 2d-3,5-Distryl-l- [2- (trimethylsilanyl) -ethoxymethyl] -lH-indazole: Styrylboronic acid (186 mg, 1.26 mmol) was added to the solution of 2c (210.0 mg, 0.42 mmol) and tetrakis (triphenylphosphino) palladium (48.5 mg, 0.042 mmol) in toluene
, (3.5 ml) and methanol (0.5 ml). A saturated aqueous solution of sodium bicarbonate (1.05 ml) was added, and the mixture was heated in an oil bath at 90 ° C (slight reflux) for 4 hours. After cooling to room temperature, the reaction was poured into water (15 ml) and extracted with ethyl acetate (4 x 50 ml). The combined organic extracts were dried over magnesium sulfate, filtered / concentrated and purified by chromatography on silica gel (toluene) to give 2d (170.9 mg, 90%) as a yellow oil. :, Rf = 0.10 (toluene); XH NMR (CDC13) d 0.01 (s, 9H), 0.98 (t, 2H, J = 8.5 Hz), 3.67 *
(t, 2H, J = 8.5 Hz), 5.73 (s, 2H), 7.17 (d, 1H, J - 16 Hz), 7.3-7.7 (m, 15H), 8.05 (s, 1H). 13C NMR ÍCDCI3) d -1.5, 17.6, 66.4, 77.7, 110.1, 119.4, 119.8, 123.3, 125.1, 126.3, 126.5, * 127.8, 128.6, 128.7, 128.9, 131.3, 137.1, 137.3, 140.6,
• 143.3. Analysis (C29H32N2OSi »0. ICHCl3) C, H, N. (e) Example 2 - 3,5-Distiryl-lH-Indazole: Example 2 was prepared in a similar manner to Example 1, by treatment of 2d with 3M HCl, 3, 5-d-Stiryl-1 -indazole (33%) as a bright yellow solid: Rf = 0.11 (25% ethyl acetate / hexanes); XH NMR (CDCl 3) d 7.2-7.7 (m, 16H) 8 \ 076 (s, ÍH), 10.05 (br s, ÍH). HRMS calculated for C23H? 9N2 323.1548 (MH +), found 323.1552. Analysis (Cg3H18N2'0.5 H20) C, H, N.
4 &
Example 3: 3- (lH-Benzoimidazole-2-? L) -S-Phenyl-lH-Indazole
3a 3b
[Reflux = reflux, Toluene - toluene, Dioxane = dioxane]
(a) Intermediate 3a-l- [2- (Trimethylsilyl) -ethoxymethyl] -1H-benzoimidazole: (See Whitten et al, J. Org. Chem. 51, 1891 (1986) incorporated herein by reference, with a similar procedure) . Solid lff-benzoimidazole (30 g, 254 mmol) was added in small portions to a suspension of sodium hydride (10.2 g of 60% dispersion in mineral oil, 254 mmol) in DMF (350 ml) at room temperature. The mixture was stirred for 3 hours, and then cooled to 0 ° C in a bath of
ice. 2- (Trimethylsilyl) ethoxymethyl chloride (46.57 g, 279 mmol) was added dropwise over 10 minutes. The reaction was stirred for 16 hours, warming to room temperature when the ice was melted, then poured into water (11) and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, concentrated and purified by chromatography on silica gel (50 to 85% ethyl acetate in hexanes) to provide 3a (56.63 g, 90%). in the form of an amber oil: .Rf = 0.40 (50% ethyl acetate / hexanes); XH NMR (CDC13) d - 0.04 (s, 9H), 0.90 (t, 2H, J = 8.1 Hz), 3.50 (t, 2H, »8.1 Hz), 5.53 (s, 2H), 7.31 (m, 2H) , 7.54 (m, ÍH), 7.81 (m, ÍH), 7.96 (s, ÍH). Analysis (C? 3H2oN2OSI • 0.5H20) C, H, N. 15 (b) Intermediate 3b-2-Iodo-l- [2- (tnmethylsilanyl) -ethoxymethyl] -lif-benzoimidazole: A solution of N-SEM -benzimidazole (intermediate 3a) (19.19 g, 77.25 mmol) in dry ethyl ether (150 ml) and cooled to -78 ° C in a dry 2ft ice bath / acetone, was added via drip via cannula to a solution of -butyl lithium (46 ml of 2.5 M in hexanes, 116 mmol) in dry ethyl ether (150 ml), also cooled to -78 ° C in a dry ice / acetone bath. The addition of the benzimidazole solution took 10 minutes. The agitation continued 15 25 more minutes, and during that time a color developed
-
M '., &' - "* * • 84
dark red. The resulting aryl lithium solution was * - * added via drip via cannula to a solution of iodide flakes (49 g, 193 mmol) in dry ether (500 ml), in turn "? \ Cooled to -78 ° c in a dry ice / acetone bath, then * ^ 5 to complete the aggregate (10 minutes), the cold bath was removed, and the reaction of the mixture was heated for 30 minutes to reach an internal temperature of - 10 ° C. Water (250 ml) was added and the mixture was washed with a saturated aqueous solution of sodium bisulfite (2 x 200 ml).; The organic layer was dried over sodium sulfate, filtered, concentrated and purified by chromatography on silica gel to provide 3-iodo-n-SEM-benzimidazole 3b (22.84 g, 80%) in the form of a sodium solid. yellow color: mp * 60-63 ° C; Rf = 0.70 (ethyl acetate); XH NMR (CDC13) d -0.04 tí (s, 9H), 0.92 (t, 2H, J = 8.1 Hz), 3.58 (t, 2H, J = 8.1 Hz), 5.53 (s, 2H), 7.27 (m, 2H), 7.51 (m, ÍH), 7.73 (m, 1H). HRMS calculated for C? 3H19IN2OS? Na 397.0209 (MNa +), found 397.0204. Analysis (C? 3H? 9IN2OSi) C, H, I, N. (c) Intermediate 3c-5-Chloro-l- [2-ft (t-imethylsilanyl) -ethoxymethyl] -3- (trimethylstanyl) -lH-indazolol : A mixture of intermediate Ib (6.25 g, 15.3 mmol), hexamethylditin (10.2 g, 30.5 mmol), and bis (tpfen? L phospho) palladium (II) dibromide (242 mg, 0.306 mmol) in toluene (50 mi) was heated to reflux for 30 minutes, then cooled, filtered, and concentrated. The
i < * • > * 85
purification by chromatography on silica gel (5 to 50% ethyl acetate in hexanes) provided 3c (6.34 g, 93%) as a slightly yellow oil: Rf = 0.21 (5% ethyl acetate / hexanes), Rf = 0.23 (toluene); : H NMR (CDC13) d -0.06 (s, 9H), 0.56 (s with small sidebands, 9H), 0.87 • (t, 2H, J = 8.4 Hz), 3.54 (t, 2H, J = 8.4 Hz) , 5.75 (s, 2H), 7.34 (dd, 1H, J = 8.7, 1.8 Hz), 7.51 (d, 1H, J = 8.7 Hz), 7.66 (d, ÍH, J = 1.8 Hz). Analysis (C? 6H27ClN2OSiSn) C, H, Cl, N. (d) Intermediate 3d-5-Chloro-l- [2- (trimethylsilanyl) -ethoxy? Methyl] -3-. { 1- (2- (trimethylsilyl) -ethoxymethyl] -lfi-benzoimidazol-2-yl] -lfi-indazole: A mixture of 3c (4.47 g, 10.03 mmol), 3b (4.12 g, 11.03 mmol), tetrakis (triphenylphosphmo) palladium (0) (579 mg, 0.50 mmol), and copper (I) iodide (190 mg, 1.00 mmol) in THF i (100 ml) was heated to reflux for 1 hour.Additionally, a catalyst (580 mg, 0.50 g) was added. mmol) and Cul (200 mg, 1.05 mmol), and the reflux continued for 20 hours.After cooling to room temperature, the black precipitate was filtered, the filtrate was concentrated, and the residue was purified by gel chromatography. silica (toluene) to give pure 3d (2.29 g, 43%) as a colorless oil that crystallizes upon settling: mp = 80-82 ° C; Rf = 0.12 (10% ethyl acetate / hexanes), Rf = 0.13 ( toluene);? H NMR (CDC13) d -0.15
(s, 9H), "-0.06 (s, 9H), 0.85 (t, 28, J» 8.1 Hz), 0.91 (t,
• 2H, J = 8.4 Hz), 3.60 (t, 2H, J = 8.4 Hz), 3.61 (t, 2H, J *
, 8.1 Hz), 5.80 (s, 2H), 6.24 (s, 2H), 7.36 (m, 2H), 7.47 (dd, 1H, J = 9.0, 2.1 Hz), 7.57 (d, ÍH, J = 9.0 Hz ), 7.62 (m, ÍH), 7.91 (m, ÍH), 8.73 (d, ÍH, J = 2.1 Hz). Analysis (C26H37ClN402Si2) C, H, Cl, N. (e) Intermediate 3e-5-Phenyl-1 - [2- (trimethylsilanyl) -ethoxymethyl] -3-. { 1- [2- (trimethylsilanyl) * ethoxymethyl] -lH-benzoimidazol-2-yl} -lff-indazole: A mixture of 3d (192.0 mg, 0.363 mmol), phenylboronic acid (66.4 mg, 0.544 mmol), palladium (II) acetate (3.3 mg, 0.0145 mmol), CyMAP-1 (See Oíd et al. J. Am, Chem. Soc., 120, 9722 (1998) with a similar procedure) (3.7 g, 0.0145 mmol), and cesium fluoride (165 mg, 1.09 mmol) in, 1,4-dioxane (3.6 ml) it was heated in an oil bath to 100
° C for 1 hour. After cooling to room temperature, the mixture was diluted with ethyl acetate (20 ml) and filtered to remove the black precipitate. The filtrate was washed with aqueous 1M sodium hydroxide (20 ml), dried over magnesium sulfate, concentrated and purified by chromatography on silica gel (0 to 4% methanol in dichloromethane) to give 3e (107.0 mg, 52%). %) in slightly yellowish oil fort: Rf = 0.26 (dichloromethane); XH NMR (CDC13) d -0.15 (s, 9H), -0.04 (s, 9H), 0.86 (t, 2H, J = 8.1 Hz), 0.95 (t, 2H, J = 8.1 Hz), 3.61 (t, 2H, J = 8.1
Hz), 3.66 (t, 2H, J - 8.1 Hz), 5.85 (s, 2H), 6.28 (s, 2H), 7.37 (m, 3H), 7.49 (t, 2H, J = 7.5 Hz), 7.63- 7.80 (, 5H), 7.91 (m, ÍH), 8.88 (s, ÍH). Analysis (C32H42NO2Si2 * 0.4H2O) C, H, N.
Example 3-3- (1-Benzoimidazol-2-yl) -5-phenyl-1H-indazole: Tetrabutylammonium fluoride (1.0 M in THF, 3.16 mL) and 1,2-diaminoethane (95 mg, 1.58 mmol) were added. to intermediate 3e (90.2 mg, 0.158 mmol). The solution was heated in an oil bath at 70 ° C for 20 hours, then heated to reflux for a further 24 hours. After cooling to room temperature, the solution was diluted with ethyl acetate (30 ml) and washed with a saturated aqueous solution of sodium bicarbonate (20 ml). The organic layer was dried over magnesium sulfate, filtered, it was concentrated and purified by chromatography on silica gel (25 to 50% ethyl acetate in hexanes) to provide 3- (li? -Benzo? midazole-2?) -5-Fenyl-lii-Indazole 2 (33.9 mg, 69%) in the form of a white solid: Rf = 0.30 (50% ethyl acetate / hexanes); XH NMR (CDC13) d 7.21 * (quintet of d, 2H, J = 5.7, 1.5 Hz), 7.39 (t, ÍH, J - 7.4 Hz), 7.53 (t, 3H, J = 7.5 Hz), 7.76 (m , 5H), 8.71 (s, 1H), 13.01 (s, ÍH), 13.70 (s, 1H). HRMS calculated for C2oH? 5N4 311.1297 (MH +), found 311.1283.
Example 4: 3- [3- (lH-Benzoimidazol-2-yl) -lg-indazol-S-yl] -phenol
[dioxane = dioxanoj (a > Intermediate 4a -5- (3-Methoxyphenyl) > ~ 1-. {2- (trimethylsilyl) -ethoxymethyl] -3- { 1- [2- (trimethylsilanyl) - ethoxymethyl] -lH-benzoimidazol-2-yl.}. -lfi-indazole: A mixture of the intermediate 3d (371.5 mg, 0.702 mmol), 3-methoxyphenylboronic acid (160 mg, 1.05 mmol), palladium acetate (II ) (7.9 mg, 0.0355 mmol), CyMAP-1 (See Oyd et al., J. Am. Chem. Soc., 120, 9722 (1998),
"incorporated herein by reference, with a similar procedure) (14 mg, 0.0355 mmol), and cesium fluoride (320 mg,
• 2.11 mmol) in 1,4-dioxane (7.1 ml) was heated in an oil bath at 90 ° C for 22 hours. After cooling until the
} , 89 I. *. At room temperature, the mixture was diluted with ethyl acetate (50 ml) and filtered to remove the black precipitate. * The filtrate was dried over magnesium sulfate, concentrated; and purified by chromatography on silica gel (10% ethyl acetate in hexanes) to give 4a (178.3 mg »42%) as a slightly yellow oil: Rf = 0.20, (10% ethyl acetate / hexanes); XH NMR (CDC13) d -0.14 (s, 9H), -0.03 (s, 9H), 0.86 (t, 2H, J = 8.1 Hz), 0.95 (t, 2H, J- * »8.1 Hz), 3.61 ( t, 2H, J = 8.1 Hz), 3.66 (t, 2H, J »8.1 Hz), 3.91 (s, 3H), 5.85 (s, 2H), 6.27 (s, 2H), 6.93 (ddd, ÍH, J = 1.1, 2.5, 8.1 Hz), 7.27-7.40 (m, 5H), 7.63-7.70 5 (m,, 2H), 7.77 (d, IH, J = 1.5, 8.7 Hz), 7.93 (m, ÍH) 8.87 (e, ÍH). Analysis (C33H44N403Si2) C, H, N. (b) Example 4-3- [3- (l-Benzoimidazol-2-yl) -lH-indazol-5-yl] -phenol: A solution of intermediate substance 4a (88.3 mg, 0.147 mmol) in 1,2-dichloroethane (3.0 ml) was treated with a complex of boron-methyl sulfide trichromide (1.0 M in diechloromethane, 0.588 ml) and heated to reflux for 1 hour. Stirring was continued at room temperature for 16 hours. Water (5.0 ml) was added, and stirring continued for 30 minutes at room temperature. The mixture was diluted with diethyl ether (30 ml) and washed with saturated aqueous sodium bicarbonate solution (20 ml). The organic layer was washed with 1 M NaOH (3 x 30 ml). The
, * & t 1 * í «l
The aqueous wash combination was acidified to pH = 1 with 6 M HCl and extracted sequentially with ether (30 mL), ethyl acetate (30 mL), and dichloromethane (2 x 20 mL). The organic extracts were combined, dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (50 to 75% ethyl acetate in hexanes) to give phenol 4 (11.6 g, 24%) in the form of white powder: lE NMR (DMSO-tíé) d 6.78 (dd, ÍH, J = 1.9, 7.7 Hz), 7.12-7.27 (m, 4H), 7.31 (t, 1H, J = 7.7 Hz), 7.52 (dd, ÍH, J = 2.1, 6.6 Hz), 7.71 (d, 2H, J = 1.1 Hz), 7.76 (dd, ÍH, J = 1.5, 6.8 Hz), 8.67 (s, 1H) , 9.57 (s, ÍH), 13.00 (s, ÍH), 13.68 (s, lH) HRMS calculated for
327. 1246 (MHT), found 327.1231.
Example 5: 3- (1-Benzoimidazol-2-yl) -5- (3-methoxyphenyl) -1H-mdazole
(a) Example 5 -3- (lH-Benzoimidazol-2-yl) -5- (3-methoxyphenyl) -IH-indazole: The same crude reaction mixture from which example 4 was obtained also provided the ethoxyphenyl analogue 5 as follows:
r ^ * í 91
A solution of intermediate 4a (88.3 tng, 0.147 mmol) in 1,2-ylichloroethane (3.0 ml) was treated with a complex of boron tribromide-methyl sulfide (1.0 H in dichloromethane, 0.588 ml) and heated to reflux for 1 hour. The stirring was then continued for 16 hours at room temperature. Water (5.0 ml) was added, and stirring continued for 30 minutes at room temperature. The mixture was diluted with diethyl ether (30 ml), and washed with a saturated aqueous solution of sodium bicarbonate (20 ml). The organic layer was washed with 1 M NaOH (3 x 30 ml). The organic layer was then dried, filtered, concentrated and purified by chromatography on silica gel (50 to 75% ethyl acetate and hexanes) to give 5 (9.3 mg, 19%) as a white powder: XE NMR (DMSO-d6) d 3.86 (s, 3H), 6.98 (dd, ÍH, J = 2.1, 7.8 Hz), 7.19-7.23 (m, 3H), 7.30 (d, ÍH, J = 7.8 HZ), 7.45 (t, 1H, J = 7.8 Hz), 7.52 (dd, ÍH, J = 1.8, 5.7 Ha), 7.75 (, 3H), 8.70 (s, ÍH), 13.00 (s, ÍH), 13.70 (s, lH ). HRMS calculated for C2? H16N4ONa 363.1222 (MNa +), found 363.1225.
¿A «a
• 4- '' r 92
Indazol
[dioxane = dioxane] (a) Intermediate 6a -5- (2-Fluorophen? l) -l- [2- (trimethylsilane) -ethoxymethyl] -3-. { l- [2- (Trimethylsilanyl) -ethoxymethyl] -lH-benzo? m? dazol-2-? l} -lH-? ndazol: A mixture of intermediate substance 3d (419.0 mg, 0.792 mmol), 2-fluorofen? lboromach acid (166 mg, 1.19 mmol), palladium (II) acetate (9.0 mg, 0.04 mmol), CyHUP- l (See Oíd et al., J. Am. Chem. Soc., 120, 9722 (1998) incorporated herein by reference, with a similar process) (16 mg, 0.04 mmol) and cesium fluoride (361 mg, 2.38 mmol ) in 1,4-d-oxane (8.0 ml) was heated in an oil bath at 70 ° C for 1 hour. When only a partial conversion was observed, more palladium (II) acetate (12 mg, 0.05 mmol) and CyMAP-1 (14 mg, 0.035 mmol) were added and stirring continued.
X: ~ '^' X '^' X- '"v.-Ü» 93
. 70 ° C for 16 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 ml) and filtered to remove the black precipitate. The filtrate was dried over magnesium sulfate, concentrated by evaporation. ",, and purified by chromatography on silica gel. (10% ethyl acetate in hexanes) to provide 6a (155.6 mg, 43%) as a colorless oil: XH NMR (CDC13) d - 0.1 (s, ': 9H), -0.03 (s, 9H), 0.86 (t, 2H, J = 8.1 HZ), 0.95 (t, 2H, < j ": - - = 8.1 Hz), 3.61 (t , 2H, J = 8.1 Hz), 3.66 (t, 2H, J = 8.1. 10 Hz), 5.86 (s, 2H), 6.27 (s, 2H), 7.15-7.39 (m, 5H), 7.57- .. 7.75 (m, 4H), 7.88 (m, iH) 8.82 (s, 1H), Analysis / '"' •;, (C32H4i N4? 2Si2 * 0.4H2O) C, H, N. (b) Example 6 3- (1H-Benzoimidazol-2-yl) -5- (2-fluorophenyl) -lH-indazole: 15'-r Example 6 was prepared by a method.
• Synthetic analogous to that of example 3. Treatment of intermediate substance 6a with tetrabutylammonium fluoride gave 6 (21.2 mg, 18%) as a color powder. "White: Rf = 0.35 (50% ethyl acetate / hexanes ); XH NMR; 20;; -'-. (DMSO-dβ) d 7.20 (m, 2H), 7.33-7.52 (m, 4H), 7.62- (m, 2H), 7.74 (m, 2H), 8.65 (s, ÍH), 13.02 (s, ÍH), 13.75 (s, lH) HRMS calculated for C20H14FN4 329.1202 (MH +) "found 329.1212 Analysis (C20H13FN4 • 1.1H20) C, H, N.
*?: hí.
*% 94
Example 7 ': 3- (1-Benzoimidazol-2-yl) -5- (4-methoxyphenylene) -1 indazole
(a) Intermediate 7a '- 5-Iodo-3"- ((E) - 15 styryl) -1- (2-tr? met? ls? lanil-ethoxy? met l) -IH-indazole: The intermediate 7a 'was prepared with 5-nitromdazole (Acros organics, a division of Fisher Scientific, Pittsburgh, PA) in five steps according to the method used to prepare 6-Iodo-3- ((E) -styryl) -1- (2 - 0 trimethylsilanyl-ethoxymethyl) -lif-mdazole from 6-mtromdazole (Found in: Kania, Braganza, et al., Patent application "Compounds and Pharmaceutical Compositiones for Inhibitmg Protein Kmases, and Methods for Their Use", page 1 , 52, line 10 to page 53, line 26, and page 59, line 16 to page - 5 60, line 4, US Provisional Serial No. 60 / 142,130,
i v 4 95
filed on July 2, 1999, incorporated herein by reference in its entirety): XH NMR (CDC13) d -0.06 (s, 9fej, 0.89 (t, 2H, J = 8.4 Hz), 3.57 (t, 2H, J = 8.4 Hz), 5.70 (S, 2H), 7.29-7.44 (m, 6H), 7.59 (d, 2H, J - 7.0 Hz), 7.67 (dd, ÍH, J = 8.7, 1.5 Hz), 8.36 (s, ÍH) (b) Intermediate 7b '- 5-Iodo-l- (2 * trimethylsilane-ethoxymethyl) -lH-indazole-3-carbaldehyde: Ozone bubbles were added to a solution of 5-iodo-3-styrene 2-SEM-mdazole 7a '(4.93 g, 10.35 mmol) in diechloromethane (500 ml) at -78 ° C. After 20 minutes the color of the solution changed from orange to deep blue.The mixture was purged with Argon for 30 minutes to remove the excess ozone, then dimethylsulfide (1.29 g, 20.7 mmol) was added, the cold bath was removed and the stirring continued for about 2 hours, until the internal temperature reached 15 ° C. washed with water (2 x 200 ml), dried over magnesium sulfate, filtered and concentrated. After chromatography on silica gel (10% ethyl acetate in hexanes) provided the aldehyde 7b '(2.74 g, 66%) as a yellow oil: XH NMR (CDC13) d -0.05 (s, 9H) , 0.89 (t, 2H, J = 8.4 Hz), 3.56 (t, 2H, J = 8.4 Hz), 5.79 (s, 2H), 7.43 (d, ÍH, J = 8.7 Hz), 7.76 (dd, ÍH, J = 8.8, 1.5 Hz), 8.71 (s, 1H), 10.22 (s, ÍH).
^ f (c) Intermediate substance 7 < 2'-3- (lH-Benzo? M? Dazol-2-? L) -5-iodo-l- (2-tr? Methyl? Lanyl-ethoxymethyl) -lH-mdazole: > To a solution of aldehyde 7b '(2.74 g, 6.81 irniol.ff in DMF (130 ml) was added 1,2-phenolylenediamine (0.74 g, 6.01 mmol) and elemental sulfur (0.26 g, 8.2 mmol). The mixture was heated in an oil bath at 95 ° C for 14.5 hours / cooled to room temperature, and diluted with ethyl acetate (500 ml) The solution was washed with a mixture of aqueous sodium chloride saturated (100 ml) and water f (100 ml) The organic layer was then washed with saturated aqueous sodium licarbonate (100 ml), followed by water (100 ml), dried over magnesium sulfate, filtered, The mixture was concentrated and purified by chromatography on silica gel (20% ethyl acetate in hexanes) to give impure 7q 'as a pale yellow solid, and precipitation in chloroform / hexanes gave pure 7c' (2.15 g, 64%). %) in the form of white powder: Rf = 0.23 (20% ethyl acetate / hexanes); XH NMR (DMS0-d6) d -0.12 (s, 0), 0.82 (t, 2H, J = 7.9 Hz), 3.59 (t, 2H, J = 7.9 Hz), 5.87 (s, 2H), 7.23 (m, 2H), 7.52 (d, 1H, J = 7.2 Hz), 7.73- 7.84 (m, 3H), 8.94 (s, ÍH), 13.13 (s, 1H). HRMS calculated for C2oH23IN4Os? 491.0759 (MH +), found 491.0738.
Y*
(d) Intermediate 7d'-3- < lH- -Benzo? p? idazol-2-yl) -5- (4-methoxyphenyl) -1- (2-trimethylsilaftiJ.- ethoxymethyl) -lfi-indazole: A 2M aqueous sodium carbonate solution (6.4 ml) was added to a solution of 7c '(2.50 g, 5.10 mmol), 4-methoxy phenylboronic acid (1.01 g, 6.63 mmol) and tetrakis (triphenylphosphmo) palladium (0.59 g, 0.51 mmol) in 1,4-dioxane (35 ml) and methanol (15 ml). The mixture was heated to reflux for 5 hours, then cooled and partitioned between ethyl acetate (300 ml) and a mixture of saturated aqueous sodium chloride (100 ml) and water (100 ml). The organic layer was dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (20% ethyl acetate in hexanes) to give a dark brown solid. The precipitation in dichloromethane / hexanes gave pure 7d '(948.6 mg, 40%) as a white powder: f = 0.13 (20% ethyl acetate / hexanes); XH NMR (DMSO-d6) d -0.10 (s, 9H), 0.85 (t, 2H, J = 7.9 Hz), 3.63 (t, 2H, J = 7.9 Hz), 3.82 (s, 3H), 5.91 (s) , 2H), 7.10 (d, 2H, J = 8.7 Hz), 7.23 (m, 2H), 7.43 (m, 1H), 7.54 (d, ÍH, J - 6.8 Hz), 7.69 (d, 2H, J = 8.7 Hz), 7.80 (m, ÍH), 7.92 (d, ÍH, J = 8.9 Hz), 8.70 (s, ÍH), 13.08 (s, ÍH). (e) Example 7'-3- < lH-Benzoimidazol-2-yl) -5- < 4metoXi enyl) -lfí-indazol:
A solution of intermediate 7d '(148.4 mg, 0.315 mmol) in ethyl acetate (15 ml) at -78 ° C was treated with boron tribromide (1.0 M in dichloromethane, 4.73 ml). The solution was stirred for 17 hours, allowing the mixture to gradually warm to reach room temperature. Water (10 ml) was added, and the mixture was stirred at room temperature for 6 days. The solution was treated with a 3 M sodium hydroxide solution to a pH of 10, then extracted with ethyl acetate (3 x 20 ml). The combined organic extracts were dried over magnesium sulfate, filtered and concentrated. Purification by chromatography on silica gel (50% ethyl acetate in hexanes) provided 7 '(60.5 mg, 56%) gn as a white solid: Rf = 0.21 (50% ethyl acetate / hexanes); 1H NMR (DMSO-d6) d 3.82 (s, 3H), 7.08 (d, 2H, J = 8.9 Hz), 7.21 (m, 2H), 7.53-7.78 (m, 6H), 8.66 (s, ÍH), 12.96 (s, ÍH), 13.63 (s, ÍH). Analysis (C2? H? 6N4O-0.25CH2C12) C, H, N.
2i •
Example 8 ': - [3- (lH-Benzo? M3.dazol-2 »-? L) -lH- ^ ndazol-5? L] -phenol xfa >
A mixture of 7 'anisole (44.6 mg, 0.131 mmol) and pipdin hydrochloride (912 mg, 7.9 mmol) was heated in an oil bath at 180 ° C for 3 hours. Pindma salt 0 is liquid at this temperature. After cooling to room temperatureThe mixture was partitioned between ethyl acetate (20 ml) and saturated aqueous sodium bicarbonate (15 ml). The aqueous layer was then extracted further with ethyl acetate (3 x 20 ml). The combined organic extracts were dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (50% ethyl acetate / hexanes) to give pure phenol 8 '(29.4 mg, 69%) as of a pale yellow solid: Rf = 0 0.23 (60% ethyl acetate / hexanes); XH NMR (DMSO-ds) d 6.91"(d, 2H, J = 8.4 Hz), 7.21 (m, 2H), 7.53 (m, 3H), 7.68 (s, 2H), 7.75 (d, ÍH, J = 6.9 Hz), 8.61 (s, 1H), 9.53 s, ÍH), 12.98 (s, ÍH), 13.63 (s, 1H) HRMS calculated for C20H14N4O 327.1256 (MH +), found 327.1253 Analysis (C20H? 3N4O »0.8
5 DMSO) C, H, N.
* < * - «, *
?
, r%. * t phenyl) -lj-T-indazole
(a) Intermediate 9a'- 3-Methoxy-2-metuphenylamin: A suspension of 2-met? i-3-n? troanisole (Aldrich Chemicals) (8.87 g, 53 mmol) and palladium on 10% carbon (800 mg) in ethanol (400 ml) was stirred at hydrogen or 40 psi for 1 hour. After being filtered through a pad of Celite, the solution was concentrated and purified by chromatography on silica gel (30% ethyl acetate in hexanes) to provide aniline 9a '(6.94 g, 95%) as an oil slightly orange in color: f =
0. 20 (25% ethyl acetate / hexanes); XW WÍW (DMSO-d) d 1,88 (s, 3H), 3.68 (s, 3H), 4.74 (br s, 2H), 6.17 (d, ÍH, J = 8.1 Hz), 6.26 (d, ÍH, J = 8.1 Hz), 6.81 (t, ÍH, J = 8.1 Ht) * Analysis (C8HuNO) C, H, N. (b) Intermediate 9b'-l-Iodo-3-methoxy-2-methyl-benzene: 3-Methoxy? -2-met? L-fen? Lamma was diazotized (5.28 g, 38.5 mmol) according to the method of DeGra, et al. [DeGra,,, J.I .; Brown, V.H .; Colwell, .T .; Morpson, NE, J. Med. Chem., 17, 762 (1974)], incorporated herein by reference, which yielded aryl iodide 9b '(4.17 g, 44%) as a yellow oil: Rf = 0.53 (10% ethyl acetate / hexanes); XH NMR (CDC1) d 2.36 (s, 3H), 3.80 (s, 3H), 6.81 tm, 2H), 7.42 (dd, ÍH, J = 7.5, 1.5 Hz). (c) Intermediate substance 9c'- 2- < 3-Methoxy-2-pt txl-phenyl) -4,4,5,5-tetramet? L- [1,3,2] dioxaborolan: l-Iodo-3-methox? -2-met l-benzene was dissolved
(3.80 g, 15.3 mmol), Bis (pmacolato) diborro (4.28 g, 16.8 mmol), potassium acetate (4.51 g, 46.0 mmol), and 1,1'-bis (diphenylphosphmo) ferrocene dichloropalladium (II) (625 mg, 0.766 mmol) in DMSO (70 ml) and heated to 80 ° C internal temperature for 1 hour. After cooling, the mixture was diluted with toluene (400 ml), washed with water (2 x 100 ml), dried over magnesium sulfate, filtered and concentrated. Purification by gel chromatography
- rm t
t silica (5 to 20% ethyl acetate in hexanes) provided "boronic ester 9c '(19.6 g, 52%) as a white crystalline solid: Rf = 0.27 (5% ethyl acetate / hexanes); AH NMR ( CDC13) d 1.34 (s, 12H), 2.42 (s, 3H), 3.81 (s, 3fi) «5 € .91 (d, 1H, J = 8.1 Hz), 7.14 (t, ÍH, J = 7.8 Hz) , 7.34 (d, * *,? ~. ÍH, J - 7.5 Hz) Analysis (C? 4H2? B03) C, H. (d) Intermediate 9d'-3- (lH-Benzoimidazol-2-yl) -5- (3-methoxy-2-methyl-phenyl) -1- (2-trimethylsilanyl-ethoxymethyl) -lff-indazole: 0 A solution of aqueous sodium carbonate (2M, 2.65 ml) was added to a solution of 7c. '(519.4 mg, 1.06 mmol), boronic ester 9c' (262.8 mg, 1.06 mmol), and 1,1'-bis (diphenylphosphmo) ferrocene dichloropalladium (II) (43.2 mg, 0.053 mmol) in DMF (12 ml). The mixture was heated in an oil bath at 75 ° C for 4.5 hours, then cooled and partitioned between ethyl acetate (100 ml) and a mixture of saturated aqueous sodium chloride (50 ml) and water (50 ml). The organic layer nica dried over magnesium sulfate, filtered, concentrated, but 1H NMR of this crude material showed only 60% 0 conversion. The crude mixture was redissolved in DMF (12 ml) and additional boronic ester * (253 mg, 1.01 mmol), catalyst (140 mg, 0.17 mmol) and sodium carbonate solution (2.65 ml) were added. Stirring continued at 80 ° C for 15.5 hours. After the same process as above, XH NMR crude showed less than 5% of
7c 'remnant. Purification by chromatography on f fc * - - *; of silica (10 to 30% ethyl acetate in hexanes) gives 9 d '(410.7 mg, 80%) as a white foam * Rf = 0.37 (30% ethyl acetate / hexanes, equal to 7c'); XH MÉJ (DMSO-de) d -0.10 (s, 9H), 0.85 (t, 2H, J = 7.9 Hz), 2.06 (s, 3H), 3.64 (t, 2H, J = 7.9 Hz), 3.85 (s) , 3H), 5.92 (s, 2H), 6.92 (d, 1H, J = 7.2 Hz), 7.02 (d, 1H, J = 8.3 Hz), 7.17-7.30 (, 3H), 7.47-7.53 (m, 2H ), 7.70 (d, 1H, J = 7.7 Hz), 7.90 (d, 1H, J = 8.7 Hz), 8.45 (s, ÍH), 13.09 (s, 1HH-Analysis (C28H32N? 2SY O. 3H2?) C, H, N. (e) Example 9'-3- (1H-Benzoimidazol-2-yl) -5- (3-methoxy-2-methyl-phenyl) -IH-indazole: In a manner analogous to example 3 , the treatment of intermediate 9d * with fluoride and tetrabutylamome gave 9 '(47.2 mg, 30%) as white powder: Rf = 0.23 (5% methanol / dichloromethane); XH NMR (DMSO-de) d 2.07 (s, 3H), 3.85 (s, 3H), 6.91 (d, ÍH, J = 7.4 Hz), 7.01 (d, 1H, J = 8.1 Hz), 7.24 (m, 3H), 7.39 '(d4 / 1H, J = 8.7, 1.5 Hz), 7.50 (m, ÍH), 7.68 (d, 2H, J - 8.5 Hz), 8.40 (s, ÍH), 12.96 (s, ÍH) , 13.66 (s, ÍH). Analysis (C22H? 8N4O'0.3H2O) C, H, N.
?
Example 10 ': 3- [3- (lH-Benzoimidazol-2-j.l) -lii-indazol-5 »l]'? Xr¡
Phenol 10 'was prepared by a synthetic method analogous to that of phenol 8', by treatment of 9 * (31.6 mg, 0.089 mmol) with pyridine hydrochloride provided 10 'phenol (20.8 mg, 70%) in the form of a solid whitish in color: Rf = 0.21 (60% ethyl acetate / hexanes); "H NMR (DMS0-d6) d 2.04 (s, 3H), 6.75 (d, ÍH, J - 7.0 Hz), 6.85 (d, ÍH, J = 7.7 Hz), 7.08 (t, 1H, J = 7.7 Hz ), 7.19 (qumt, 2H, J = 7.7 Hz), 7.39 (dd, 1H, J = 8.7, 1.5 Hz), 7.50 (d, ÍH J = 7.5 Hz), 7.68 (m, 2H), 8.39 (s, ÍH), 9.39 (s, ÍH), 12.95 (s, 1H), 13.64 (s, 1H) HRMS calculated for C2? H? 6N40 341.1402 (MH "), found 341.1410. Analysis (C2? H? 6N4O'1.0MeOH) C, H, N.
Example 11: 5- (2-Methylphenol) -3-phen l-lH-indazole
• \ »'JT * 105 I
OH
11e 11
[Toluene = Toluene, Dioxane = Dioxane] (a) Intermediate substance lla - 5-N? Tro-3-phenyl-1-mdazole: To a solution of 2-chloro-5-n? Trobenzophenone (15 g, 57 mmol) in ethanol (300 ml) was added hydracma monohydrate (50 ml, 1 mol). The resulting solution was stirred overnight (16 hours) at room temperature, then poured into water (2 1) and stirred for another 2 hours. The precipitate that formed was collected by filtration, washed with water (2 x 100 ml), and dried with air to provide
5-N? Tro-3-phenol-lH-mdazole (13.1 g, 80%) in the form of a yellow solid: XH NMR (DMSO-d6) d 7.48 (tt, 1H, J = 1.3 , 7.4, Hz), 7.58 (dd, 2H, J = 7.1, 7.4 Hz), 7.78. { $, 1H, J = 9.2 Hz), 8.01 (dd, 2H, J = 1.3, 7.1 Hz), 8.25 (dd, "ÍH, J = 2.1, 9.2 Hz), 8.91 (d, ÍH, J = 2.1 Hz) 13.88 (s 1H) Analysis (C? 3H9N302) C, H, N. (b) Intermediate llb-5-N? Tro-3-phen? II- [2- (trimethylsilanyl) ethoxymethyl] lH-mdazole: Dnsopropylethylamine (15 ml, 86.1 mmol) was added dropwise to a solution of 5-n? Tro-3-phen? Ll # -indazole (13 g, 54.3 mmol) and 2- (trimethylsilyl) ethoxymethyl chloride (15 g. 90 mmol) in acetonitrile (400 ml) The resulting reaction mixture was stirred at room temperature for 2 hours, then poured into water (11) and extracted with ethyl acetate (3 x 300 ml). The combined organic extracts were dried over sodium sulfate and concentrated, the residue obtained was dissolved in toluene (40 ml), and 2- (trimethylsilyl) ethoxymethyl chloride (3 ml, 17 mmol), tetrabutylammonium bromide (500 ml) was added to this solution. mg) and silica (40 g) This mixture was stirred overnight at room temperature and Then it leaked. Subsequently the filtrate was concentrated. Chromatography was performed on silica gel (5% ethyl acetate / hexanes), which yielded llb (15 g, 75%) in the form of a yellow solid: XH NMR (DMSO-de) d -
0. 11 (s, 9 H) 0.83 (t, 2H, J = 7.9 Hz), 3.62 (t, 2H, J = * 7.9 Hz), 5.91 (s, 2H), 7.52 (tt, ÍH, J = 0.7, 7.4 Hz), 7.60 (dd, • 2H, J = 7.1, 7.4 Hz), 8.00 (d, ÍH, J = 9.2 Hz), 8.02 (dd, 2H, J = 0.7, 7.1 Hz), 8.35 (dd, ÍH, J = 2.1, 9.2Hz), 8.91 (d, 1 ?, J = 2.1 Hz). (c) Intermediate 11c-5-Amino-3-phenyl-1- [2- (tnmet? lysian? l) ethoxy? met? l] -lH-? ndazole: A mixture of S-nitro-S-phenyl- l-1 [2- (trimethylsilanyl) ethoxymethyl] lH-mdazole lb (14 g, 37.9 mmol) and 10% palladium on carbon (1 g) in ethyl acetate (500 ml) was stirred under an atmosphere of hydrogen during the night. The reaction mixture was filtered through celite, then concentrated to provide 11c (12.2 g, 95%) in the form of a white solid: XH NMR (DMSO-d6) d -QJ12 (s, 9 H) , 0.80 (t, 2H, J = 8.0 Hz), 3.54 (t, 2H, J = *, i8.0
-Hz), 5.01 (br s, 2H), 5.67 (s, 2H), 6.89 (dd, ÍH, J - 1.8,
8. 8 Hz), 7.12 (d, ÍH, J = 1.8, Hz), 7.37 (tt, 1H, J = 0.5,
7. 4 Hz), 7.47 (d, ÍH, J = 8.8 Hz), 7.50 (dd, 2H, J = 7.2,
7. 4 Hz), 7.87 (dd, 2H, J = 0.5, 7.2 Hz). (d) Intermediate substance lid-5-i © do-3-phenyl-l- [2- (tr? methylsilaml) ethoxy? met? l] -lH-mdazole: Intermediate He was dissolved (12 g, 35.3 mmol) in a mixture of acetic acid (300 ml) and water (50 ml). The mixture was cooled in an ice bath and salt at a temperature of -5 ° C. A mixture was slowly added
* - & 108
solution of sodium nitrite (4.5 g, 65.2 mmol) in water, (10 ml) at a rate such that the reaction temperature could be maintained below 3 ° C. The resulting diazonium solution was stirred at a temperature of 0 ° C for 20 minutes. A solution of potassium iodide (6.5 g, 39.2 mmol) in water (10 ml) was slowly added to the reaction, again at such a rate that the reaction remained below 3 ° C. Then the reaction was allowed to stir overnight, gradually equilibrated until reaching t at room temperature. The crude reaction mixture was poured into water (300 ml) and extracted with ethyl acetate (2 x 500 ml). The combined organic extracts were dried over sodium sulfate and concentrated. Chromatography was performed on silica gel (5% ethyl acetate / hexanes), which afforded lid (4 g, 25%) in the form of a yellow oil: aH NMR (DMSO-de) d -0.12 (s) , 9 H), 0.83 (t, 2H, J = 7.9 Hz), 3.57 (t, 2H, J * 7.9 Hz), 5.80 (s, 2H), 7.45 (tt, ÍH, J = 1.3, 7.5 Hz), 7.54- (dd, 2H, J »7.1, 7.5 Hz), 7.67 (d, ÍH, J = 8.8 Hz), 7.75 (dd, ÍH, J = 1.5, 8.8 Hz), 7.94 (dd, 2H, J = 1.3 , 7.1 Hz), 8.40 (d, ÍH, J = 1.5 Hz). (e) Intermediate substance He-5 - (^ - Methylfeml) -3-pheny1-1- [2 - (trimethylsilanyl) ethoxymethyl] -lphi-indazole:
Aqueous saturated sodium bicarbonate (2 ml) was added to a mixture of the intermediate lid (130 mg 0.3 mmol), 2-methylphenylboronic acid (120 mg, 0.9 mmol) and tetrakis (triphenylphosphine) palladium (0) (25 mg, 0.02 mmol) in 1,4-dioxane (10 ml). The resulting reaction mixture was heated in an oil bath at a temperature of 90 ° C for 18 hours. After cooling to room temperature, the crude reaction mixture was poured into water (50 ml) and extracted with ethyl acetate (2 x 25 ml). The combined organic extracts were dried over sodium sulfate and concentrated. Chromatography was carried out on Cfel * (silica (10% ethyl acetate / hexanes), which yielded He (100 mg, 84%) in the form of a whitish solid: XH NMR (DMSO-de) d - 0.10 (s, 9 H), 0.85 (t, 2H, J - 8.0 Hz), 2.24 (s, 3H), 3.62 (t, 2H, J - 8.0 Hz), 5.85 (s, 2H), 7.29 (m , 4H), 7.42 (tt, ÍH, J = 1.4, 7.4 Hz), 7.47 (dd, ÍH, = 1.5, 8.3 Hz), 7.52 (dd, 2H, J = 7.1, 7.4 Hz), 7.84 (d, ÍH , J = 8.3 Hz), 7.93 (d, 1H, J = 1.5 Hz), 7.99 (dd, 2H, J = 1.4, 7.1 Hz). (F) Example 11-5- (2-Methylphenyl) -3-phenyl -lH-indazole: Tetrabutylammonium fluoride (1.0 M in THF, 2 ml) was added to a solution of the intermediate He (100 mg, 0.24 mmol) in tetrahydrofuran (5 ml) This solution was heated in an oil bath at a temperature
X 110
60 ° C for 18 hours, then poured into water (25 ml) and extracted with ethyl acetate (2 x 25 ml). The extracts.
The combined organics were dried over sodium sulfate and concentrated. Chromatography was performed on silica gel (20% ethyl acetate / hexanes), which gave 5- (2-methylphenyl) -3-phenyl-1H-indazole 11: (55 mg, 80%) in the form of a solid. whitish color: XH NMR (DMSO-de) d 2.24 (s, 3H), 7.28 (m, 4H), 7.37 (dd, 1H, J = 1.5, 8.6 Hz), 7.38 (tt, ÍH, J = 1.4, 7.5 Hz), 7.50 (dd, 2H, J = 7.1, 7.5 Hz), 7.64
0 (d, ÍH, J = 8.6 Hz), 7.91 (d, ÍH, J = 1.5 Hz), 7.99 (dd, H, J = 1.4, 7.1 Hz), 13.30 (s, 1H). 7 Analysis (C20H16N2 »0.25HaO) C, H, N.
Example 12 3-Phenyl-5- [2- (trifluoromethyl) phenyl3-lH ~
5
> . ". i I 111
(a) Intermediate 12a-3-Phenyl-5- [2 - * - (trifluoromethyl) phenyl] -1- [2-trimethylsilanyl) ethoxymethyl-1-indazole:
The intermediate solution 12a was prepared through a synthetic method analogous to the intermediate substance. The palladium-catalyzed coupling of the intermediate substance lid with 2- (trifluoromethyl) phenylboronic acid resulted in 12a (48%) of a white solid. : XH NMR (DMSO-d6) d - 0.12 (S, 9H), 0.87 (t, 2H, J = 8.1 Hz), 3.72 (t, 2H, J = 8.1 Hz), 5.62 (s, 2H), 7.32 ( m, 1H) 7.38 (tt, ÍH, J = 0.8, 7, '* Hz), 7.48 (dd, 2H, J = 7.1, 7.4 Hz), 7.51 (m, ÍH), 7.63 (<; M, ~ ÍH, J = 7.2, 7.7 Hz), 7.66 (dd, ÍH, J = 1.6, 8.6 Hz), 7.75 (m, ÍH), 7.82 (d, ÍH, J = 8.6 Hz), 7.91 (d , ÍH, J = l.ß Hz), 7.96 (dd, 2H, J - 0.8, 7.1 Hz). (b) Example 12-3-Phenyl 5- [2- (trifluoromethyl) phenyl] -lH-indazole: The substance of Example 12 was worked up in a similar manner to Example 11. Treatment of 12a with tetrabutylammonium fluoride resulted in 3 -Fenyl 5- [2-trifluoromethyl) phenyl] -IH-indazole 12 (74%) as a solid * * white: 1H NMR (DMSO-d6) d 7.34 (m, 1H), 7.38 (tt, 1H, J * 1.3, 7.3 Hz), 7.49 (dd, 2H, J = 7.1, 7.3Hz), 7.52 (m, ÍH) «. 7.62 (dd, 1H, J = 7.4, 7.7 Hz), 7.65 (dd, ÍH, J = 1.9, 8.6 *
Hz), 7.73 (dd, J = 7.2, 7.5 Hz), 7.85 (d, ÍH, J = 8.6 Hz * -,? R / * '»f - t
2. 22 (s, 3H), 3.62 (t, 2H, J = 8.0 Hz), 3.73 (t, 2H, J »8.1 Hz), 5.25 (s, 2H), 5.85 (s, 2H), 6.93 (dd, ÍH , J = 2.6, 8.3 Hz), 6.98 (d, ÍH, J = 2.6 Hz), 7.22 (d, ÍH, J = 8.3 Hz),? ! 7.43 (tt, 1H, J = 0.9, 7.7 Hz), 7.45 (dd, ÍH, J = 1.3, 8.6 Hz), 7.52 (dd, 2H, J = 7.2, 7.7 Hz), 7.82 (d / ÍH, J «8.6 Hz), 7.89 (d, ÍH, J = 1.3 Hz), 7.99 (dd, 2H, J = 0.9, > 7.2Hz). (b) Example 13-5- (4-Hydroxy-methyl-1-phenyl) -3-feml-lH-indazole: The substance of Example 13 was prepared in a manner similar to Example 11. Treatment of 13a with tetrabutylammonium fluoride gave 5- (4-hydroxy-2-methyl-lfene) -3- phenyl-lH-indazole 13 (75%) as a pale yellow solid: XH NMR (DMSO-d6) d 2.17 (s, 3 H), 6.66 (dd, ÍH, J = 2.3, 8.2Hz), 6.70 (d, ÍH, J = 2.3 Hz), 7.08 (d, ÍH, J = 8.2Hz), 7.32 (dd, 1H, J = 1.5, 8.6 Hz), 7.39 (tt, 1H, J = 1.4, 7.7 Hz), 7.50 (dd, 2H, J = 7.2, 7.7 Hz), 7.59 (d, 1H, J = 8.6 Hz), 7.83 (d, ÍH, J = 1.5 Hz), 7.97 (dd, 2H, J * 1.4, 7.2Hz) 9.28 (s, ÍH), 13.22 (s, ÍH). Analysis (C20 H16 'N2 O »0.8 H20) C, H, N.
Example 14: 3-Phenol-5- (pyrid-4-yl) -lH-indazole
*
14 (a) Intermediate 14a-3-phenyl? -5- (p? R? D-4-yl) -1- [2-tr? Met? L?? L? L) ethoxymethyl] -lfl-indazole: The substance of Example 14a was prepared in a manner similar to Example He. The palladium-catalyzed coupling of the intermediate substance Hd with p? Pdm-4-boron acid co, gave substance 14a (76%) as a white solid: NMR (DMSO-d6) 6 - 0.11 (s, 9H), 0.84 (t, 2H, J = 7.9 Hz), 3.62 (t, 2H, J = 7.9 Hz), 5.86 (s, 2H), 7.46 (ct, ÍH, J = 1.1, 7.4 Hz ), 7.51 (d, ÍH, J = 8.3 Hz), 7.56 0 (dd, 2H, J = 7.1, 7.4 Hz), 7.80 (dd, ÍH, J = 1.4, 8.3 Hz), 7.85 (dd, 2H, J = 1.6, 4.5 Hz), 8.07 (day, 2H, J = 1.1, 7.1 * * Hz), 8.41 (d, ÍH, J = 1.4 Hz), 8.64 (dd, 2H, J = 1.6, 4.5 Hz).
Item
116
(a) Intermediate 14b-3 Phenyl-5- (pyrid-3-yl) -1- [2- (trimethylsilanyl) ethoxymethyl] -lff-indazole: Substance 14b 'was prepared in a manner similar to the intermediate substance He . The palladium-catalyzed coupling of the intermediate substance lid with pyridin-3-boronic acid gave substance 14b '(66%) as a white solid: XH NMR (DMSO-d6) d -0.10 (s) , 9H), 0.83 (t, 2H, J = 7.9 Hz), 3.63 (t, 2H, J * 7.9 Hz), 5.86 (s, 2H), 7.43 (tt, 1H, J = 1.2, 7.5 Hz), 7.51 (dd, ÍH, J = 4.7, 10 8.0 Hz), 7.54 (dd, 2H, J = 7.1, 7.5 Hz), 7.65 (d, ÍH, J = 8.6 Hz), 7.73 (dd, ÍH, J = 1.5, 8.6 Hz), 8.07 (dd, 2H, J = 1.2, 7.1 Hz), 8.18 (ddd, ÍH, J = 1.6, 2.3, 8.0 Hz), 8.32 (d, ÍH, J = 1.5 Hz), 8.56 (dd, 1H, J = 1.6, 4.7 Hz), 8.90 (d, ÍH, J = 2.3 Hz). 15, (b) Example 14b-3-Phenyl-5- (pyrid-3-yl) -l-indazole: Similarly to Example 11, treatment * e 14b 'with tetrabutylammonium fluoride provided 3-phenyl-5- (py d-3-yl) -lH-indazole 14b (79%) as a white solid: XH NMR (DMS0-d6) d 7.41 (tt, ÍH, J = 1.3, 7.4 Hz), 7.49 (dd) , ÍH, J = 4.7, 7.9 Hz), 7.53 (dd, 2H, J = 7.1, 7.4 Hz), 7.70 (d, 1H, J = 8.7 Hz), 7.76 (dd, ÍH, J = 1.5, 8.7 Hz) , 8.08 (dd, 2H, J = 1.3, 7.1 Hz), 8.17 (ddd, ÍH, J = 1.7, 2.0, 7.9 Hz), 8.31 (d, ÍH, J = 1.5 Hz) 8.56 (dd, ÍH, J =
ai s 117
1. 7, 4.7 Hz), 8.99 (d, 1H, J = 2.0 Hz), 13.35 (s, Iph). Analysis (Cis H13 N3) C, H, N.
• / *
Example 15: 2-Met? L-3- [3- ((E) -est? Ril) -lff-índagol-S-illfgrtol
(a) Intermediate 15a '-5- (3-Methoxy-2-methyl-phenyl) -3- ((E) -styryl) -1- (2-tpmet ls? lan? l-ethoxymethyl) -lfi-indazole Intermediate 15a 'was prepared from substance 7a' (571.8 mg, 1.42 mmol) through a synthetic method which is analogous to 9d ', which provided an analogue of styryl 15a' (442.5 ramol, 66% ) in the form of a yellow oil: 2H NMR (DMSO-d6) d -0.10 (s, 9H), 0.83 (t, 2H, J = 8.1 Hz), 2.07 (s, 3 H), 3.58 (t, 2H, J -7.9 Hz), 3.84 (s, 3H), 5.79 (s, 2H), 6.91 (d, 1H, J = 7.6 Hz), 6.99 (d, ÍH, J = 8.3 Hz), 7.22-7.41 ( m, 5H), 7.56 (d, -2H, J = 5.1 Hz), 7.70-7.78 (m, 3 H), 8.09 (s, ÍH).
(b) Intermediate 15b '-5- (3-Met? x? -2-methyl-phenyl) -3- ((E) -styryl) -lfl-mdazole: Substance 15b' was prepared in a manner similar to Example 3. Treatment of 15 a '(211.4 mg, 0.449 mmol) gave 15b' (132.7 mg, 87%) as a white foam: Rj = 0.38 (50% ethyl acetate / hexanes): XH NMR ( DMSO-de) 5 1.98 (s, 3 H), 3.84 (s, 3 H), 6.91 (d, ÍH, J = 7.5 Hz), 6.98 (d, ÍH, J = 8.1 Hz), 7.21-7.61 (m , 8H), 7.70 (d, 2H, J = 7.4 Hz), 8.05 (s, ÍH), 13.18 (s, ÍH). HRMS calculated for C 23 H 20 N 2 O 341.1648 (MH +), found 341.1638. Analysis (C23H2oN20 »0.2H20) C, H, N. (c) Example 15-2-Meth1-3-. { 3- ((E) -est? Nl) -1H-? Ndazol-5? LJ-phenol: The phenol 15 'was prepared in a manner similar to the phenol 8'. The treatment of intermediate 15b '(63.1 mg, 0.185 mmol) with pyridine hydrochloride afforded phenol 15' (39.7 mg, 66%) as a whitish solid: R = 0.24 (50% ethyl acetate / hexanes): AH NMR (DMSO-de) d 2.05 (s, 3H), 6.74 (d, 1H, J = 7.5 Hz), 6.83 (d, 1H, J = 7.9 Hz), 7.05 (t, ÍH, J = 7.7 Hz) , 7.25-7.62 (m, 7 H), 7.70 (d, 2H, J, '= 7.2Hz), 8.03 (s, ÍH), 9.34 (s, 1H), 13.16 (s, ÍH). HRMS calculated for C22H18N20 327.1497 (MH *), found 327.1487. Analysis (C22H? 8N2O »0.5H2O) C, H, N.
of ethylhexanes (2: 1), s MgSO4 and concentrated. It is with hexanes-Et20 (in one
1. 09 g of 16a (55%). XH NMR (CDC13) d 8.51 (s, ÍH), 7.8 & (d, - '$ 1H, J = 8.4 Hz), 7.64 (d, ÍH, J = 7.2Hz), 7.58 (m, 2H), 7.48 (s, ÍH), 7.41 (m, 3H), 7.31 (m, ÍH), 3.59 (t, 2H, J = 7.3 Hz), 1.41 (s, 12H), 0.91 (t, 2H, J = 8.3 Hz), -0.06 (s, 9H). Analysis (C27H37N203SiB) C, H, N. (b) Intermediate 16b-4- [3- ((E) -Styryl) -l- (2-trimethylsilanyl-ethoxymethyl) -lH-indazol-5-yl] -isoquinoline : Intermediate 16a (0.218 g, 0.47 mmol), 4-bromoisoquinoline (0.082 g, 0.39 ramol) and Na2C03 (0.1 g, 0.95 mol) were combined with 3 ml of DME and 0.5 ml of water and the mixture was degassed and it was purged with argon. Tetrakis (triphenylphosphino) palladium (0) (0.023 g, 0.02 mmol) was added, the mixture was re-degassed and then heated to reflux under argon for 15 hours. Aqueous treatment as with intermediate 16a and chromatography on silica (hexanes-ethyl acetate in a ratio of 4: 1) yielded O.lβl (96%) e 16b: XH NMR (CDC13) d 8.59 ( s, ÍH), 8.13 (m, 2H), 7.97 (d, ÍH, J = 7.6 Hz), 7.73 (m, 3H), 7.58 (m, 3H), 7.50 (d, 2H, J = 9.5 Hz), 7.26 (m, 4H), 5.82 (s, 2H), 3.68 (t, 2H, J = 8.1
Hz), 0.97 (t, 2H, J = 8.3 Hz), -0.03 (s, 9H). Analysis (C3oH3? N3OSi »0.75 H20) C, H, N. (c) Example 16-4- [3- ((E) -Styryl) -lH-indazol-5-yl] -isoquinoline: A solution of 16b ( 0.17 g, 0.35 mmol) in 3.6 ml of IM tetrabutylammonium fluoride in THF and ethylenediamine (0.475 ul, 0.427 g, 7.1 mmol) was heated to the reflux point for 1 hour. The reaction was diluted with ethyl acetate and brought to pH 7 with 0.4 M HCl, washed with brine, dried over MgSO4, and concentrated. Chromatography on silica (hexanes: ethyl acetate in a ratio of 1: 1) gave 0.079 g. { 64%) of the substance 16 in the form of a white solid. 1H NMR (CDC13) § -10.20 (brs, 1H), 9.31 (s, ÍH), 8.59 (s, ÍH), 8.16 (s, 1H), 8.09 (d, ÍH, J = 7.2Hz), 7.93 (d , ÍH, J = 7.2Hz), 7.20-7.75, (m, 11H). Analysis (C24HpN3"0 .H20) C, H, N. >
Example 17 4- [3 - ((E) -Estirili, ^ lH-indazol * S-l > | ft- quinoline
and
[Chloroquinoline = Chloroquinoline, Ethylenediamner * - Ethylenediamine, Re flux = Reflux] (a) Intermediate substance 17a - 4- [3- ((E) -Estyryl) - 1- (2-tpmethylsilanyl-ethoxymethyl) -lfi-indazole -5-yl] -quifioline: Substance 17a was prepared by a synthetic method analogous to intermediate 16b. With him ^. Using 4-cyoroquinolma, substance 17a was prepared with, a yield of 79%. 2H NMR (CDC13) d 8.99 (d, ÍH, J * 4.4 Hz), 8.21 (d, 1H, J = 7.9 Hz), 8.15 (s, ÍH), 7.95 (d, ÍH, J¡ = 8.4 Hz), 7.72 (m, 2H), 7.42-7.62 (m, 10H), 5.82 (s, 2H), 3.67 (t, 2H, J = 9.3 Hz), 0.97 (t, 2H, J = 8.3 Hz), -0.02 ( s, 9 H). Analysis (C3oH3? N3OSI »0.5 H20) C, H, N. (b) Example 17-4- [3- ((E) -Styryl) -lH-indazol-5-l] -quinoline:
Example 17 was prepared in a manner similar to intermediate 16. Substance 17a was deprotigated to give 17 in a 50% level yield as a white solid. * H NMR (CDC13) 13.10 (brs, ÍH), 8.98 (d, ÍH, J = 4.4 Hz), 8.37 (s, 1H), 8.15 (d, 1H j = 8.4 Hz), 8.00 (d, ÍH, J = 8.4 Hz), 7.54-7.79 (m, 9H), 7.37 (m, 2H), 7.26 (m, ÍH). Analysis (C24H17N3 * 1.0 H2Q) C, H, N.
Example 18: 5- (4-P r d l) -3- (2-Pyrrol l) -IfHtnd zol
18a 18b
18c 18d OH (TVB OH n * y
• K. 124
(a) Intermediate 18a-2-Fluoro-5-nitrobenzoyl chloride: A solution of 2-chloro-5-nitrobenzyl-oic acid (10.3 g, 56 mmol) in thionyl chloride (90 mL, 1.2 mol) was heated at reflux for 2 hours. The excess thionyl chloride was removed by concentration, under vacuum. The residue obtained was dissolved in ether (150 ml), then concentrated to give 2-fluoro-5-nitrobenzoyl chloride 18a (11.21 g, 99%) as an off-white solid, lH NMR (DMSO-de) d 7.62 (dd, ÍH, J = 9.1, 9.6 Hz), 8.48 (ddd, ÍH, J = 3.0, 6.9, 9.1 Hz), 8.60 (dd, 1H, J = 3.0, 6.3 Hz). Analysis (C7H3NO3CIF) C, H, N, Cl. (B) Intermediate 18b-1- (2 ~ Fluoro »* 5-nitrophenyl) -1- (1-pyrrol-2-yl) methanone: A solution of 2-Chloro-5-nitrobenzoyl-18a (10.04 g, 49 mmol) and pyrrole (3.4 mL, 3.29 g, 49 mmol) in 1,2-dichloroethane (110 mL) was cooled to a temperature of 0 ° C before A1C13 (6.61 g, 49.6 mmol) was added as a solid. The resulting reaction mixture was stirred overnight, and was gradually warmed to room temperature. Subsequently, the crude reaction was poured into a mixture of concentrated HCl (20 ml) and ice water (00 ml). After stirring for another 90 minutes, the layers were separated and the aqueous phase was extracted with CH2C12
(2 x 200 ml). The combined organic extracts were washed with water (200 ml) and saturated NaHCO 3 (200 ml), dried over sodium sulfate and concentrated. Chromatography was performed on silica gel (25% ethyl acetate / hexanes), which afforded 18b (7.23 g, 63%) in the form of a pale yellow solid: XH NMR (DMSOrde) d 6.28 (ddd, 1H). , J = 2.1, 2.3, 3.6 Hz), 6.74 (ddd, 1H, J = 1.3, 2.3, 2.5 Hz), 7.32 (ddd, ÍH, J = 1.3, 2.4, 3.6 Hz), 7.65 (dd, 1H, J = 9.0, 9.1 Hz), 8.39 (dd, ÍH, J = 3.0, 5.8 Hz), 8.45 (ddd, ÍH, J = 3.0, 4.4, 9.1 Hz), 12.33 (broad, ÍH). Analysis (CnH7N2O3F «0.1HC1) C, H, N. (c) Intermediate 18c-l- (2-Fluoror * -5- nitro eml) -1- (1- [2- (tpmethylsilanyl) ethoxymethyl] -Ifi- pitrol-2-yl) methanone: A solution of 1- (2-fluoro-5-n? trofen? l) -1- (1 H- p? rrol-2-? l) methanone 18b (1.72 g, 7.3 mmol) in THF (30 ml) was added dropwise, under an argon atmosphere, to a stirred suspension of NaH (350 mg, 8.75 mmol) in THF (15 ml) at 0 ° C. This mixture was stirred at a temperature of 0 ° C for 45 minutes before the addition of 2- (trimethylsilyl) ethoxymethyl chloride (1.70 g, 10.2 mmol) in a single portion as the pure liquid. The reaction mixture
50 ml). The combined organic extracts were washed with brine (60 ml), dried over sodium sulfate and concentrated. Chromatography was performed on silica gel (10% ethyl acetate / hexanes), which provided the
"Substance 18c (2.24 g, 84%) in the form of a yellow syrup: XH NMR (DMSO-d6) d -0.07 (s, 9H) 0.83 (t, 2H, J = 7.8 Hz), 3.53 ( t, 2H, J = 7.8 Hz), 5.74 (s, 2H), 6.27 (dd, ÍH, J = 2.5, 4.0 Hz), 6.75 (dd, ÍH, J = 1.4, 4.0 Hz), 7.57 (dd, ÍH , J = 1.4, 2.5 Hz), 7.64 (dd, 1H, J = 9.0, 9.1
10 Hz), 8.29 (dd, ÍH, J = 3.0, 5.8 Hz), 8.45 (ddd, ÍH, J = 3.0, '4.6, 9.1 Hz). Analysis (C? 7H2? N204FSl) C, H, N. (d) Intermediate 18d-l- (5-Am? No-2-fluorophenyl) -1- (1- [2- (trimethylsilanyl) ethoxy? Met? l] -lH-pyrrole-2-? l) methanone: u A mixture of 1- (2-fluoro-5-n? trofen? l) -1- (1- [2- (trimethylsilanyl) ethoxymethyl] -lif- pyrrol-2?) methanone 18c (3.63 g, 10 mmol) and 10% palladium on carbon (365 mg) in ethyl acetate (90 ml) was stirred under a hydrogen atmosphere overnight. The reaction mixture was filtered through celite and then concentrated to provide 18d (3.30 g, 99%) as an amber colored syrup: aH
NMR (DMSO-de) d -0.07 (s, 9 H) 0.82 (t, 2H, J = 8.0 Hz), 3.50 (t, 2H, J = 8.0 Hz), 5.12 (br s, 2H), 5.71 (s) , 2H), 6.20 (dd, 1H, J = 2.5, 3.9 Hz), 6.59 (dd, ÍH, J = 2.9, 5.6 HZ), 5 6.60 (dd, ÍH, J = 1.8, 3.9 Hz), 6.66 (ddd , ÍH, J = 2.9, 4.3,
Í
4 £? 127
8. 8 Hz), 6.93 (dd, ÍH, J = 8.8, 9.7 Hz), 7.42 (dd, ÍH, J »1.8, 2.5 Hz). Analysis (C? 7H23N202FSI) C, H, N. (e) Intermediate 18e-1- (2-Flaor-5-iodophenyl) -1- (1- [2- (trimethylsilanyl) ethoxymethyl] -lfi-pi -2-) methanone: Intermediate 18d (332 mg, 1.0 mmol) was dissolved in a mixture of acetic acid (10 ml) and acetonitrile (10 ml). The solution was stirred vigorously and then cooled in an ice-bath and salt to a temperature of -5 ° C, before adding a solution of sodium nitrite (83 mg, 1.2 mmol) in water (10 ml). The resulting diazonium solution was stirred for 45 minutes and gradually warmed to 5 ° C. The reaction was again cooled to a temperature of -5 ° C prior to the addition of a solution of potassium iodide (232 mg, 1.4 mmol) in water (3 ral). The resulting mixture was stirred for another 2 hours, with heating to reach 15 ° C, then poured into a mixture of K2CO3 (30 g) and ice water (100 ml). This aqueous mixture was extracted with ethyl acetate (2 x 50 ral). The combined organic extracts were washed with 10% aqueous NaS03 (50 mL), dried over sodium sulfate and concentrated. Chromatography was performed on silica gel (5% ethyl acetate / hexanes), which afforded substance 18e (160 mg, 36%) in the form of a colorless oil: H NMR (DMSO-de) d -0.08 (s) , 9H), 0.81 (t, 2H, J =
7. 9 Hz), 3.50 (t, 2H, J = 7.9 Hz), 5.71 (s, 2H), 6.24 (dd, ÍH, J = 2.6, 4.0 Hz), 6.63 (dd, ÍH, J = 1.7, 4.0 Hz) , 7.18 • -
(dd, 1H, J = 8.7, 9.7 Hz), 7.51 (dd, ÍH, J = 1.7, 2.6 Hz), *, s X 7.74 (dd, ÍH, J = 2.3, 6.4 Hz), 7.90 (ddd, ÍH , J = 2.3, 4.9,, * 8.7 Hz). Analysis (C? 7H2? N02FSÍI) C, H, N, I. (f) Intermediate 18f-l- [2-Fluoro-5- (4-pyridyl) phenyl] -1- (1- [2-trimethylsilanil) ethoxymethyl] -1J ~ -, * pyrrol-2-yl) methanone: Diisopropylethylamine (1.3 ml, 7.5 mmol) was added to a mixture of 1- (2-fluoro-5-iodophenyl) -1- (1- [2 - tpmethylsilanyl) ethoxymethyl] -lif-pyrrol-2-yl) methanone 18e (798, * mg, 1.8 mmol), tetrakis (triphenylphosphma) palladium (0) (65 mg, 0.06 mmol) and pyridin-4-boronic acid (323 mg, 2.6 mmol) in DMF (20 ml). The resulting reaction mixture was heated in an oil bath at a temperature of 90 ° C for 18 hours under an argon atmosphere. After cooling to room temperature, the crude reaction mixture was poured into water (100 ml) and extracted with ethyl acetate (2 x 75 ml). The combined organic extracts were washed with water (6 x 75 ml), dried over sodium sulfate and concentrated. Chromatography was performed on silica gel (20% ethylacetate / CH2Cl2), which gave the "substance 18f (407 mg, 57%) in the form of a pale yellow oil: XH NMR (DMSO-d6 ) d -0.06 (s, 9H) 0.84 (t, 2H, J = 7.9 Hz), 3.54 (t, 2H, J = 7.9 Hz), 5.76 (s, 2H), J *,
6. 24 (dd, 1H, J = 2.6, 4.0 Hz), 6.68 (dd, ÍH, J = 1.8, 4.0 Hz), 7.49 (dd, ÍH, J = 8.7, 9.3 Hz), 7.51 (dd, ÍH, J = 1.8, 2.6 Hz), 7.72 (d, 2H, J = 6.2 Hz), 7.87 (dd, ÍH, J = 2.4 ', 6.5 Hz), 8.02 (ddd, ÍH, J = 2.4, 4.9, 8.7 Hz), 8.63 (d, 2H, J = 6.2 Hz). Analysis (C22H25N202FSi) C, H, N. (g) Intermediate 18g-5- (4-Pyridyl) -3-Xl- [2- (trimethylsilanyl) ethoxymethyl] -lfi-pyrrol-2-yl) ? daz? > l: A solution of 1- [2-fluoro-5- (4-pyridyl) phenyl] -1- (1- [2-trimethylsilanyl) ethoxymethyl] -lif-pyrrol-2-yl) methanone 18f (504 mg, 1.3 mmol) and hydrazine monohydrate (1.7 ml, 35 mmol) in ethanol (35 ml) was heated to reflux for 42 hours. Then the ethanol was removed by concentration, under vacuum. The obtained residue was partitioned between water (25 ml) and ethyl acetate (25 ml). The layers were separated and the aqueous phase was extracted with ethyl acetate (25 ml). The combined organic extracts were washed with saturated NaHCO3 (30 ml), dried over sodium sulfate and concentrated. Chromatography was carried out on silica gel (3% CH0H / CH2C12), which gave substance 18g (430 mg, 87%) in the form of an off-white solid: XH NMR (DMSO-de) d -0.28 (s) , 9H), 0.63 (t, 2H, J = 8.0 Hz), 3.28 (t,
2H, J = 8.0 Hz), 5.72 (s, 2H), 6.26 (dd, ÍH, J = 2.8, 3.5
Hz), 6.79 (dd, ÍH, J = 1.7, 3.5 Hz), 7.10 (dd, 1H, J = 1.7,
2. 8 Hz), 7.67 (d, ÍH, J = 8.9), 7.77 (d, 2H, J = 6.2Hz), 7.81 (dd, ÍH, J = 1.6, 8.9 Hz), 8.19 (d, ÍH, J = 1.6 Hz),
8. 61 (d, 2H, J = 6.2Hz), 13.25 (s, "ÍH) Analysis (C:; H26N4OS?) C, H, N. (h) Example 18 - 5- (4-P? Ndal) - 3- (2-pyrrolidol) -lfl-indazole: Tetrabutylammonium fluoride (1.0 M in THF, 5 ml) was added to a solution of the intermediate 18g (366 mg, 0.9 mmol) and 1-2. d-ammoethane (150 mg, 2.5 mraol) in tetrahydrofuran (20 ml) This solution was refluxed for 42 hours, then poured into saturated NaHCO 3 (30 ml) * and extracted with ethyl acetate (2 x 25 ml). The combined organic extracts were dried over sodium sulfate and concentrated, chromatographed on silica gel (3% CH3OH / CH2Cl2), which afforded 5- (4- P? Pd? L) -3- (2 -p rrol? l) -líf-? ndazol 18 (71 mg, 29%) in the form of a whitish solid: XH NMR (DMSO-d6) d '6.20 (dd, ÍH, J = 2.6, 5.6 Hz ), 6.82-6.92 (m, 2H), 7.64 (d, 1H, J = 8.7 Hz), 7.81 (dd, ÍH, J = 1.4, 8.7 Hz), 7.83 (d, 2H, J = 6.1 Hz), 8.37 (d, 1H, J = 1.4 Hz), 8.62 (d, 2H, J * 6.1 Hz), 11.37 (s, ÍH), 13.09 (s, ÍH). Analysis (C? 6H12N4 * 0.05 CH2C12) C, H, N.
Example 18b ': 5-N? Tro-3- (2-P? Rrol l) -lfí-mdazol
The substance 18b 'was prepared in a manner similar to the intermediate substance lla. The treatment of l- (2-flubro-5-nitrophenyl) -1- (1-pyrrol-2-yl) methanone 18b with hydrazine hydrate gave 5-nitro-3- (2-pyrrolyl) -lfi-indazole 18b ' (75%) in the form of a reddish-orange solid: XH JfR (DMSQ-d6) d 6.23 (ddd, ÍH, J = 2.4, 2.6, 3.6 Hz), 6.81 (d, ÍH, J = 1.5, 2.5, 3.6 Hz) 6.93 (ddd, 1H J = 1.5, 2.1, 2.6 Hz), 7.70 (d, ÍH, J = 9.2Hz), 8.21 (dd, ÍH, J = 2.0, 9 * J Hz), 8.90 (d, ÍH, J = 2.0 Hz), 11.57 (broad, ÍH), 13.62 (s, ÍH). Analysis (CnH8N402) C, H, N.
Example 19: 4- [3- (4-Chloro-lH-benzoimidaa Ql-2-yl) -lfi-indazpl »5-yl] -isoquinoline
Zf, *
rt *
(a) Intermediate 19a-lfl-Inda2-l-3-carboxylic acid methoxy-m-amide: 0 3-Carboxydazole (100 g, 617 mmol) in 1-DMF was treated with carbonildumidazole (110 g, 678 mmol ) at a temperature of 25 ° C with evolution of gas during a lapse of 15 minutes. The reaction was heated to a temperature between 60 and 65 ° C for 2 hours and then cooled down to 25 ° C. N, O-dimethylhydroxylamine- 5 was added
* Í,
P "* -t 133
HCl (66.2 g, 678 mmol) in the form of a solid and the mixture was heated to 65 ° C for 3 hours. The reaction was concentrated to a paste and reduced in 21 C? FtCla, washed with water and then 2N HCl. It was observed that the product came out of the solution. The solid was filtered and rinsed separately with ethyl acetate. The ethyl acetate and CH2C12 layers were washed separately with NaHCO3 and brine, dried over MgSO4 and concentrated. The resulting solids were combined, triturated with a mixture of CH2C12 and ether in a ratio of 1: 1, filtered, dried to provide 106 g (84%) of intermediate 19a as a white solid: j = 0.38 (75% ethyl acetate in hexanes); 1H NMR (DMSO-dβ) d 13.60 (s, ÍH), 7.80 (d, ÍH, J = 8.2 Hz), 7.60 (d, ÍH, J = 8.2 Hz), 7.41 (t, 1H, J = 8.0 Hz) , 7.22 (t, ÍH, J = 8.0 Hz), 3.77 (s, 3H), 3.44 (s, 3H). Analysis (C10H11N3O2) C * H, N. (b) Intermediate 19b - 5-Iodo-lido-indazole-3-carboxylic acid co-methoxy-methyl-amide: To amide 19a (20 g, 97.4 mmol) in 1 1 CH2C12 added bis (trifluoroacetoxy) iodobenzene (46 g, 107 mmol) followed by adding in portions of iodine (14.84 g, 58.5 mmol) at a temperature of 25 ° C. After one hour, 600 ml of saturated Na2HS03 was added and a solid was started to precipitate which was filtered and rinsed with the surplus
CH2C12 The filtrate was washed with brine, dried over MgSO4, concentrated and the remaining solid was triturated with a minimum amount of CH2C12. The combined solids were dried UP * • in vacuo over KOH to provide 29.26 g (91%) of 19b in the form of a pale white solid: R / = 0.31 (50% ethyl acetate in haxanes); XH NMR (DMSO-de) d 13.79 (s, ÍH), 8.39 (s, ÍH), 7.65 (d, ÍH, J - 8.7 Hz), 7.48 (d, ÍH, J = 8.7 Hz), 3.76 (s, 3H), 3.44 (s, 3H). Analysis (CÍOHÍSOIOZ) C, H. (c) Intermediate substance 19c - 5-Yodo-l- (4-methoxy-benzyl) -lfl-ndazol-3-carboxylic acid-co-methoxy-methyl-amide: To iodine 19b ( 15 g, 45.3 mraol) in 200 ml of THF was added in portions NaH (1.9 g of a dispersion of 60% mineral oil, 1.14 g, 47.6 mmol), with evolution of gas. After 15 minutes, the reaction was cooled to a temperature of 0 ° C and p-methoxybenzyl chloride (8.51 g, 54.4 mmol) was added followed by Nal (679 mg, 4.5 mmol). The mixture was heated to 45 ° C for 9 hours and allowed to cool to 25 ° C. The solution was diluted with ethyl acetate, washed with saturated aqueous NHC1, brine and dried over MgSO4 and concentrated to a viscous oil. Ether was added to the oil and a solid formed which was filtered and rinsed with ether to provide 14.18 g (70%) of 19c as a pale yellow solid: Rj = 0.42 (50% ethyl acetate in
«*" - 135
* c 'habanos); XH NMR (CDC13) d 8.60 (s, 1H), 7.56 (dd, ÍH, J, "8.8, 1.6 Hz), 7.11 (m, 3H), 6.80 (dd, 2H, J = 6.7, 2.1 HzJ, 5.52 ( s, 2H), 3.81 (s, 3H), 3.75 (s, 3H), 3.51 (s, 3H). / Analysis (C? 8H18N302I) C, H, N, I. 5 (d) Intermediate substance 19d - 5 -Iodo-l- (-methoxy-benzyl) -lfi-indazole-3-carbaldehyde: Amide 19c (12.8 g, 28.3 mmol) in 300 ml of THF was cooled to -5 ° C and LiAlH was added in portions ( 1.29 g, 34 mmol) for 10 minutes After 1: after 30 minutes, the reaction was warmed by the slow addition of ethyl acetate at -5 ° C and poured into 0.4 N NaHS04.The organic layer was washed with water. brine, dried over MgSO4 and concentrated to give a slightly whitish solid which was triturated with a minimum amount of ether, filtered, washed with ether and dried to give 9.79 g (88%) of aldehyde 19d. as a white solid: Rf = 0.57 (50% ethyl acetate in hexanes), 1 H NMR (CDCl 3) d 10.20 (s, ÍH), 8.96 (s, ÍH), 7.63 (dd, 1 H, J =
8. 8, 1.6 Hz), 7.18 (m, 3H), 6.83 (d, ÍH, J = 8.7 Hz), 5.57
20 '' (s, 3H), 3. 75 (s, 3H). Analysis . (C? 6H? 3N2O2I »0. 1 ethyl acetate) C, H, N, I. (e) Intermediate 19e-l- (4-Mei? xibenzyl) -5- (4,4,5,5-tetramethyl- [1,3,2] -dioxaborolan-2-yl) -1H- Indazole -3-carbaldehyde:
Bis (pmacolato) diboro (Aldrich Chemicals) (7.05 g, 27.8 mmol), iodide 19d (9.90 g, 25.24 mmol), potassium d® acetate (12.4 g, 126 mraol), and 1,1 '-bis (diphenylphosphine) ) ferrocene dichloropalladium (II) (515 mg, 0.631 mmol) was dissolved in dimethylsulfoxide (150 ml), degassed and heated in an oil bath at a temperature of 80 ° C for one hour. After cooling to room temperature, the mixture was partitioned between ethyl acetate (200 ml) and water (150 ml). The organic layer was dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (25% ethyl acetate in hexanes) to give boronic ester 19e (9.75 g, 98%).
'as a whitish solid: Rf = 0.37 (25% ethyl acetate in hexanes); XH NMR (DMSO-de) d 1.31 (s, 12 H), 3.69 5 (s, 3 H), 5.75 (s, 2 H), 6.87 (d, 2 H. J - 8.7 Hz), 7.27 (d. 2 H, J = 8.7 Hz), 7.74 (d, 1H, J = 8.4 Hz), 7.91 (d, 1H, J = 8.4 Hz), 8.52 (s, ÍH), 10.17 (s, ÍH). Analysis. (C22H25BN20) C, H, N. (f) Intermediate substance 19f-5-Isoquinolin-4-yl-0 l- (4-methoxy-benzyl) -l-triazole-3-carbaldehyde To a degassed solution of boronic ester 19e (6.00 g, 15.30 mmol) and 4-bromoisoquinoline (5.17 g, 24.8 mmol) in ethylene glycol dimethyl ether (DME, 76 mL) was added. aqueous sodium carbonate solution (2.0 M, 38.2 ml 76.4 5 mmol) followed by tetrakis (triphenylphosphine) palladium (0) (883)
stirred at room temperature for 10 minutes, filtered through a pad of celite, acidified with 3N aqueous hydrochloric acid, and extracted with dichloromethane (3 x 200 ml). The combined organic layers were dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (1 to 20% ethyl acetate in dichloromethane), to give the diamine 19g (2.13 g, 60%) in form of a yellow oil: R / = 0.30 (dichloromethane); X H NMR (DMSO-d 6) d 4.60 (br s, 2 H), 4.80 (br s, 2 H), 6.37 (t, 1 H, J = 7.8 Hz), 6.48 (m, 2 H). Analysis (C6H7C1N) C, H, Cl, N. (h) Intermediate substance 19h-4- [3- (4-Chloro-lJi-r> benzo? M? Dazol-2-? L) -1- (4 -metox? -benc? l) -lfi-indazol-5-yl] - isoquinoline: The aldehyde 19f (405.6 mg, 1.03 mmol) and the diam
19g (147 mg, 1.03 mmol) were condensed in the presence of elemental sulfur (50 mg, 1.55 mmol) analogously to the synthesis of intermediate 7c ', which gave the intermediate substance 19h (275.5 mg, 52%) as a pale yellow solid R / = 0.12 (50% ethyl acetate in hexanes); XH NMR (DMSO-d6) d 3.74 (s, 3H). 5.83 (s, 2H), 6.93
(d, 2H, J = 8.8 Hz), 7.22 (m.2H), 7.38 (d, 2H, J = 8.5 Hz),
7. 48 (d, ÍH, J = 7.2 Hz), 7.67 (dd, 1 H, J = 8.7, 1.5 HE),
7. 76 (m, 3H), 8.04 (d, ÍH, J = 8.7 Hz), 8.26 (dd, 1 H, J =
7. 4, 1.5 Hz), 8.54 (s, ÍH), 8.64 (s, 1H), 9.40 (s, ÍH), 13.41 (s, ÍH). (i) Example 19-4- [3- (4-Chloro-1-benzo-m-dazol-2-yl) -lfl-ndazol-5-l] -α-soquol-nol: § Acid was added concentrated sulfuric acid (0.3 ml) to a solution of substance 19h (121.6 mg, 0.236 mmol) and tpfluoroacetic acid (3.0 ml), and stirred at room temperature for 19 hours. The mixture was then diluted coft water (50 ml), treated with concentrated aqueous ammonium hydroxide until a pH = 8 was reached and extracted with ethyl acetate (3 x 50 ml). The combined organic extracts were dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel to provide substance 19 (41.5 5 mg, 44%) as a white solid: Rf = 0.40 (75% ethyl acetate in hexanes), 1E NMR (DMSO-de) [Some peaks * are doubled due to tautomeric isomerization] d 7.22 (m, 2H), 7.48 (d, ÍH, J = 7.2 Hz), 7.64 (d, 1H, J = 8.7), 7.79 (m, 4H), 8.27 (d, IH, J = 7.5), 8.55 (S, IH), 8.63 (s, 1H), 9.40 (s, IH), 13.39 and 13.56 ( 2 s, ÍH as a whole), 13.94 (s, ÍH). Analysis, (C23H? 4ClN5 »l .2 CH3OH) C, H, Cl, N.
E xemployment 20: 4-. { 3- [5- (4-Met? L-p? Peyacm-l-? L) -lH-benzo? Pu.dazol-2-? 3 -lflundazol -5- l} -isoquin.pl ina
After cooling to room temperature, the ethyl sol (150 ml) was washed and
saturated aqueous sodium chloride (50 ml). The organic layer was dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (1: 20: 400 conc. Aqueous NH 4 OH: EtOH: CH 2 C 12), which gave substance 20a (623 mg, 50%). %) as a brownish-orange colored foam Rf = 0.20 (10% ethanol in dichloromethane), XH AÚ «(DMSO-d6) [Some peaks double due to tautomeric isomerization] d 2.23 (s, 3 H), 2.49 (m, 4H), 3.10 (m, 4H), 3.71 (s, 3H), 5.80 (s, 2H), 6.91 (m, 4H), 7.36 and 7.47 (2 d, 3H as a whole, J = 8.3, 8.7 Hz), 7.64 (d, 1H, J = 8.9 Hz), 7.77 (m, 3H), 7.99 (m. ÍH), 8.25 (d, ÍH, J = 7.2 'Hz), 8.53 (s, ÍH), 8.62 and 8.64 (2 s, 1H as a whole), .3 '(s.1H). 12.78 and 12.83 (2s, ÍH as a whole). Analysis (C36H33N; O »0 .9 H20) C, H,?. (b) Example 20-4. { 3- [5- (4-Meti1-p-peraci-1-yl) -lfi-benzoim? Dazol-2-? L] -lfl-indazol-5-l] -isoquinoline: Anisole (229.4 mg, 2.12) was added mmol) to a solution of substance 20a (123.0 mg, 0.212 mmol) in glacial acetic acid (2.12 ral). Concentrated aqueous brohydric acid (2.12 ml) was added, and the mixture was heated to *, refluxing for 21 hours. After cooling, the reaction solution was added dropwise to a mixture that was
a »*" 142 4"was rapidly stirring dichloromethane (50 ml), tetrahydrofuran (20 ml) and saturated aqueous sodium bicarbonate (30 ml), the layers were separated, and the organic layer X? washed with saturated aqueous sodium bicarbonate (20 ml), followed by water (20 ml) The organic layer was dried over magnesium sulfate, filtered, concentrated and purified by chromatography on silica gel (1: 20: 100). Concentrated aqueous NH 4 OH: EtOH: CH 2 C 12), which gave the slightly impure substance (76.0 mg, 78%) in the form of a red foam, The further purification by precipitation of dichloromethane / hexanes gave substance 20 in its pure state (47.1 mg, 48%) as a solid and pink color: Rf = 0.20 (1:20:50 concentrated aqueous NH4OH: EtOH: CH2C12); XH NMR (DMSO-de) [Some peaks double due to tautomeric isomerization] d 2.23 (á, 3H), 2.49 (m, 4H), 3.11 (m, 4H), 6.91 (m, 2H), 7.35 and 7.47 (2 d, ÍH as a whole, J = 9.0, 8.9 Hz), 7.61 (d, ÍH. J = 8: 9 Hz), 7.80 (m, 4H), 8.26 (d, ÍH, J - 7.7 Hz), 8.54 (s, 1H), 8.59 and 8.62 (2 s, HI as a whole), 9.39 (s, ÍH), 12.74 and 12.79 (2s, 1H as a whole), 13.73 and 13.76 (2s, ÍH as a whole). Analysis (C28H25N »0.7 H20) C, H, N.
fix it 21: 2- [5- (3-H droxy-2-methyl-f-enyl) -lH-indazol-3-yl-l-yl-benzoijnidazol-4-ol
- •
(a) Intermediate 21a-2- [5-Iodo-l- (2-tpmethylsilanyl-ethoxyethyl) -lfl-indazol-3? l] -1-fibenzo-m-dazol-4-ol: The aldehyde 7b '(2.66 g, 6.62 mmol), and 2,3-diamylphenol (sold by Aldrich Chemicals) (822 mg, 6.62 mmol) were condensed in the presence of elemental sulfur in a manner analogous to the synthesis of intermediate 7c', what gave substance 21a (2.04 g, 61%) as a yellow solid: Rj = 0.15 (25% ethyl acetate in hexanes); H NMR (DMSO-de) [Some peaks double due to tautomeric isomerization] d-0.13 (s, 9H), 0.82 (t, 2H, J = 8.1 Hz), 3.59 (t, 2H, J = 7.8 Hz) , 5.85 (s, 2H), 6.59 (d, ÍH, J = 7.5 Hz), 7.01 (m, 2H), 7.71 (d, ÍH, J = 8.7 Hz), 7.81 (dd, ÍH, J = 8.8 , 1.5 Hz), 8.90 and 9.04 (2 s, ÍH as a whole), 9.49 and 9.74 (2 s, ÍH as a whole), 12.69 and 12.96 (2 s, ÍH as a whole). Analysis' (C20H23IN402S?) C, H, N.
• *
(b) Intermediate 21b-2- [5- (3-Methoxy-2? '• i * methyl-phenyl) -1- (2-trimethylsilanyl-ethoxymethyl) lH-indazol-3-yl] -lH-benzoimidazole- 4-ol: Boronic ester 9c '(250 mg, 1.01 mmol) and iodide 21a (510.6 mg 1.01 mmol) were coupled by the analogous procedure to the synthesis of intermediate 9d', which gave substance 21b (256.7 mg, 51%) in the form of a yellow foam Rf = 0¿2?
(30% ethyl acetate in hexanes, mixed spots with substance 21a). 1H NMR (DMSO-de) [Some peaks double due to tautomeric isomerization] d -0.11 (s.9H), 0.85 (t, 2H, J = 8.1 Hz), 2.06 (s, 3H), 3.64 (t 2H , J = 7.7 Hz),
3. 85 (s, 3H), 5.90 (s, 2H), 6.55 (dd, ÍH, J = 7.2, 1.1 Hz), '6.96 (m, 4H), 7.26 (t, ÍH, J = 7.9 Hz), 7.46 ( dd, 1 H, J - 8.7, 1.5 Hz), 7.87 (d, 1H, J = 8.7 Hz), 8.40 and 8.55 (2 s, HI as a whole), 9.45 and 9.61 (2 s, HI as a whole), 12.62 and 12.91 (2 s, HI as a whole). Analysis (C28H32N4O3Si »0.4H20) C, H, N. (c) Intermediate 21c -2- [5- (3-Methoxy-2-methyl-phenyl) -lfi-indazol-3-yl] -lfi-benzoimidazole- 4-ol: Analogously to Example 3, treatment of substance 21b (174.5 mg, 0.349 mmol) with tetrabutylammonium fluoride gave 21c (59.8 mgr 46%) in the form of a whitish solid: Rf = 0.26 ( 5% methanol in dichloromethane); 1H NMR (DMSO-de) [Some peaks double
ff *
> • #; * • * 145
due to tautomeric isomerization] d 2.07 (s, 3H), B. 1 ^ (s, 3H), 6.53 and 6.62 (2 d, 1H as a whole, J = 7.4, 7.7'Hz), 6.96 (m, 4H), 7.26 (t, ÍH, J = 7.9 Hz), 7.37 (d , ÍH, J = B * S 1 * 'Hz), 7.66 (d, ÍH, J * 8.5 Hz), 8.35 and 8.49 (2 s, ÍH as a whole), 9.45 and 9.55 (2 s, ÍH as a whole), 12.53 and 12.78 (2 s, ÍH as a whole), 13.57 and 13.62 (2 s, 1H as a whole). '-! »
HRMS calculated for C22H? 9N402 371.1508 (MH +), found 371.1523. '' * (d) EXAMPLE 21-2- [5- (3-Hydraxy-2-methyl-phenyl) -l-yldazol-3-yl] -lfi-benzoimidazole-4-ol: A Via a procedure analogous to synthesis of phenol 8 ', treatment of substance 21 c (45.9 mg, 0.124 mmol) with pipdin hydrochloride gave substance 21 (29.0 mg, 66%) in the form of a colored powder * toasted: Rf = 0.28 (10% methanol in dichloromethane); lE NMR (DMSO-de) [Some peaks double due to the,. tautomeric isomeptation] d 2.04 (s, 3H), 6.54 and 6.62 (dd and d, ÍH as a whole, J = 7.2, 1.3 and 7.7 Hz), 6.75 (d, 1H, J = 7.4 Hz), 6.85 (d, ÍH, J = 7.9 Hz) 7.01 (m, 3H), 7.37 and 7.38 '(dd and dd, 1H as a whole, J = 8.5, 1.5 Hz for each nail), 7.65 and 7.66 (2 d, 1H as a whole, J - 8.7 Hz for each), 8.35 and 8.48 (2 s, HI as a whole), 9.38 and 9.39 (2 s, 1H as a whole), 9.46 and 9.56 (2 s, HI as a whole), 12.52 and 12.77 * (2 s, ÍH as a whole), 13.55 and 13.60 (2 s, 1H as a whole) -.
HRMS calculated for C2, H.7N402 357.1351 (MH +), found 357.1360. Analysis (C2lH? 6N4O2 «0.8 CH3OH) C, H, N.
Ejeraplo 22: 6- (3-H? Drox? -prop? L) -2-methyl-3- [3- ((E -
(a) Intermediate 22a-3-Am? no-2-met? l- -phenol: A suspension of 2-met? l-3-n? tro-phenol (Aldrich Chemicals) (29.8 g, 194.6 mmol) and Pallad or 10% carbon (3.01 g) in ethanol (350 ml) was stirred under hydrogen at a pressure of 40 psi for 3.5 hours. After filtration through a pad of celite, the solution was concentrated and purified by chromatography on silica gel (50% ethyl acetate in hexanes) to give 1a.
aniline 22a (20.32 g, 85%) in the form of a colorless solid: Rf = 0.50 (50% ethyl acetate / hexanes); 1 H NMR (DMSO-de) d 1.87 (s, 3 H), 4.63 (s, 2 H), 6.08 (dd, 2 H, J-7.9, 10.5 Hz), 6.64 (t, ÍH, J = 7.9 Hz), 8.76 ( s, 1H). Analysis (C7H9NO) C, H, N. (b) Intermediate 22b-3-Yodo-2-methyl-phenol: 3-Amino-2-methyl-phenol 22a (18.35 g, 149 mmol) was diazotized in accordance with DeGraw method, et al. [DeGraw, J. I .; Brown, V. H .; Colwell, W. T .; Morrison, N.E., J. Med. Chem. , 17, 762 (1974)]. After performing column chromatography (10-50% ethyl acetate in hexanes), the aryl iodide 22b (9.06 g, 26%) was isolated in the form of an orange solid. Further purification by recrystallization of hexanes gave 5.63 g of pale orange needles: Rf = 0.35 (20% ethyl acetate / hexanes); E NMR (DMSO-de) d 2.22 (s, 3H), 6.80 (m, 2H), 7.24 (dd, ÍH, J = 7.5, 1.5 Hz), 9.75 (s, ÍH). (c) Intermediate 22c-1-Allyloxy-3-iode-2-methyl-benzene: Allyl bromide (1.57 g, 13.0 mmol) was added to a solution of 3-iodo-2-methylene phenol (2.026). g, 8.66 mmol) in acetone (18 ml). The solution was heated to reflux temperature for 2 hours, then cooled to room temperature, diluted with ethyl acetate (50 g.
The complex of bo-ranor ... dimethylsulfide (0.159 ml, 1.68 mmol borane) was added dropwise to a frozen solution (0 ° C) of intermediate 22d (459.8 nitrate *, ^, V.} 1.677 mmol) in dry ether (5.0 ml). The cooling P bath was removed, and stirring was continued for 1 hour. Absolute ethanol (2.5 ml) was added, followed by aqueous sodium hydroxide (2.5 N, 3.35 ml). The mixture was again cooled to 0 ° C, and hydrogen peroxide (30 wt% in H20, 0.27 ml) was added. After stirring at a temperature of 0 ° C for 15 minutes, the cooling bath was removed and the mixture was allowed to warm to room temperature for 1 hour. The solution was partitioned between ether (50 ml) and IN aqueous hydrochloric acid (final aqueous pH 2-3). The organic layer was dried over magnesium sulfate, filtered and concentrated in an orange oil. Purification by chromatography on silica gel provided alcohol 22e (353.1 mg, 72%) as a yellow oil Rf = 0.11 (20% ethyl acetate / hexanes); 1H NMR (DMSO-de) d 1.64 (quint, 2H, J = 7.0 Hz), 2.29 (s, 3H), 2.54 (t, 2H, J = 7.5 Hz) 3.39 (t, 2H, J = '6.5 Hz), 4.54, (br & * V 's, ÍH), 6.68 (d, ÍH, J - 8.1 Hz), 7.23 (d, ÍH, J = 8.1 Mz), v * 8.58 (s, 1H). (f) Intermediate 22f-6- (3-Hydroxypropyl) -2-methyl-3- [3- ((E) -styryl) -1- (2-trimethylsilanyl-ethoxymethyl) -lfi-indazole -5- il] -phenol:
Aqueous sad carbonate solution (2M, 1.79 ml) was added to a degassed ester solution or j .QQ-i
16a (534.1 mg, 1.12 mmol), aryl iodide 22e (209.1 | 8J 0.716 mmol), and 1, 1-bis (diphenyl-1'-ferrocenedichloroprone) (II) (29 mg, 0.036 mmol) in DMF f >3.2 * ml) The mixture was heated in an oil bath at W? ß temperature of 80 ° C for 1.5 hours, then cooled and S ** - partitioned between ethyl acetate (50 ml) and water (10 ml). ml) The organic layer was dried over magnesium sulfate, filtered and concentrated, purification by chromatography on silica gel (20 to 50% ethyl acetate in hexanes) gave I the substance 22f (301.9 mg, 82%). ) as a yellow foam: Rf = 0.07 (20% ethyl acetate / hexanes); XH MBfc (DMSO-de) 6.-0.09 (s, 9H), 0.83 (t, 2H, J = 7.9 Hz), 1.73 (qumt, 2H, J = 7.5 Hz), 2.09 (s, 3H), 2.65 (t, 2H, J - 7.5'-Hz), 3.46 (t, 2H, J - 6.5 Hz), 3.58 (t , 2H, J = 8.0 H¿), 5.78 (s, 2H), 6.74 (d, ÍH, J = 7.7 Hz), 6.98 (d, ÍH, J = 7.9 Hz), 7.27 (m, ÍH), 7.37 ( ra, 3H), 7.56 (m, 2H), 7.73 (m, 3H), 8.06 (s, 1H), 8.25 (br s, 1H).
CH2C12) C, H, N. (g) Intermediate 22 - 6- (3-Hi | dr3? I-propyl) -2-methyl-3- [3- ((E) -styryl) -1 phydazole -5-ilJ-feaolr Substance 22 was prepared in a similar way to •
Example 3, the treatment of the intermediate substance? £ * * (202.9 mg, 0. 394 mraol) with tetrabutylamine fluoride?? Ig g?
•H.H. f < rr
Substance 9a ', intermediate 23a (3.16 g, 18.8 mmol) was hydrogenated in ethanol (300 ml) to. provide 23 (2.23g, 86%) in the form of a yellow-brown solid. The subsequent purification by recrystallization * P--. of ethanol resulted in substance 23b (1.04 g ,: 40%). •
X in the form of yellow needles: Rf = 0.17 (75% acetate "'
-2 ethyl in hexanes); ? E NMR (DMSOd6) d 4.36 (br s, -6H), 4.90 (br s, ÍH), 6.42 (m, 3H). Analysis (CH? 0N2O) C, H, N. "(c) Intermediate substance 23c. { 2- [5-iodo-l * | 2-trimethylsilanyl-ethoxymethyl) -lfí- '' inñ3t¿ol-3-xl í-% IÍX? benzoimidazol-4-yl} -methanol:
? "Í # M:;« «- A-
Substance 23c was prepared in a manner similar to the synthesis of substance 7c '. Condensation of the diamine to "23b (587.3 mg, 4.25 mmol) with the aldehyde 7b '(1.71 g, 4.25 tf'r * ramol) in the presence of elemental sulfur gave the substance 23c (1.57 g, 71%) in the form of a solid of color A yellow:? E NMR (DMSO-de) [Some peaks double due to tautomeric isomerization] d.-0.13 (s, 9H), 0.82 (t, yA ... 2H, J * 7.7 Hz ), 3.58 (t, 2H, J = 7.9 Hz), 4.87 (br s, ÍH), 5.04 (br s, ÍH), 5.22 (br s, 1H), 5.87 (s, 2H), 7.26 (, 2H) , 7.39 and 7.67 (m and br s, ÍH in conjunction), 7.75 (d, 1H, J = 8.7 Hz), 7.83 (dd, ÍH, J = 8.8, 1.5 Hz), 8.95 (d, ÍH, "J - 1.1 Hz), 12.97 and 13.13 (2 s, ÍH as a whole). Analysis (C2? H25IN02S?) C, H, I, N. (d) Intermediate 23d-2-Met? L-3- (4, 4, 5,5- tetramethyl- [1,3,2] dioxaborolan- 2-? L) -phenol: Through a synthetic method analogous to the synthesis of substance 9c, the iodide 22b (1.21 g, 5.17 mmol) was converted to the boronic ester 23d (1.15 g, 95%), a solid crystalline white: Rf = 0.18 (10% ethyl acetate in hexanes); XH NMR (CDC13) d 1.35 (s, 12H), 2. $, * * (s, 3H), 6.87 (dd, 1H, J «7.9, 1.0 Hz), 7.08 (t, ÍH, J - 7.5 Hz) , 7.35 (dd, ÍH, J = 7.4, 1.1 Hz). Analysis (C13H19BO3 »0.2 H20) C, H.
(e) Intermediate 3e-3- [3- (4-Hydroxymethyl-1-yl-benzoimidazol-2-yl) -1- (2-tr? methylsilane-ethoxymethyl) -lfi-indazol-5-yl] -2- methyl-phenol: Substance 23e was prepared in a manner similar to the synthesis of substance 9d '. Iodide 23c (276.3 mg, 0.514 mmol) and boronic ester 23d (300 mg, 1.28 mmol) were coupled to give substance 23e (128.2 mg, 50%) as a yellow solid: Rf = 0.16 (40%) ethyl acetate in hexanes); XH NMR (DMSO-d6) [Some peaks double due to tautomeric isomerization] d.-O.ll »(s,
A 9H), 0.85 (t, 2H, J = 7.9 Hz), 2.03 and 2.07 (2 s, 3H as a whole), 3.63 (t, 2H, J = 7.7 Hz), 4.87 and 4.97 (2 d, 2H as a whole) , J = 5.8 and 5.5 Hz), 5.11 and 5.25 (2 t, ÍH as a whole, J - 5.6 and 6.1 Hz), 5.92 and 5.93 (2 s, 2H as a whole), 6.76 (dd, ÍH, J = 7.5, 3.4 Hz), 6.86 (d, 1H, J = 7.9 Hz), 7.17 (m, 3H), 7.39 and 7.60 (dd and d, ÍH as a whole, J = 6.8, 2.1 and 7.9 Hz), 7.49 (d, ÍH, J - 8.7 Hz), 7.89 (d, ÍH, J = 8.9 Hz), 8.44 and 8.47 (2 s, 1H as a whole), 9.46 and 9.48 (2 s, ÍH as a whole), 12.91 and 13.09 (2 s, ÍH on the whole) . Analysis (C28H32N03S? »0 .3H20) C, H, N. (f) Example 23 -3- [3- (4-Hydroxymethyl-1-yl-benzoimidazol-2-yl) -lfi-indazol-5-yl ] -2-methyl-phenol: The substance of Example 23 was prepared in a manner similar to Example 3. The treatment of substance 23e (130.7 mg, 0.261 mraol) with tetrabutylammonium fluoride
é * »> * 155
gave substance 23 (61.6 mg, 64%) as a white solid: Ry = 0.22 (70% ethyl acetate and hexanes); XH NMR (DMS0-d6) [Some peaks double due to / * to the tautomeric isomerization] d 2.04 and 2.07 (2 s, 3H tn set), 4.86 and 4.97 (2 d, 2H together, J = 6.0 and 5.7 2 Hz), 5.10 and 5.23 (2 t, ÍH as a whole, J = 5.6 and 6.0 Hz), 6.76 (d, ÍH, J = 7.2 Hz), 6.85 (d, ÍH, J «8.1 Hz), 7.14 (m, 3H), 7.37 and 7.58 (dd and d, ÍH as a whole, J = 7.2, 1.9 and 7.7 Hz), 7.40 (dd, ÍH, J = 8.5, 1.5 Hz), 7.67 (d, ÍH, J - 8.1 Hz ), 8.39 and 8.42 (2 s, HI as a whole), 9.43 and 9.45 (2 S, 1H as a whole), 12.81 and 12.96 (2 s, HI as a whole), 13.65 and 13.70 (2 s, HI as a whole). Analysis (C224H? 8N402 * 1 .0 CH3OH) C, H, N.
Example 24: 7- [3- ((E) -Estyril) -lfí-lnda ^ ol-5- l] -isoquinolipa * < * '>
^
[Pyridme = Pipdma, Dioxane = Dioxane]
J = 8.4, 1.8 Hz), 8.51 (m, 3H), 9.41 (s, 1H), 13.28 (s, ÍH). Analysis (C24H1 N3 «0.6 CH2OH) C, H, N.
Example 25: 4- [3- (1-Benzoimidazol-2-yl) -lfl »indaz; Dl-5-yl] - ', isoquinoline
(a) Intermediate 25a-3- (1-Benzoimidazol-2-yl) -5- (4, 4, 5, 5-tetramethyl- [1,3,2] -dioxaborolan-2-yl) -1- ( 2-trimethylsilanyl-ethoxymethyl) -lfi-indazole: Through a procedure analogous to the synthesis of the boronic ester 19e, the iodide 7c '(2.36 g, 4.81 mmol) was converted to boronic ester 25a (1.43g, 61% ), a white crystalline solid: lE NMR (DMSO-de) 5.-0.13 (s, 9H), 0.82 (t, 2H, J = 7.7 Hz), 1.35 (s, 12H), 3.59 (t, 2H , J --7.9 Hz), 5.89 (s, 2H), 7.24 (m, 2H), 7.53 (m, ÍH), 7.83 (m,,
3H), 8.95 (s, ÍH), 13.15 (s, ÍH). Analysis (C2eH35B 4? 3Si) C ^ H, N. * (b) Intermediate 25b-4-t3- (10- ^ Ben2? Imidazol-2-yl) -1- (2-tpmethylsilanyl-ethoxymethyl) -1H- mdazol-5-? l] -isoquinoline: Through a procedure analogous to the synthesis of substance 19f, 4-bromoisoquinolma (238 rag, 1.14 mmol) was coupled with boronic ester 25a (280.4 mg, 0.572 mmol) to provide 25b (237.5 mg, 84%) as a white solid: Rf = 0.20 (50% ethyl acetate in hexanes); 1 H NMR (DMSO-de) 5.-0.07 (s, 9H), 0.86 (m, 2H), 3.67 (t, 2H, J = 7.9 Hz), 5.98 (s, 2H), 7.20 (br m, 2H) , 7.55 (br m, ÍH), 7.65 (br m, ÍH), 7.71 (m, 4H), 8.07 (d, ÍH, J = 8.7 Hz), 8.27 (dd, ÍH, J- 7.2, 1.7 Hz), 8.56 (s, ÍH), 8.66 (d, ÍH, J = 0.8 Hz), 9.41 (s, ÍH), 13.17 (s, ÍH). (s) Example 25-4- [3- (1-Benzoimidazol-2-yl) * 1-X-ndazol-5-yl] -isoquinoline: Substance 25 was prepared in a manner similar to that of Example 3. Intermediate 25b (152.4 mg, 0.310 mmol) was treated with tetrabutylammonium fluoride to give substance 25 (61.9 mg, 55%) as a white foam: Rf = 0.16 (70% ethyl acetate in hexanes); XH NMR (DMSO-de) d 7.18 (br m, 2H), 7.56 (br m, 2H), 7.63 (dd, ÍH, J = 8.5, 1.7 Hz), 7.81 (m, 4H), 8.27 (dd /
ÍH, J 1H), 1
Example 26: 3- [3- (l-Benzo-m-dazol-2-ll) -lfi-mdazoI-
(a) Intermediate 26a-3- [3- (l-Benzo-mrdazole-2-? l) -1- (2-tmetmet? ls? lan? l-ethox? met? l) -lfl-ndazole- 5-?] -6- (3-hydroxy? -prop?) -2-methyl-1-phenol: Via a procedure analogous to the synthesis of substance 25b, boromco-25a ester (303 mg, 0.618 mmol) with iodide 22e (180.5 mg, 0.618 mmol), which gave substance 26a (124.4 mg, 38%) as a white solid: R; = 0.30 (50% ethyl acetate in hexanes); * H NMR (DMS0-d6) d -0.11 (s, 9H), 0.85 (t, 2H, J «7.9 Hz), 1.74 (quint, 2H, J = 7.0 Hz), 2.08 (s, 3H), 2.66 ( t, 2H, J = 7.7 Hz), 3.47 (q, 2H, J - 5.3 Hz), 3.63 (t, 2H,
J = 7.9 Hz), 4.60 (t, ÍH, J »5.0 Hz), 5.91 (s, 2H), 6.75- ** 4k (d, ÍH, J = 7.7 Hz), 7.01 (d, ÍH, J = 7.7 Hz), 7.20. { quint ', 2H, J = 8.1 Hz), 7.49 (m, 2H), 7.71 (d, 1H, J = 7.7 Hfc), / 7.88 (d, 1H, J = 8.7 Hz), 8.33 (s, ÍH), 8.42 (s, ÍH), 13. H (s, ÍH). Analysis (C3oH36N4? 3S? "0.6 ethyl acetate) C, H, N. * * (b) Example 26 -3- [3- (1-Benzoimide = ol-2-yl) -liimidazole-5-yl ] -6- (3-hydroxy-propyl) -2-methyl-phenol: Through a procedure analogous to Example 3, deprotection of 26a (99.4 mg, 0.188 mmol) with tetrabutylammonium fluoride provided substance 26 (26.9 m < |, 36%) in the form of a white solid: = 0.19 (70% ethyl acetate in hexanes); 1 H NMR (DMSO-d 6) 6 1.74 (quint, 2 H, J - 7.4 Hz), 2.08 (s, 3 H), 2.66 (t, 2 H, J = 7.4 Hz) * 3.47 (q, 2 H, J - 5.1 Hz) , 4.59 (t, ÍH, J - 5.1 Hz), 6.74 (d, 1H, J - 7.7 Hz), 7.00 (d, ÍH, J = 7.7 Hz), 7.19 (quint, 2H, J = 7.9 Hz), 7.38 (dd, 1H J = 8.5, 1.5 Hz), 7.50 (d, 1H, J = 7.4 Hz), 7.67 (m, 2H), 8.30 (s, ÍH), 8.37 (s, ÍH), 12.96 (S, ÍH) ), 13.66 (s, ÍH). Analysis (C 24 H 22 N 2"0.4 ethyl acetate) C, H, N.
Example 27: 1- [3- ((E) -Estipl) -lfl-indazol-5-yl] -piperidii | H4- ol
[Imidazole = Imidazole] (a) Intermediate 27a-4- (tert-Butyl-dimethyl-silanyloxy) -piperidine: Imidazole (4.18 g, 61.4 mmol), 4-hydroxypiperidine (2.07 g, 20.46 mmol) were dissolved, and chloride of tert-but-dimethylsilyl (4.63 g, 30.7 mmol) in diechloromethane (50 ml) and stirred at a temperature of 23 ° C for 4 hours. The mixture was then washed with saturated aqueous sodium bicarbonate solution (3 x 50 ml) and water (50 ml), dried over magnesium sulfate, filtered and concentrated under high vacuum to provide 27a (2.60 g, 59% ) as a yellow oil that crystallizes when at rest: XH NMR (CDCI3) d 0.05 (s, 6H), 0.90 (s, 9H), 1.46 (m, 2H), 1.81 (m, 2H), 2.71 (m, 2H), 3.09 (m, 3H), 3.77 (septet, ÍH, J = 3.9 Hz). Analysis (CnH25NOS? * 0.2 C H2C12) C, H, N.
(b) Intermediate substance 27b - §-. { 4-. { (Dimefcyi-ethyl) -dimethyl-silanyloxy] -piperidin-1-yl} -3- ((E) -styryl) -1- (2-trimethylsilanyl-ethoxymethyl) -Ify-indazole: Sodium tert-butoxide (163 mg, 1.70 mmol), tris (dibenzyl-idinacetone) dipalladium (0) were added. (26 mg, 0.03 * mmol), and CyMAP-1 (see Oíd et al., J. Am. Chem. Soc., 120, 9722 (1998) regarding the structure of this ligand) (33 mg, 0.085 ramol) to a degassed solution of substance 27a (241.1 mg, 1.12 mmol) and iodide 7a '(269.3 mg, 0.565 mmol), in ethylene glycol dimethyl ether (DME, 2.0 ml),
The mixture was heated in an oil bath at a temperature of 80 ° C for 17 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 ml) and filtered to remove the black precipitate. The filtrate was washed with water (10 ml) and saturated aqueous sodium chloride (10 ml), dried over magnesium sulfate, filtered, concentrated, and purified by chromatography on silica gel (10 to 50% ethyl acetate). ethyl in hexanes) to provide the substance 27b (177.7 mg, 56%) as an orange oil: Rf = 0.28 (20% ethyl acetate in hexanes); XE NMR (CDC13) d. ~~. 06 (s, 9H),
0. 09 (s, 6H), 0.90 (m, 2H), 0.92 (s, 9H), 1.80 (m, 2H), 1.97
(m, 2H), 3.07 (m, 2H), 3.44 (m, 2H), 3.58 (t, 2H, J - 8.4)
Hz), 3.92 (m, ÍH), 5.69 (s, 2H), 7.29 (m, 2H), 7.41 (ra, 6H), 7.61 (d, 2H, J = 8.7 Hz).
164 1 4 *
(c) Example 27-1- [3- ((E) -Styryl) -l-mdazol-5-yl] -piper? din-4-ol: Through a procedure analogous to that of Example 3, the treatment of intermediate 27b (121.4 mg, 0.22 mmol) with tetrabutyllaubstituted fluoride gave 27 (33.1 mg, 47%) as a yellow foam: Rf = 0.15 (70% ethyl acetate / hexanes); 1 H NMR (DMSO-de) d 1.55 (m, 2H), 1.86 (m, 2H), 2.83 (m, 2H), 3.47 (m, 2H), 3.61 (m, 1H), 4.68 (d, ÍH, J = 4.2 Hz), 7.22 (m, 2H), 7.37 (m, 5H), 7.55 (d, ÍH, J = 16.5 Hz), 7.69 (d, 2H, J - 7.2 Hz), 12.89 (s, ÍH). Analysis (C2CH21N3O «0.4 H20« 0.4 ethyl acetate) C, H, N.
Example 28: l- [3- ((E) -Est r l) -lfí ~ ndazol-5- »i3.3 *. pipe? d? n-3-ol
[Imidazole = Imidazole] (a) Intermediate 28a-3- (tert-Butyl-dimethyl-silanyloxy) -piperidine:
-
(181.5 mg, 0.322 mmol) with tetrabutylammonium fluoride gave substance 28 (47.6 mg, 46%) as a yellow foam: R, = 0.19 (70% ethyl acetate / hexanes); * H NMR (DMSO-de) d 1.34 (m, 1H), 1.70 (m, 1H), 1.95 (m, 2H), 2.55 (m, 1H), 2.72 (mIH), 3.46 (m, ÍH), 3.63 (m, ÍH), 3.74 (m, 1H), 4.88 (d, ÍH, J - 4.5 Hz), 7.24 (dd, ÍH, J = 9.0, 1.8 Hz), 7.33 (t, ÍH, J = 7.2 Hz ), 7.42 (m, 5H), 7.63 (d, ÍH, J = 16.5 Hz), 7.76 (d, 2H, J = 7.2 Hz), 12.97 (s, ÍH). Analysis (C20H2? N30 »0.3 H20) C, H, N.
Example 2 »: [2- (5-Isoquinol? N-4-? L-l-nidazol-3? L) -lfi-benzoim dazol-4-yl] -methanol
(a) Intermediate substance 29a -. { 2- [5- (4, 4, 5, 5-Tetramet? L- [1, 3, 2] d? Oxaborolan-2? L) -l- (2-
-.
trimethylsilanyl-ethoxymethyl) -lfl-indazol-3-yl] -1K-benzoimidazol-4-yl} -methanol: Through the use of a procedure similar to the synthesis of I9e boronic ester, iodide 23c (512.8 mg, -0,985 mmol) was converted to boronic ester 29a (312.0 mg, 61%), a white foam: Rf = 0.28 (5% methanolic in dichloromethane); XH NMR (DMSO-d6) [Some peaks double due to tautomeric isomerization] d.-0.13 (s, 9 H), 0.83 (t, 2H, J = 7.7 Hz), 1.35 (s, 12H), 3.60 ( t, 2H, J = 8.1 Hz), 4.87 (br s, ÍH), 5.06 (br s, ÍH), 5.24 (m, ÍH), 5.90 (s, 2H), 7.26 (m, 2H), 7.40 and 7.71 (2 d, ÍH as a whole, J = 7.2 and 7.9 Hz), 7.82 (m, 2H), 8.95 (s, 1H), 12.93 and 13.10 (2 s, ÍH as a whole). Analysis,. (C27H37BN4O4Si »0.5 H20) C, H, N. b) Intermediate substance 29b-. { 2- [5-isoquinolin-4-yl-1- (2-trimethylsilanyl-ethoxy-methyl) -lfl-indazol-3-iD-lyn-benzoimictezol-4-yl} -methanol: Through the use of a procedure similar to the synthesis of the substance 19f, 4-bromoisokoline (193 mg, 0.927 mmol) was coupled with boronic ester 29a (241.2 mg, 0.463 mmol) to provide 29b (171.1 mg, 71%). %) in the form of a white foam: R = 0.22 (75% ethyl acetate in hexanes); XH NMR (DMSO-de) [Some peaks double due to tautomeric isomerization] 5.-0.08 (s, \ 9H), 0.88 (t, 2H, J = 7.7 Hz), 3.68 (t, 2H, - J = 7.9 H ^),
r. .. *. * & ,,
"168
4. 88 (d, 2H, J = 5.3 Hz), 5.05 and 5.25 (2 br, ÍH in P set), 5.98 (s, 2H), 7.22 (m, 2H), 7.40 and 7.57 (2m, ÍH "together ), 7.77 (m, 4H), 8.07 (d, 1H, J = 8.5 Hz), 8.27 ^ (dd, 1H, J = 7.2, 1.5 Hz), 8.57 (s, ÍH), 8.70 (br s, 1H) , • **. 9.41 (s, ÍH), 12.97 and 13.14 (2 s, ÍH as a whole) Analysis (C3? H31N5? 2Si «0.4 H20) C, H, N. (c) Example 29- [2- (5-Isoquinolin-4-yl-lfl-inda2dl-s »«, 3-yl) -lfi-benzoimidazol-4-i1] -methanol: Substance 29 was prepared in a manner similar to that of Example 3. The treatment of Intermediate 29b (129.0 rag, 0.247 mmol) with tetrabutylammonium fluoride provided 29 (58.3 mg, 60%) in the form of white powder: XH NMR (DMSO-de) [Some peaks double because of, the tautomeric isomerization] d 4.88 (t, 2H, J = 6.2 Hz), 5.03 and 5.23 (2 t, ÍH as a whole, J = 5.6 and 6.2 Hz), 7.20 (m, 2H), 7.38 and 7.53 (myd, ÍH in set, J = 7.4 Hz ta the doublet), 7.63 (dd, ÍH, J - 8.7, 1.3 Hz), 7.82 (m, 4H, 8.27 (d, ÍH, J = 7.4 Hz), 8.55 (s, ÍH), 8.63 and 8.66 (2 s, 1H as a whole), 9.40 (s, ÍH), 12.87 and 13.02 (2 s, ÍH as a whole), 13.81 and 13.86 ( 2 s, HI as a whole). Analysis- (C24H17N5O »0 .4 H2O« 0 .3 CH2C12) C, H, N. %.
Example 30: 2 - [2 - (5-Isoquinolin-4-yl-l-yn-2-yl-3-yl) -, - 1-yl-benzoimidazol-4-yl] -ethanol? i _
. * * t * BS & A
"X- 169
(a) Intermediate 30a-2-. { 2- [5- * Iso-ainolin-4-yl-1- (4-methoxy-benzyl) -lfi-indazol-3-yl} -lfi-benzoimidazol-4-yl} Ethanol: A suspension of 10% carbon palladium (66 mg) and 2- (2-amino-3-nitrophenyl) ethanol [see Seno, K ^ oru; Hagishita, Sanji; Sato, Tomohiro; Kuriyama, Kaoru; J. Chem. Soc. Perkin Trans. 1; 2012 (1984) regarding the synthesis of, * - this reagent] (531.5 mg, 2.92 mmol) at all etanc * l (50 ml) was stirred under nitrogen at a pressure of 40 psi for t 3 hours. After filtration and concentration, crude 2- (2,3-diaminophenyl) ethanol (474.4 mg) was obtained in the form of a red oil, which crystallized on standing: f = 0.08 (75% ethyl acetate in hexanes); XH NMR (DMSO-de) 5 2.58 (t, 2H, J = 6.9 Hz), 3.53 (t, 2H, J * 7.2 Hz), 4.32 (br s, 5 H), 6.29 (m, 2H), 6.40 ( dd, ÍH, J = 6.9, 2.1 Hz). Without further purification, this crude diamma was condensed to aldehyde 19f (1.10 g, 2.81 mmol) in the presence of sulfur, similar to the synthesis of intermediate 7c ', to provide substance 30a (930.8 mg, 63%) as a yellow foam: R = 0.19 (ethyl acetate); XH NMR (DMSO-de) [Some peaks double because of the
Example 31: [2- (5-Isoquinol-4-yl-l-yl-mctazol-3-yl) -lfl-benzoimidazol-4-ylmethyl] -dimet-l -amine?
[Anisol = Anisole] (a) Intermediate 31a - (2- [5-Isoquinolin-4-? Ll- (4-methox? -benzyl) -lfl-ndazol-3? L] -lfi-benzoimidazole - '' r 4-íl.}. Methanol: Through a synthesis similar to the synthesis of substance 19h, the aldehyde 19f (3.67 g, 9.33 mmol) and diamma 23b (1.29 g, 9.33 mmol) were condensed in the presence of sulfur to provide 31a (2.60 g, 54%) as a yellow solid: Rf = 0.19 (^ 5% ethyl acetate in hexanes); XH NMR (DMS0-d6) [Some peaks double because to tautomeric isomerization] 5 3.71 (s, 3H), 4.88 (d, 2H, J = 5.5 Hz), 5.04 and 5.25 (2 t, 1H as a whole, J = 5.6 and 6.1 Hz), 5.81 and 5.83 (2 s) , 2H in
^ -
set), 6.93 (d, 2H, J = 8.5 Hz), 7.21 (, 2H), 7.38 and 7.54 (2 d, 3H together, J = 7.4 and 7.5 Hz), 7.66 (d, ÍH, J = 8.7 Hz ), 7.77 (m, 3H), 8.01 (dd, ÍH, J = 8.7, 4.0 Hz), 8.26 (d, ÍH, J = 7.7 Hz), 8.54 and 8.55 (2 s, HI as a whole), *** »8.65 and 8.68 (2 s, ÍH as a whole), 9.39 (s, ÍH), 12.88 and 13.05 (2 s, ÍH as a whole). Analysis (C32H25N5? 2 * 0.3H20) C, H, N. (b) Intermediate 31 b- (2- [5-isoquinolin-4-yl-l- (-methoxy-benzyl) -lfi-indazol-3 -yl] -lfl-benzoimidazol-4-methylmethyl] -dimethyl-amine: Sulphonyl methane chloride (119.3 mg, 1.04 mmol) was added dropwise to a solution of 31a (527.5 mg., 1.03 mmol) and diisopropylethyl amine (153.3 mg, 1.19 mmol) in ^ tetrahydrofuran (12.0 ml), was cooled to a temperature of 0 ° C in an ice bath. After stirring at 0 ° C for 2.5 hours, the beaker of the reaction was conditioned with a digital condenser cooled with dry ice, and the dimethyl amine gas was condensed in the reaction solution until the volume grew in an level of about 5 ml. The stirring was continued at a temperature of 0 ° C for 4 hours, then at room temperature for 15 hours. The mixture was partitioned between ethyl acetate (100 ml) and saturated aqueous sodium bicarbonate solution (20 ml). The organic extracts were dried over magnesium sulfate, filtered, s * e
V 173
concentrated, and columned (silica gel, 5 to 10% ethanol 'in dichloromethane), to provide 31b (250.2 mg, 45%) in the form of a pale yellow solid: Rf (10% methanol in dichloromethane); XH NMR (DMSO-de) d 2.
5 6H), 3.71 (s, 3H), 3.84 (s, 2H), 5.83 (s, 2H), 6.93 (d, 21,, J = 8.7 Hz), 7.14 (m, 2H), 7.36 (d, 2H) , J - 8.5 Hz), 7-48 (m, 1H), 7.67 (d, ÍH, J - 8.9 Hz), 7.77 (quintet, 2H, J - 6.4 Hz), 7.89 (m, ÍH), 8.00 (d , ÍH, J = 8.9 Hz), 8.26 (d, ÍH, J = 7.5 Hz), 8.55 (s, ÍH), 8.71 (s, ÍH), 9.39 (s, 1H) \ 10 13.03 (br s, ÍH) . Analysis (C34H3oNeO "1 .1 H20) C, H, N. (c) Example 31 - [2- (5-Isoquinolin-4-yl-l-yl-indazol-3-yl) -l-benzoimidazol-4-ylmethyl] - dimethylamine: A mixture of 31b (125.7 mg, 0.233 mmol), anisole (252 mg, 2.33 mmol), trifluoroacetic acid (2.3 ml), and concentrated sulfuric acid (0.2 ml) was stirred at room temperature for 66 hours , then added dropwise to a rapidly stirring mixture of saturated aqueous sodium bicarbonate (75 ml) and ethyl acetate (25 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 50 ral). The combined organic layers were dried over magnesium sulfate, filtered, concentrated, and purified by chromatography on silica gel (25 to 40% methanol in dichloromethane) to give 31 (35.8 mg, 5 37%) in the form of powder of white color: Rf = 0.09 (10%
JM-,
* * - 174
methanol in diechloromethane); H NMR (DMSO-de) [Some peaks double due to tautomeric isomerization] d 2.15 and 2.21 (2 br s, 6H as a whole), 3.80 (s, 2H), 7.12 (br s, 2H), 7.40 and 7.54 (2 m, ÍH as a whole), 7.64 (d, ÍH, J = 9.0 Hz), 7.83 (m, 4H), 8.26 (d, ÍH, J - 7.5 Hz), 8.55 (s, ÍH), 8.63 and 8.73 (2 brs, ÍH as a whole), 9.39 (s, 1H), 13.02 (br s, ÍH), 13.83 (br s, ÍH). Analysis (C26H22 6 «0.7 H2O» 1.0 CH3OH) C, H, N.
.Example 32: [2- (5-Isoquinol n-4- l-l-nidazol-3-i3,) -Líf- * benzom? Dazol-4-? Lmet l] -met l-amine
[Anisol = Anisol] (a) Intermediate substance 32a-. { 2- [5-Isoquinoline-4- * 1-l- (4-methox? -benzyl) -lfl-ndazol-3-? L] -lfi-benzo? M? Dazo |.-4-limethyl} -methyl-amine: X- Through the use of a procedure similar to the synthesis of substance 31b, alcohol 31a (516.6 μg, 1.01 mmol) was treated with methanesulfonyl chloride and dusopropylethyl amine at a temperature of 0 °. C for 1 hour. Instead of a condensed gas, a
"*" * 175 *
solution of methylamine in tetrahydrofuran (2.0 M, 5-.0) and stirring was continued at ambient temperature for 15 hours.The extractive treatment and the # silica gel chromatography similar to those applied to substance 31b gave analogue mono-methyl to
(170.5 mg, 32%) in the form of a whitish solid:
Rf = 0.16 (1: 20: 300 conc. Aqueous NH40H: ethanol: dichloromethane); X NMR (DMSO-de) d 2.26
(S, 3fi), 3.71 (s, 3H), 4.03 (s, 2H), 5.82 (s, 2H), 6.93 (d,
2H, J - 8.7 Hz), 7.14 (d, 2H, J = 4.7 Hz), 7.37 (d, 2H, J * '
8. 7 Hz), 7.46 (m, ÍH), 7.67 (dd, ÍH, J - 8.7, 1.3 Hz), 7.77
(m, 2H), 7.89 (d, ÍH, J = 7.7 Hz), 8.01 (d, ÍH, J * 8.5 Hz>, 3.25 (dd, ÍH, J - 7.0, 1.8 Hz), 8.55 (s, ÍH ), 8.68 (s, 1H), "
9. 39 (s, 1H). Analysis (C33H28NeO »0.6 H20) C, H, N. (b) Example 32 - [2- (5-? Soqu? Nolin-4 ~ al-lIf ~ indazol-3? L) -lfí-benzo? M? dazol-4-? lmet? l] -myl-amine: Deprotection through the use of a procedure similar to the synthesis of 31 provided the substance 32 (47.5 mg, 63%) in the form of a foam d @ color whitish: Rf = 0.29 (1: 20: 100 NH40H concentrated water: ethanol: dichloromethane); XH NMR (DMSO-de) d 2.30 (s, 3H), 4.07 (s, 2H), 7.15 (d, 2H, J = 4.5 Hz), 7.47 (A, ÍH), 7.64 (dd, ÍH, J * 8.5 , 1.5 Hz), 7.83 (m, 4H), 8.26 (d, 'ÍH, J - 7.2 Hz), 8.56 (s, ÍH), 8.66 (s, ÍH), 9.39 (s, IB) • Analysis (C25H2oN6 «1.0EtOH« 0.2 hexanes) C, H, N.
1H), 9.39 (s, ÍH), 13.03 (br s, ÍH). Analysis (C36H32N6? »0.2 CH2C12) C, H, N. (b) Example 33-4- [3- (4-Pyrrolidin-1-ylmethyl * lJfc >; benzoimidazol-2-yl) -lfl-indazol-5-yl] -isoquinoline: A solution of 33a (109.2 mg, 0.193 mmol) in ^ 5% concentrated sulfuric acid / trifluoroacetic acid (2.0 ml) was stirred at room temperature for 20 minutes. hours, then added dropwise to a rapidly stirring mixture of tetrahydrofuran (25 ml), and saturated aqueous sodium carbonate (25 ml). Ethyl acetate (25 ml) and water (15 ml) were added, and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 50 ml), and the combined organic fractions * were dried over magnesium sulfate, filtered and concentrated. Purification by chromatography on silica gel (1: 20: 100 conc. Aqueous NH 4 OH: ethanol dichloromethane) provided 33 (25.4 mg, 30%) in the white powder form: 1 H NMR (CD3OD) d 1.77 (br s) , 4H), 2.69 (br s, 4H), 4.12 (s, 2H), 7.24 (d, 2H, J «4.0 Hz), 7.80 (m, 5H), 8.06 (d, ÍH, J = 7.9 Hz), 8.23 (d, ÍH, J = 7.5 Hz), 8.53 (s, ÍH), 8.69 (s, 1H), 9.29 (s, ÍH). Analysis (C28H24Ne «0.9 MeOH) C, H, N.
Example 34: 4-. { 3- [4- (2-Pyrrolidin-1-yl-ethyl.) - lB- - 'benzoimida-2-yl-2-yl] -lfl-indazol-5-yl) -isoquinoline
t m > &
Four . 178
(a) Intermediate substance 34a-4-. { l- (4-MetFxi- * 'benzyl) -3- [4- (2-pyrrolidm-l-yl-ethyl) -l, l-benzoimidazole-2-? l] -lfl-ndazol-5-? } - Soquínolina: With a similar procedure to the synthesis of substance 33a, alcohol 30a (441.5 mg, 0.84 ramol) was • made into the substance 34a (204.6 mg, 42%), a whitish foam: Rf = 0.08 (1: 20: 400 concentrated aqueous NH 4 OH: ethanol: dichloromethane); XH NMR (DMSO-de) d 1.38. (br s, 4H), 2.31 (br s, 4H), 2.79 (m, 2H), 3.07 (m, 2H), 3.71 (s, 3H), 5.81 (s, 2H), 6.93 (d, 2H, J = 8.8 Hz), 6.98 (d, ÍH, J = 7.2 Hz), 7.08 (t, ÍH, J = 7.7 Hz), 7.36 (d, 2H, J = 8.7 Hz), 7.39 (m, 1H), 7.66 ( dd, ÍH, J = 8.5, 1.5 Hz), '7.76 (m, 2H), 7.89 (d, ÍH, J = 7.7 Hz), 8.01 (d, ÍH, J = 8.7 Hz), 8.25 (d, 1H, J = 7.4 Hz), 8.53 (s, 1H), 8.75 (br s, 1H), 9.38 (s, ÍH), 13.00 (br s, ÍH). Analysis (C37H34N6O »0.6 H20) C, H, N.
(b) Example 34-4. { 3- [4- (2-Pyrrolidin-1-l-ethyl) -l, -benzo-m-dazol-2-yl] -lfl-ndazol-5-l} Isoquinoline: Substance 34 was prepared in a similar manner to example 33. The treatment of substance 34a (66.2 mg,
0. 114 mmol) with trifluoroacetic acid / sulfuric acid (© the ratio of 3: 1) gave substance 34 (24.7 mg ^ 47%) in the white powder form: Rf = 0.38 * (1: 20: 100 aqueous NHOH) concentrate: ethanol: dichloromethane); "H NMR (DMSO-de) d 1.37 (br m, 6H), 2.27 (br m, 2H), 2.80 (m, 2H), 3.07 (m, 2H), 6.98 (d, ÍH, J = 7.2 Hz) , 7.09 (t, 1H, = 7.5 Hz), 7.36 (br s, ÍH), 7.63 (dd, ÍH, J »8.5, 1.5 Hz)
7. 82 (va., 4H), 8.26 (d, ÍH, J * 7.4 Hz), 8.54 (s, 1H), 8.75 (br s, ÍH), 9.39 (s, ÍH), 12.98 (br s, 1H), 13.79 (s, ÍH). Analysis (C29H26N6 «0.7 EtOH) C, H, N.
Example 35: 3-. { [2- (5-? So-nol? N-4- l-l-nidazol-3-? L | -lfíbenzo? M dazol-4-? Lmet l] -am no.} -2-met ? l-pfopan-l-ol
(a) Intermediate substance 35a C? cloprop lmet? l-. { 2- [5-? Soqu? Nolm-4-? L-l- (4-methox-bensyl) -lfl-mdazol-3-? L] -lfl-benzo? M? Dazol-4-? Lmethyl} - amine: With a procedure similar to the synthesis of 31b, alcohol 31a (512.0 mg, 1.00 mmol) was treated with
methanesulfonyl and diisopropylethyl amine at a temperature of 0 ° C for 1 hour. Then aminomethylcyclopropane (712 mg, 10.0 mmol) was added, and stirring was continued at room temperature for 15 hours. After * dfel extractive treatment and column chromatography similar to substance 31b, intermediate 35a (209.3 mg, 37%) was obtained in the form of a whitish powder: Rf = 0.16 (1: 20: 300 aqueous NHOH) concentrate: ethanol: dichloromethane); XH NMR (DMSO-de) 6.-0.24 (br s, 2H), - 0.04 (br s, 2H), 0.66 (br s, ÍH), 2.30 (br s, 2H), 3.71 s, * 3H), 4.04 (brs, 2H), 5.83 (s, 2H), 6.93 (d, 2H, J = 8.7 Hz), 7.11 (m, 2H), 7.37 (d, 2H, J «8.7 Hz), 7.42 ( m, 1H), 7.67 (dd, ÍH, J = 8.7, 1.5 Hz), 7.76 (m, 2H), 7.87 (d, ÍH, J = 8.1 Hz), 8.02 (d, 1H, J = 8.7 Hz), 8.25 (dd, ÍH, J = 6.8, 1.9 Hz), 8.53 (s, ÍH), 8.68 (br s, ÍH), 9.38 (s, ÍH). Analysis (C36H32N6O »0.5H20) C, H, N.
(b) Example 35-3. { [2- (5-Isoquinolin-4-yl-l-yl-indazol-3-yl) -lfl-benzoimidazol-4-ylmethyl] -amino} -2-methyl-propan-1-ol: Substance 35 was prepared in a similar manner to
• example 33. The treatment of 35a (107.1 mg, 0.19 mmol) With trifluoroacetic acid / sulfuric acid in a proportion of
3: 1 supplied the open ring analog 35 (25.3 mg,
29%) in the form of white powder: Rf = »0.35 (1: 20: 100 concentrated aqueous NH4OH: ethanol: dichloromethane); l
T. f
, v * <
NMR (CD3OD) d 0.67 (d, 3H, J = 6.8 Hz '), 1.33 (m, 1H), 1.80 * (m, 1H), 2.60 (m, ÍH), 2.75 (m, ÍH), 3.20 (m , 1H), 4.26 (S, 2H), 7.22 (m, 2H), 7.57 (d, ÍH, J = 7.7 Hz), 7.63 (dd, 1H, - 7- = 8.7, 1.7 Hz), 7.79 (m, 3H), 7.99 (d, ÍH, J * 7.5 Hz), 8.22 '(d, ÍH, J = 7.5 Hz), 8.51 (s, ÍH), 8.72 (br s, 1H), 9.29 (S, ÍH). 13C NMR (CD3OD, DEPT) d 15.0 (CH3), 35.6 (CH), 50.9 (CH2), 54.0 (CH2), 67.4 (CH2), 111.7 (CH), 123.4 (CH), 124.0 (CH), 124.3 ( CH), 125.8 (CH), 128.9 (CH), 129.3 (CH), 130.4 (CH), 132.6 (CH), 142.9 (CH), 152.6 (CH). Analysis (C28H26N6O »0.6 CH2C12» 0.4 hexanes) C, H, N. 0
Example 36: Diethyl- [2- (5-isoquinolin-4-yl-l-yl-indazol-3-yl) -1-fy-benzoimidazol-4-ylmethyl] -amine
(a) Intermediate 36a-Diethyl-. { 2- [5-0 isoquinolin-4-yl-l- (4-methox? -benz? -1) -1H-indazol-3-yl] -lfl-benzoimidazol-4-ylmethyl} -amin: With a procedure similar to substance 33Ub, alcohol 31a (511.4 mg, 1.00 mmol) was treated with methanesulfonyl chloride and diisopropylethyl amine at a temperature of 5 0 ° C for 2.5 hours. Then diethylamine was added (731.4
íü * "%?
*? mg, 10.0 mmol), and stirring was continued at room temperature for 25 hours. After carrying out 1 extractive treatment and column chromatography similar to substance 31b, intermediate 36av ^ s (434.6 mg, 77%) was obtained as a yellow foam: Rf = 0.22 (1: 20: 400 aqueous NH 4 OH) concentrate: ethanol: dichloromethane); XH NMR (DMSO-de) [Some peaks are doubled due to the tautomeric isomerization] 5 0.87 and 1.01 (2 brs, 6H ea 'set), 2.41 and 2.56 (2 brs, 4H as a whole), 3.71 ( s? - 10 3H), 3.89 and 3.94 (2 brs, 2H as a whole), 5.82 (s, 2H), 6.92 (d, 2H, J »8.7 Hz), 7.13 (m, 2H), 7.37 (d, 2H , J = 8.5 Hz), 7.50 (m, ÍH), 7.67 (d, ÍH, J - 8.7 Hz), 7.76 (m, 2H), 7.91 (m, ÍH), 8.01 (d, ÍH, J = 8.7 Hz), 8.25 (dd, ÍH, J - ß-. ß, * 1.9 Hz), 8.53 (s, ÍH), 8.63 and 8.77 (2 brs, ÍH as a whole) 7
9.38 (s, ÍH), 13.02 (s, ÍH). Analysis (C36H34N6? 0.4 H20) C, H, N.
(b) Example 36 - Diethyl- [2- (5-isoquinolin-4 * -yl-1-yldazol-3-yl) -lfi-benzoimidazol-4-ylmethyl] -amine: Similar to example 33, the treatment of the
Substance 36a (266.5 mg, 0.47 mmol) with 3: 1 trifluoroacetic acid / sulfuric acid yielded 36 (67.5 mg, 32%) in the white powder form: Rf = 0.30 (1: 20: 200 concentrated aqueous NH4OH: ethanol: dichloromethane); XH NMR (DMSO-de) [Some peaks double because of the
25 tautomeric isomerization] 5 0.94 (br m, 6H), 2.44 and 2.55 (2
?
??? ', «
br, 4H as a whole), 3.94 (brs, 2H), 7.14 (brs, 2H), - * "7.39 and 7.50 (2 brs, ÍH as a whole), 7.64 { dd, ÍH, J - ß.? * 1.5 Hz), 7.77 (m, 4H), 8.25 (d, ÍH, J = 7.4 Hz), 8.54 (faith, - | & H 1), 8.63, and 8.74 (2 brs, 1H altogether ), 9.39 (s, ÍH), * t V * ";? 12.99 (s, 1H), 13.81 (s, 1H). Analysis (C28H2eN6 »0.5 EtOH) 'C, H, N.
Example 37: Ethyl- [2- (5-isoquinolin-4-yl-l-y-indazol-3-yl) -fí-? benzoimidazol-4-ylmethyl] -amine
(a) Intermediate 37a - Ethyl-. { 2-. { 5- isoquinolin-4-yl-l- (4-methoxy-benzyl) -lfl-indazol-3-yl] -l-yl-benzoimidazol-4-ylmethyl} -amine: Through a synthetic method similar to 31b, alcohol 31a (371.5 mg, 0.726 mmol) was treated with
raetanesulfonyl and diisopropylethyl amine at a temperature of 0 ° C for 2.5 hours. Then the beaker of the reaction was conditioned with a digital condenser cooled with dry ice, and the ethylamine gas was condensed in the reaction solution until the volume increased in the order of 5 ral. Stirring was continued at room temperature for 15 hours. After the extractive work-up and column chromatography similar to substance 31b, intermediate substance 4a 37a (260.1 mg, 67%) was obtained in the form of a foam. pale yellow color: H NMR (DMS0-d6) d 0.84 (br s, '3H), 3.39 (br s, 2H), 3.71 (s, 3H), 4.04 (s, 2H), 5.82 (s, 2H), 6.93 (d, 2H, J = 8.7 Hz), 7.12 (m, 2H), 7.37 (d, 2H, J = 8.7 * * Hz), 7.44 (m, ÍH), 7.67 (dd, ÍH, J = 8.7, 1.5 Hz), 7.76 (m, 2H), 7.89 (m, ÍH), 8.01 (d, 1H, J = 8.7 Hz), 8.25 (dd, 1H, J = 6.6, 1.9 Hz), 8.54 (s, ÍH) , 8.67 (s, ÍH), 9.39 (s, 1H). Analysis (C34H3oNeO »0.7 H20) C, H, N.
(b) Example 37-Ethyl- [2- (5-isoquinolin-4-yl-l-yl-indazol-3-yl) -lfi-benzoimidazol-4-ylmethyl] -amine: Similar to example 33, the treatment of the substance 37a (123.3 mg, 0.229 ramol) with 3: 1 trifluoroacetic acid / sulfuric acid provided 37 (21.8 mg, 23%) in the form of a whitish powder: 1 H NMR (DMSO-de) d 0.84 (br s, 3H ), 2.57 (br, 2H), 4.10 (s, 2H),. 7.13 (m, 2H), 7.46 (m, ÍH), 7.64 (dd, ÍH, J = 8.7, 1.7 Hz),
"* 185
7. 80 (m, 4H), 8.26 (dd, ÍH, J = 7.2, 1.7 Hz), 8.55 (s, 1H), € .66 (s, ÍH), 9.39 (s, ÍH), 13.85 (br s, 1H ). Analysis' ^ (C2eH22N6 »0.6 EtOH« 1.0 CH2C12) C, H, N.
Example 38: Isoprop l- [2- (5- soqu? Nol n-4-? L-l-nidazol-3"l) -lfi-benzo m dazol-4- lmet l] -amine
(a) Intermediate substance 38a - Isopropyl. { 2- [5-? -substituted-4-l-l- (4-methox? -benzyl) -lfl-ndazol-3-? L] -lflbenzo-m? Dazol-4-ylmethyl} -amine: With a procedure similar to substance 31b, alcohol 31a (518.0 mg, 1.01 mmol) was treated with methanesulfonyl chloride and dusopropylethyl amine at a temperature of 0 ° C for 2.5 hours. Then, isopropyl amine (597 mg, 10.1 mmol) was added and the mixture was stirred at room temperature for 24 hours. After carrying out the extractive treatment and column chromatography in a manner similar to substance 31b, intermediate 38a (417.8 mg, 75%) was obtained in the form of a yellow foam: lE NMR (DMSO-ds) d 0.77 (br s, 6H), 2.63 (br s, ÍH), 3.71 (s,
3H), 4.02 (br s, 2H), 5.82 (s, 2H), 6.93 (d, 2H, J = 8.7"Hz) # 7.11 (m, 2H), 7.37 (d, 2H, J = 8.7 Hz), 7.42 (m, 1H, 7.67 (dd, ÍH, J = 8.7, 1.5 Hz), 7.76 (m, 2H), 7.88 (d, 1H, J = 7.7 Hz), 8.02 (d, ÍH, J = 8.7 Hz), 8.25 (dd, 1H, J = 6.6, 2.1 Hz), 8.53 (s, ÍH), 8.69 (br s, 1H), 9.38 (s, ÍH) Analysis (C35H32 6? »0.7 H20) C, H, N.
(b) Example 38 - Isopropyl- [2- (5-isoquinolin-4-yl-yl-mdazol-3-yl) -lfi-benzo-imidazol-4-ylmethyl] -amine: The substance of example 38 was prepared from Similar to example 33. The treatment of 38a (243.3 mg, Ó.44 mmol) with 3: 1 trifluoroacetic acid / sulfuric acid provided 38 (89.9 mg, 47%) in an off-white powder coating: 2H NMR (CD3OD ) 5 1.03 (d, 6H, J - 6.4 Hz), 2, '99 (septet, ÍH, J = 6.4 Hz), 4.27 (s, 2H), 7.23 (m, 2H), 7.57 (dd, 1H, J = 7.7, 1.1 Hz), 7.67 (dd, 1H, J - 8.7, 1.7 Hz), 7.81 (m, 3H), 8.01 (d, ÍH, J = 8.3 Hz), 8.23 (d, ÍH, J * 7.5 Hz ), 8.51 (s, 1H), 8.71 (br s, ÍH), 9.30 (s, 1H).
Example 39: tert -Butyl- [2- (5-? Soqu? Nolm-4-yl-l-yldazol; -3-, yl) -f-benzoimidazol-4-ylmethyl] -amine
< * '
(a) Intermediate substance 39a-tert-Butll-t2- [5 ~ -. isoquinolin-4-yl-l- (4-methoxy-benzyl) -l-fy-indazol-3-yl] -lH-benzoimidazol-4-yl-methyl} -amine: By a method analogous to 31b, alcohol 31a
(623.2 mg, 1.22 mmol) was treated with t-methanesulfonyl chloride and diisopropylethyl amine at a temperature of 0 ° C for 1 hour. Then tert-Butylamine f890"* mg, 12.2 mmol) was added and stirring was continued at room temperature for 20 hours.
Extractive treatment and column chromatography of man V similar to substance 31b, intermediate 39a (299.7 mg, 43%) was obtained in the form of a yellow foam: XH NMR (CD30D) 5 1.01 (s, 9H) , 3.76 (s, 31), 4.11 (s, 2H), 5.78 (s, 2H), 6.91 (d, 2H, J = 8.7 Hz), 7.19 (m, 2H), 7.36 (d, 2H, J = 8.7 Hz), 7.50 (dd, ÍH, J = 7.9,; -1.1Hz), 7.62 (dd, ÍH, J = 8.7, 1.7 Hz), 7.77 (m, 3H), 7.95 (d, ÍH, J * 7.9 Hz ), 8.22 (dd, ÍH, J = 7.0, 1.7 Hz), 8.48 (s, ÍH), 8.74 (s, 1H), 9.29 (s, ÍH). Analysis (C36H34NeO »0.3 * • 'H20) C, H, N. (b) Example 39 - tert -Butyl- [2- (5-isoquinolin-4-yl-lfl-indazol-3-yl) -lfi- benzo-imidazol-4-yl-met? l] -amine: A solution of 39b (103.7 mg, 0.183 mmol), trifluoromethanesulfonic acid (0.48 ml) and trifluoroacetic acid (1.6 ml), was stirred at room temperature for 17 hours and then at 100 ° C for 1.5 hours.The solution was added by
faith '* * S
By a method analogous to 31b, alcohol 3j¿
(572., O mg, 1.12 ramol) was treated with methanesulfonyl chloride and dusopropylethyl amine at an a cc temperature, 0 ° C for 1 hour. Then 1-idazole (761 mg, 11.2 mmol) was added and stirring continued at room temperature for 24 hours. After performing the extractive treatment and column chromatography in a manner similar to substance 31b, intermediate 40a (269.1 mg, 43%> as a white powder: XH NMR (CD3OD) d 3.77 (s, 3H), 5.58 (s, 2H), 5.79 (s, 2H), 6.73 (br s, ÍH), 6.91 (d, 2H, J = 8.8 Hz), 7.07 (d, ÍH, J = 7.4 Hz), 7.23 (m, 2H), ^ 7.36 (d, 2H, J = 8.8 Hz), 7.53-7.83 (m, 6H), 8.03 (d, ÍH ,, = 7.9 Hz), 8.22 (d, 1H, J * 7.9 Hz ), 8.51 (s, ÍH), 8.73 (bg _ '^ s, ÍH), 9.28 (s, ÍH), Analysis (C35H27N70) C, H, N.
(b) Example 40-4- [3- (4-Im? dazol-1-yl-metrA-l-2-benzyl or 2-ol-2-? l) -lfl-nda-2-yl-yl] -isoquinolma: A solution of 40a (152.0 mg, 0.271 mmol), trifluoromethanesulfonic addict (0.271 ml) and trifluoroacetic acid
(2.71 ml) was stirred at a temperature of 60 ° C for 1 hour. The solution was added dropwise to a mixture which was kept under rapid stirring of concentrated aqueous NH40H. - (10 ml), water (10 ml), THF (10 ml) and ethyl acetate (2fr »? Ml). Extraction and purification similar to example 33, gave the crude compound 40 in the form of solid pink (24.9 mg), which still had impurities
* "V ,,
t < 190
in the 1H NMR spectrum. Trituration of acetonitrile gave pure compound 40 (11.0 mg, 9%) as a pink powder: H NMR (CD3OD) d 5.59 (s, 2H), 6.74 (br s, 1H), 7.08 (d, 1H, J = 7.4 Hz), 7.25 (m, 2H), 7.55-7.85 (m, 6H), 8.07 (d, ÍH, J = 7.9 Hz), 8.24 (d, ÍH, J = 7.5 Hz), 8.54 ( s, ÍH), 8.72 (br s, ÍH), 9.30 (s, ÍH). HRMS calculated for C27H2oN- 442.1780 (MH +), found 442.1794.
Example 41 5- (3-Met? L-p nd? N-4-? L) -3- (E) -est? Ril-lH-mdazole
(a) Intermediate 41a-5- (3-Met? l-pyridin-4-yl) -3- ((E) -est ril) -1- (2-tr? met? ls? lan? l-etox ? met l) -lfí-indazol: Intermediate 16a (300 mg, 0.63 mmol), 4-bromo-3-met? lp? r? dma (See Baliki et al., Gazz. Chim. Ital. 124, 9 , 1994, 385-386) (112 mg, 0.65 mmol) and carbonate
v4 191
Sodium (140 mg, 1.3 mmol) was stirred in DME (6 ml) / H20 (1 * ml) in a beaker purged with argon. "Tetrakis (tp-phenylphosphine) palladium (0) (60 mg, 0.05 mmol) was added and the reaction was stirred at reflux temperature for 24 hours.The solution was diluted with ethyl acetate, washed with H20 and brine, dried over Na2SO4 and concentrated in vacuo Purification by chromatography on silica gel (20% ethyl acetate / hexanes) gave 234 mg (84%) of intermediate 41a as a clear oil ? E NMR (300 MHz, CDC13) d 8.56 (s, 1HX, 8.52 (d, ÍH, J = 7.8 Hz), 7.95 (s, ÍH), 7.24-7.67 (m, 10H), 5.78 (s, 2H ), 3.64 (t, 2H, J = 8.1Hz, 2.33 (s, 3H), 0.94 (t, 2H, J = 8.1Hz), -0.04 (s, 9H) Analysis (C2H3iN3OSi 0.2 H20) C, H, N.
(b) Example 41-5- (3-Met? l-pyridin-4-yl) -3- (E) -styryl-mdazole: Intermediate 41a (218 mg, 0.49 mmol) was stirred in a mixture of ethylenediamine (0.34 m, 4.9 mmol) and TBAF (1 M in THF, 2.5 m, 2.5 mmol) at a temperature of 72 ° C for 20 hours. The solution was diluted with ethyl acetate, washed with saturated NaHCO 3 and brine, dried (Na 2 SO 4) and concentrated in vacuo. Purification by chromatography on silica gel (1: 1: 1 ethyl acetate / THF / hexanes) gave 122 mg (79%) of the title compound as a white solid.1H NMR (300
MHz, DMSO-de) 5 13.29 (s, 1H), 8.52 (s, 1H), 8.46 (d, 1H, J »'*" < 4.8 Hz), 8.22 (s, ÍH), 7.55-7.73 (m , 5H), 7.26-7.44 (m, 5H), 2.31 (s, 3H) Analysis (C2iH? 7N3) C, H, N. Ms' (ES) [m + HJ / z calculated 312, found 312; mH] / z calculated 310, found 310.
Example 42: 5- (4-Chloro-p? Ridin-3-yl) -3- (E) -est? Ryl-l-yl-indazole
(a) Intermediate 42a-5- (4-Chloro-pyr-din-3-yl) -3- ((E) -estipl) -1- (2-tnmethylsilanyl-ethoxymethyl) -lfl-mdazole: The compound of the title was prepared in a 73% yield from intermediate 16a and 4-chloro-3-iodo-pyridine (See Cho et al., Heterocycles, 43, 8, 1996, 1641-1652) analogous to intermediate 41a. ^ NMR (300 MHz, CDC13) 5 8.67 (s, ÍH), 8.52 (d, ÍH, J = 7.8 Hz), 8.08 (s, 1H), 7.26-7.70 (m, 10H), 5.79 (s, 2H) 3.64
'193 ~ s • - (t, 2H, J «8.1Hz), 0.94 (t, 2H, J = 8.1Hz), * 0.03 (s, 9H). ^ t Analysis (C26H28ClN3OSi »0.3H20) C, H, N. 'X i (b) Example 42- 5- (4-Chloro-pyridin-3? l) -3- (E) -T%? f. "" estiril-lfí-indazol: it-
The title compound was prepared in q? - * 66% yield by means of the deprotection SEM of the V. "" * "intermediate 42a in a method analogous to the example -. '* < 41. ^ NMR (300 MHz, DMSO-de) d 13.30 (s, ÍH), 8.70 (s, ÍH), I 8.56 (d, 1H, J = 5.4 Hz), 8.31 (s, ÍH), 7.63-7.73 (m, 4H), * V 0 7.57 (d, 2H, J = 4.2 Hz), 7.50 (dd, ÍH, J - 8.4, 1.2 Hz), 7.26-7.40 (m, 3H). Analysis (C2oH14ClN3 • 0.05H20) C, H, N. '' - # MS (ES) [m + H] / z calculated 332/334, found 332/334; [m-H] / z *, calculated 330/332, found 330/332.
Example t 43: 5- (4-Methyl-pyrid? N-3-yl) -3- (E) -styryl-1 ^ -inda2 l
-
(a) Intermediate 43a-5- (4-Met? lp? pdin-3-yl) -3- ((E) -estipl) -1- (2-tpmethyls? lanil-etox? met? l) -lff Inda2?: The title compound was prepared in a 90% yield from intermediate 16a and 3-bromo-4-met? lp? r? dma in a manner similar to the procedure used for intermediate 41a. 1 H NMR (300 MHz, * CDCl 3) d 8.54 (s, ÍH), 8.50 (d, ÍH, J * 7.8 Hz), 7.95 (s, 1H), 7.23-7.67 (m, 10H), 5.78 (s, 2H ), 3.64 (t, 2H, J = 8.1Hz), 2.33 (s, 3H), 0.94 (t, 2H, J = 8.1Hz), -0.04 (s, 9H). Analysis (C27H3? N3OS?) C, H, N.
(b) Example 43-5 (4-Met? lp? r? din-3-? l) -3- (E) -st? pl-lfl-mda2ol: The title compound was prepared in an -end? 48% by means of the SEM deprotection of intermediate 43a in a method analogous to example 41. H NMR (300 MHz, DMSO-d6) d 13.26 (s, ÍH), 8.47 (s, 1H), 8.44 (d , 1H, J = 4.8 Hz), 8.20 (s, ÍH), 7.71 (d, 2H, J = 7.2 Hz), 7.55-7.64 (m, 3H), 7.26-7.42 (m, 5H), 2.31 (s, 3H). * Analysis (C2? H? 7N3 • 0.13 H20) C, H, N. MS (ES) [ta-H] / z calculated 312, found 312; [m-H] / z calculated 310, found 310.
to ^ -ispigtt omina
J #
(a) Intermediate 44a-4-Bromo-5-fluoro-isoquinoline: 5-Am? no-4-bromo-? soqu? nolma (See Gordon et al., J. Heterocycl. Chem., 4, 1967, 410 -411) (1.86 g, 8.34 mmol) was stirred in 48% fluoroboric acid (15 ml) / EtOH (15 ml) until completely dissolved. The solution was cooled to a temperature of 0 ° C and sodium nitrite (660 mg, 9.59 mmol) in H20 (1 ral) was added dropwise. The solution was diluted with Et20 (30 ml) and the tan-colored diazomene fluoroborate salt was collected by filtration and dried in vacuo. The solid was placed in a beaker and heated slowly over a flame to expel the nitrogen. The dark brown residue was diluted with 10% NAOH and extracted with chloroform. The organic compounds were washed with brine, dried over MgSO and
they concentrated in vacuum. Purification by chromatography on silica gel (40% to 50% ethyl acetate / hexanes),
gave 798 mg (42%) of 4-bromo-5-fluoro-isoquinoline as a white solid XH NMR (300 MHz, CDCls) 9.36 (d, 1H, J-2.4 Hz), 8.74 (s, ÍH) 8.07-8.11 (m, 1H), 7.70-7.80 (m, 2H). Analysis (C9H5BrFN) C, H, N.
(b) Intermediate 44b-5-Fluoro-4- [3- (D-styryl) -1- (2-trimethylsilanyl-ethoxymethyl) -1-fy-indazol-B-yl] -isoquinoline: The title compound was prepared in an 83% yield from intermediate 16a and 4-bromo-5-fluoro-isoquinoline similar to intermediate 41a. XH NMR (300 MHz, CDC13) d 9.32 (d, ÍH, J - 1.8 Hz), 8.52 (s, ÍH), 8.07 (s, ÍH), 7.91 (dd, ÍH, J = 8.1, 0.9 Hz), 7.26 -7.66 (m, 11H), 5.80 (s, 2H), 3.67 (t, 2H, J = 8.1Hz), 0.95 (t, 2H, J - 8.1Hz), -0.03 (s, 9H). Analysis (C30H30FN3OSÍ • 0.2 H20) C, H, N.
(c) Example 44- 5-Fluoro-4- [3- ((E) -styryl) -lfi- "indazol-5-yl] -isoquinoline: The title compound was prepared in an 83% yield by SEM deprotection of intermediate 44b in a manner analogous to example 41. XH NMR (300 MHz, DMSO-de) d 13.26 (s, ÍH), 9.44 (d, 1H, J * = 1.8 Hz), 8.47 (s) , ÍH), 8.29 (s, ÍH), 8.12 (d, 1H, J «7.2 '
Hz), 7.44-7.78 (m, 8H), 7.35 (t, 2H, J = 7.2 Hz), 7.24 (t, ÍH, J = 7.2 Hz). Analysis (C24H16 N3 • 0.6H20) C, H, N.-MS (ES) [m + H] / z calculated 366, found 366; [m-H] / z calculated, ^ 364, found 364.
E 45 4 - [3- ((E) -styryl) -lfi- adazol-5-yl - isoquinol n-8-jlam na
(a) Intermediate 45a-4 [3- ((E) -styryl) -l- (2-tr? met? ls? lan? -ethox? met? l) -lfl-? ndazol-5-? ] -? soqumol? n-8-? lam? na: The title compound was prepared in an 82% yield from the intermediate substance read and 8-am? no-4-bromo-? soqumolma (See Elpern and col., J. Amer, Chem. Soc., 68, 1946, 1436) similarly to the procedure used for intermediate 41a. 1 H NMR (300 MHz, CDCl 3) d 9.36 (d, HH, J = 0.6 Hz), 8.53 (s, 1H), 8.13 (s, HH) 7.26-7.72 (m, 11H), 6.86 (dd, HH, J = 7 «5,
'i * s? T "* 5 * 198 kr. 0.6 Hz, 5.81 (s, 2H), 51 (s, 2H), 3.66 (t, 2H, J - 8.1Hz), 0.96 (t, 2H, J 8.1 Hz), -0.03 (s, 9H).
(b) Example 45- 4- [3- ((E) -styryl) -lfl-mdaz6r-5- ^ A. I '* il] -? soqu? nolin-8-ylamine: X
The title compound was prepared in a 70% yield by means of the SEM deprotection of the. intermediate 45a analogously to the procedure used for example 41. XH NMR (300 MHz, DMSO-dg) d O 13.30 (s, ÍH), 9.50 (s, ÍH), 8.36 (s, 1H), 8.26 (s) ,? .H. T - 7.24-7.71 (m, 10H), 6.91 (d, ÍH, J = 7.8 Hz), 6.77 (t, ÍH, J = 7.8 Hz), 6.33 (s, 2H) .Analysis (C24H18N4"0.45 H20) C, H N. MS (ES) [m + H] / z calculated 363, found 363.
Example 46 5- (4-Chloro-5-ethyl-pyridin-3-yl) -3 - (»B) - styryl-1-yl-indazole
[Dioxane - Dioxane] 5 '
ml) at a temperature of -20 C. After 10 minutes, the solution was cooled to -78 ° C. 4-4 Chloro-3-iodopyridone (500 mg, 2.09 mmol) in THF (3 mL) was added dropwise, and the reaction was stirred for 30 minutes. Iodoethane (0.2 m, 2.5 mmol) was added, and the reaction was stirred for 1 hour at a temperature of -78 ° C, then for 1 hour while heating to 0 ° C. The reaction was warmed with saturated NH 4 Cl, basified with saturated NaHCO 3 and extracted with and ethyl acetate. The organic compounds were washed with brine, dried over Na 2 SO 4 and concentrated in vacuo. Purification by chromatography on silica gel (20% ethyl acetate / hexanes) provided 429 mg (77%) of 4-Chloro-3-et? L-5-iodo-p? R? Dma in the form of a waxy solid white color. ^ NMR (300 MHz, CDC13) d 8.78 (s, ÍH), 8.33 (s, ÍH), 2.83 (q, 2H, J - 7.5 Hz), 1.26 (t, 3H, J = 7.5 Hz) . Analysis (C7H7CIIN) C, H, N. r
(b) Intermediate substance 46b-5- (4-Chloro-5-et? lp? r? dm-3-? l) -3- ((E) -estipl) -1- (2-trimethylsilanyl-ethoxymethyl) -lfí-mdazol:
.2 * ?. * -fc.
The title compound was prepared in a 69% yield from intermediate 16a and 4-chloro-3-et? L-5-iodo-p? R? Dma in a manner similar to the procedure used for intermediate 41a . XH NMR (300 MHz, CDC13) d 8.49 (d, 2H, J- 3.3 Hz), 8.06 (s, 1H) 7.26-7.69 (m, 9H), 5.79 (s, 2H), 3.65 (t, 2H, J = 8.1Hz), 2.88 (q, 2H, J = 7.5 Hz), 1.35 (t, 3H, J = 7.5 Hz), 0.95 (t, 2H, J = 8.1Hz), -0.03 (s, 9H). Analysis (C28H32ClN3OSi) C, H, N.
(c) Example 46-5- (4-Chloro-5-ethyl-pyridin-3-yl) -3- (E) -styryl-1-yl-indazole: The title compound was prepared in an 80% yield by of the SEM deprotection of the intermediate substance 46b analogously to the procedure used for example 41. XH NMR (300 MHz, DMSO-de) d 13. * 25 (s, ÍH), 8.55 (s, ÍH), 8.50 (s, ÍH), 8.27 (s, 1H), 7.55-7.72 (m, 5H), 7.26-7.48 (m, 4H), 2.83 (q, 2H, J »7.5 Hz), 1.26 (t, 2H, J * 7.5 Hz). Analysis (C22H18N3C1 • 0.3H20) C, H, N. MS (ES) [m + H? / Z calculated 360, found 360.
Example 47: 3- [3- (1-Benzoimdazol-2-yl) -lfí-in < jtazol-5-yl-2-methoxy-phenol
47a 47
[Benzene = Benzene Reflux = Reflux]
(a) Intermediate 47a-3- (1-benzoamidazol-2-? l) -5-. { 2-methoxy-3-. { 2- (2-trimethylsilanyl-ethoxymethyl) -ethoxy] -phenyl} -l- (2-tr? methylsilanyl-ethoxymethyl) -Ifl-mdazole: The title compound was prepared in a yield of 92% from the intermediate 7c 'and 2-methox? -3- [2- (2-methyl-ethoxy) -ethoxy-boronic acid (See: Kania, Braganza, et al., Patent application "Compounds and Pharmaceutical Compositions for Inhibition of Protein Kinases, and Methods for Their Use", p. 52, line 10 to page 53, line 26, and page 59, line 16 to page 60, line 4, US Provisional Serial number 60 / 142,130, filed on July 2, 1999, which is incorporated herein in its entirety as a reference.), similar to the
'** V? Fk
95% yield from intermediate 7cf and intermediate 48b similarly to the procedure used for intermediate 7d .. 1H NMR (300 MHz, CDC13) d 9.90 (s, ÍH), 8.96 (d, 1H, J »0.9 Hz), 7.84-7.90 (m, 2H), 7.69 (d, ÍH, J * 8.7 Hz), 7.48-7.53 $ (m, 2H), 7.23-7.33 (m, 5H), 6.82 (d, ÍH, J «3.3 Hz), 5.8 ^? (s, 2H), 3.67 (t, 2H, J = 8.1Hz), 0.96 (s, 9H), 0.94 (t, 2H, J = 8.1Hz), 0.65 (s, 6H), - 0.03 (s, 9H) ). Analysis
(d) Example 48-3- (1-Benzo? m? dazol-2-? l) -5- (1-ylfol-4? l) -lfl-mdazole: The title compound was prepared in a yield of 79% by means of the deprotection SEM, TBDMS of intermediate 48c analogously to the procedure used for example 41. 1 H NMR (300 MHz, DMSO-de) d 13.66 (s, ÍH), 12.97 (s, 1H) , 11.25 (s, ÍH), 8.78 (s, ÍH), 7.68-7.81 (m, 3H), 7.51 (d, 1H, J = 7.2 Hz), 7.42-
(91%) of the title compound in the form of a clear oil. XH NMR (300 MHz, CDC13) d 7.11-7.20 (m, 1H), 6.74-6.89 (m, 2H), 5.20 (s, 2H), 3.77-3.83 (m, 2H), 0.93- 4. 0.99 (m, 2H), 0.01 (s, 9H). X
(b) Intermediate 49b-3-fl # ~ Benzo? m? dazol-2-? l) -5. { 2,6-difluoro-3- [2- (2-tpraet? Ls? Lanyl-ethoxy) -ethoxy] -phenyl} -1- (2-tr? Met? L? L? -ethoxymethyl) -lfi-indazole: Intermediate 49a (1.4 g, 5.38 mmol) was stirred in dry THF (16 ml) under argon at a temperature of - 78 ° C. N-Butyllithium (2.5 M in hexanes, 2.32 m, 5.8 mmol) was added dropwise, and the reaction was stirred for 20 minutes. Then, the solution was transferred by means of a cannula to a beaker of dry zinc chloride in argon at room temperature. After 30 minutes, intermediate 7c '(320 mg, 0.65 mmol) and tetrakis (tp-phenylphosphine) palladium (0) (60 mg, 0.05 mmol) were added, and the reaction was stirred at room temperature for 2 hours. it was diluted with ether and washed with H20, saturated NaHCOa, and brine. The organics were separated over Na 2 SO 4 and concentrated in vacuo. Purification by *, chromatography on silica gel (20% to 30% Et20 / hexanes) gave 372 mg (92%) of the title compound as a white solid. XH NMR (300 MHz, CDCl 3) d 9.89 (s, ÍH), 8.80 (s, ÍH), 7.86-7.89 (m, ÍH), 7.70 (dd, ÍH, J =
8. 7, 0.9 Hz), 7.58 (dd, ÍH, J = 8.7, 1.2 Hz), 7.49-7.53 (m,
1H), 7.17-7.31 (m, 3H), 6.90-6.97 (m, ÍH), 5.82 (s, 2H),
5. 28 (s, 2H), 3.86 (t, 2H, J = 8.4 Hz), 3.67 (t, 2H, J *
8. 1Hz), 0.92-1.04 (m, 4H), 0.02 (s, 9H), -0.02 (s, 9H). - * Analysis (C32H4oF2N4? 3Si2 «0.25H20) C, H, N." • * (s) Example 49 - 3- [-3- (lfl-Ben2? Imidazol-2-yl) - lfí-inda2 l-5 -yl] -2,4-difluoro-phenol: The title compound was prepared in a 70% yield by means of the SEM deprotection of intermediate 49b analogously to the procedure used for example 41, XH NMR (300 MHz , DMSO-de) d 13.75 (s, ÍH), 13.00 (s, ÍH), 9.88 (s, ÍH), 8.56 (s, 1H), 7.70-7.78 (m, 2H), 7.48-7.53 (m, 2H ), 7.17-7.25 (m, 2H), 6.99-7.05 (m, 2H). Analysis (C20H? 2FN4? • 0.33H20) C, H, N. MS (ES) [m + H] / z calculated 363, found 363; [m-H} / z calculated 361, found 361.
Example 50: 4 ^ [-3- (1-Benzyl-imidazol-2-yl) -Ifl-indazol-S -yl] -3,5-difluoro-phenol and
$ i example 51; 2- [-3- (lfl-Benzoyrazol-2-yl-2-yl) -lfl-inda2? L-5-yl]; B, 5-djf luoro-f enol
6. 40-6.48 (m, ÍH), 5.18 (s, 2H), 3.70-3.76 (m, 2H), 0. St2- 0.98 (m, 2H >, 0.01 (s, 9H).
(b) Intermediate ring of 50b and 50c-3-fifi-Benzoyl-tidazol-2-yl) -5. { 2,6-difluoro-4- [2- (2-trimethylsilartyl-ethoxy-ethoxy] -phenyl] -1- (2-trimethylsilanylethyloxymethyl) -Ifl-Indazole and 3-fi- Benzoimidazol-2-yl) -5 . { 2,4-difluoro-6- [2- (2-trimethylsilanyl-ethoxy-ethoxy] -phenyl] -l- (2-trimethylsilanyl-ethoxymethyl) -lfl-indazole: The title compounds were prepared in a yield of 52% as an inseparable mixture from intermediate 50a similar to the procedure used for intermediate 49b, 1 H NMR (300 MHz, CDC13) d 9.89 (s, HH), 8.44-8.75 (m, 1H), 7.83- 7.93 (m, ÍH), 7.45-7.69 (m, 3H), 7.26-7.39 (m, 2.5H), 6.58- 6.88 (m, 1.5H), 5.81 (s, ÍH), 5.80 (s) , ÍH), 5.26 (s, lfí), 5.13 (s, ÍH), 3.57-3.82 (m, 4H), 0.86-1.04 (m, 4H), - 0.06-0.02 (m, 18H).
(c) Example 50-4- [-3- (1-Benzoy-Nidazol-2-yl) -lfl-mdazol-5-yl] -3,5-difluoro-phenol: The title compound was prepared in a yield 36% by means of the SEM deprotection of the mixture of intermediates 50b and 50c in a manner analogous to the procedure used for the 41th model. XH NMR (300 MHz, DMSO-de) d 13.73 (s, ÍH), 13.01 (s) , 1H), 10.50 (s, ÍH) /
** '•
8. 50 (s, 1H), 7.70-7.74 (m, 2H), 7.43-7.52 (m, 2H), 7.15-7.25 (m, 2H), 6.62 (dd, 2H, J = 13.8, 1.5 Hz). Analysis (C2oHX2FN40 «0.7 H20) C, H, N. MS (ES) [m + H] / z calculated 363, / &'; Found 363; [m-H] / z calculated 361, found 361,
(d) Example 51-2- [-3- (1-Benzoimid zol -2-il) - < Í lfí-indazol-5-? L] -3, 5dif luoro-f enol: The title compound was prepared in * a yield of 40% by means of the deprotection SEM of the "r intermediate mixture 50b and 50c in an analogous manner. al
procedure used for example 41. XH NMR (300 Mfiz, DMSO-de) d 13.65 (s, ÍH), 12.98 (s, 1H), 10.39 (s, ÍH), 8.47 - ^ (s, 1H), 7.66- 7.72 (m, 2H), 7.50 (d, 1H, J - 7.2 Hz), 7.40 (d, 1H, J = 8.4 Hz), 7.14-7.24 (m, 2H), ß.73-6.80 (m, 1H) , 6.64 (d, ÍH, J = 10.5 Hz). Analysis (C20H12FN4? • 0.9H20) C, * H, N. MS (ES) [m + H] / z calculated 363, found 363; [m-IJ / z calculated 361, found 361.
Example 52: 3- (1-Benzoim dazol-2-yl) -5- (4-clpro-pyridin-3-yl) -lfi-Indazole
*
[Dioxane =
0 (a) Intermediate 52a-3- (1-Benzo-2-trifluoro-2?) -5- (4-chloro-p? R? Din-3-yl) -1- (2-t-imethylsilanyl-ethoxymethyl) -lfl-mdazole: The title compound was prepared in an 88% yield from intermediate 25a 5 and 4-chloro-3-iodo-p? r? d? na in a manner similar to the procedure used for the substance intermediate 41a. XH NMR (300 MHz, CDC13) d 9.96 (s, ÍH), 8.77 (s, ÍH), 8.72 (s, ÍH), 8.53 (d, ÍH, J - 5.4 Hz), 7.85-7.89 (m, ÍH) , 7.72 (dd, ÍH, J = 8.7,
$ 0.9 Hz), 7.61 (dd, ÍH, J = 8.7, 1.5 Hz), 7.50-7.53 (m, 1H), 7.47 (d, 1H, J - 5.4 Hz), 7.28-7.35 (m, 2H), 5.84 (s, 2H) 3.65 (t, 2H, J = 8.1Hz), 0.95 (t, 2H, J - 8.1Hz), -0.03 (s, -, 9H).
(b) E jmplo 52-3- (lfí-Benzo? m? dazol -2-il) -5- 5 '< 4 -Cloro-p? R? D? N-3 -? L) - lfí-mdazol:
The title compound was prepared in a 54% yield by means of the deprotection SEM of the intermediate substance rfi 52a analogously to the procedure used for example 41. XH NMR (300 MHz, DMSO-de) 13.81 (s, ), 13.02 (s, 1H), 8.70 (s, ÍH), 8.56-8.60 (m, 2H), 8.22 (s, ÍH), 7.55-7.80 (m, 5H), 7.20 (d, 5H, J = 3 , 6 Hz). Analysis (C22H18CI 3 • 0.5H20) C, H, N. MS (ES) [m + HJ / z calculated 346, found 346.
Example 53: 5- [3- (1-Benzoimidazol-2-yl) -lfl-indazoX-S-yl] -4-methyl- [3, 4 '] bipyridinyl
[Dioxane = Dioxane]
(a) Intermediate 53a 5- (Bromine * "4-5 methyl- [3, '] bipyridinyl:
faith 214
3, 5-D? Bromo-4-met? Lp? Pd? Na (2.21 q, 8.0 mmol), * 4-p? Rid? Lboron? Co (1.08 g, 8.8 mmol) and phosphate ** > ,you*. potassium (2.8 g, 13.2 mmol) was stirred in DMA (50 ml) / H0 (6 ml) in a beaker purged with argon. HE
Tetrakis (tpfenilfosfma) palladium (0) (812 mg, 0.7 mmol) and and ** the reaction was stirred at a temperature of 92 ° C under argon; for 16 hours. The solution was concentrated in vacuo and the residue was dissolved in ethyl acetate. The organic compounds? They were washed with H20 and brine, dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on silica gel (40% to 50% ethyl acetate / hexanes) yielded 1.14 g (60%) of the intermediate substance * * 53a as a white solid. XH M - (300 MHz, CDC13) d 8.73 (dd, 2H, J = 4.5, 1.5 Hz), 8.72 (s, "ÍH), 8.32 (s, ÍH), 7.25 (dd, 2H, J - 4.5, 1.5 Hz), 2.35 (S, 3H), Analysis (C ??H9BrN2) C, H, N.
(b) Intermediate substance 53b-5- [3- (l-Benzoim? dazol-2-? l) -1- (2-tnmet? ls? lan? l-ethoxy? tnet? l) -lfl-ndazole- 5-? L] -4-met? L- [3, 4 '] b? P? Pd? N? L:
The title compound was prepared in a 64% yield from intermediate 25a X and intermediate 53a in a manner similar to the procedure used for intermediate 41a. 1H NMR (300 MHz, CDC13) d 10.21 (s, ÍH), 8.70-8.76 (m, 3H), 8.61
(s, ÍH), 8.46 (s, ÍH), 7.85 8.7, 0.9 Hz), 7.47-7.53 (m,
2H), 3.64 (t, 2H, J = 8.1Hz), 2.19 (s, 3H), 0.94 (t, 2H, J *. 8.1Hz), -0.04 (s, 9H).
(c) Example 53-5- [3-l-Benzoimidazol-2? l) -lfl-mdazol-5? l] -4-met? l [3,4 '] b? p? r? d? ml: The title compound was prepared in a 71% yield by means of SEM deprotection dβ intermediate 53b analogously to the procedure used for example 41. XE NMR (300 MHz, DMSO-dβ) d 13.79 (s) , ÍH), 13.02 (s, ÍH), 8.71 (d, 2H, J = 4.8 Hz), 8.55 (s, ÍH), 8.51 (s, ÍH), 8.47 (s, ÍH), 7.78 (d, ÍH, J - $ .7 Hz), 7.52-7.58 (m, 5H), 7.18-7.21 (m, 2H), 2.17 (s, 33.} .. Analysis (C25Hi8N6 • 0.75 H20) C, H, N. MS (ES) [m + H] / z-calcified 403, found 403; [mH] / z calculated 401, found 401.
Example 54: 5- [3- (l-Benzo-m-dazol-2-yl-l-l-ndazol-5-yl] -l, -2, 3, 4, 4a-8a-hexahydro- [l, 7] ] naft? r dina <
* * * For 1 hour at a temperature of -78 ° C and then last 1 hour while heating it to 0 ° C. ! * > & , reaction was warmed with saturated NHC1, basified with saturated NaHCOg and extracted with ethyl acetate. The organic compounds were washed with brine, dried over Na 2 SO 4 and concentrated in vacuo. Purification by chromatography on silica gel (15% MeOH / CHCl3) provided 2.72 g (54%) of the intermediate 54a in the form of a light brown oil. XH NMR (300 MHz, CDCl 3) d 8.55 0 (d, 2H), 2.72-3.05 (m, 6H), 1.70-1.77 (m, 2H).
(b) Intermediate substance 54b - 2- Jí acid > * Trimethylalanyl-ethanesulfonic acid [3- (3,5-dibromo-pi idin-> 4-yl) -propyl] -amide: "i. Intermediate 54a (2.7 g, 9.2 mmol) was stirred with dry triethylamine (1.92 m, 13.8 ramol) in DMF (20 ml) at a temperature of 0 ° C. 2-Tpmethylsilyanil-ethanesulfonyl chloride, SES-CI, was slowly added (See einreb and COl., Tet.Lett., 27, 19, 1986, 2099-2102) (1.9 g, 9.5 mmol), and the reaction was stirred for 1.5 hours at a temperature 0 of 0 ° C. The reaction was diluted with H20 and extracted with ether. The organic compounds were washed with brine, dried over Na 2 SO and concentrated in vacuo. Purification by chromatography on silica gel (33% ethyl acetate / hexanes) provided 2.37 g (56%) of the intermediate 54b as a colored solid
White. lE NMR (300 MHz, CDC13) d 8.58 (s, 2H), 4.36 (t, 1H J «6.3 * Hz), 3.26 (q, 2H, J = 6.3 Hz), 2.93-3.06 (m, 4H),« 1.81-1.89 (m, 2H), 1.00-1.07 (m, 2H), 0.07 (s, 9H). Analysis (C13H22Br2N202SS?) C, H, N, S.
(c) Intermediate 54c-5-Bromo-l- (2-trimethylsilanyl-ethanesulfonyl) -1,2,3,4-tetrahydro- [1/7] naphthyridine: Intermediate 54b (860 mg, 1.88 mmol) and Potassium carbonate (390 mg, 2.82 mmol) was stirred in dry toluene (15 ml) in a beaker purged with argon. Tetrakis (triphenylphosphine) palladium (0) (218 mg, 0.19 mmol) was added and the reaction was stirred under argon at 102 ° C for 48 hours. The reaction was diluted with ethyl acetate and washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on silica gel (25% ethyl acetate / hexanes) gave 372 mg (52%) of intermediate 54c in the form of a white waxy solid. XH NMR (300 MHz, CDCl 3) d 8.70 (s, ÍH), 8.42 (s, ÍH), 3.72-3.76 (m, 2H), 3.07-3.14 (m, 2H), 2.83 (t, 2H, J »6.9 Hz), 2.07-2.12 (m, 2H), 1.04-1.11 (m, ~ 2H), 0.05 (s, 9H). Analysis (C13H2iBrN2? 2SSÍ) C, H, N, S.
(d) Intermediate 54d-5- [3- (1-Benzo [mu] midazol-2-yl) -1- (2-tr? methylsilyl-ethoxymethyl) -Ifl-
? > *
indazol-5-yl] -1- (2-trimethylsilanyl-ethand ulfo? il) -l, ^ 3 and 4, 4a, 8a-hexahydro- [1,7] naphthyridine: The title compound was prepared in T-yield of the 51% from the intermediate substance - '/ and from the intermediate 54c similar to the procedure used for intermediate 1 & 1H: '.-: NMR (300 MHz, CDC13) d 10.36 (s, ÍH), 8.88 (s, 1H), 8.6; (t,.;;,. ÍH, J »0.9 Hz), 8.29 (s, ÍH), 3.82-3.86 (m, '1H), 7.69 (dd,; lH, J * 8.7, 0.9 Hz), 7.50 -7.52 (m, ÍH), 7.41 (dd, ÍH,; J = "y
10 8.7, 1.5 Hz), 7.26-7.33 (m, 2H), 5.83 (s, 2H), 3.80 (t, 2H ,; - J = 5.7 Hz), 3.63 (t, 2H, J = 8.1Hz), 3.13-3.20 (m, 2H), \ 2.72 (t, 2H, J = 6.6 Hz), 1.93-1.99 (m, 2H), 1.10-1.16 (m, r '.2H), 0.94 (t, 2H, J - 8.1Hz), 0.09 (s, 9H), - 0.O5 (s, 9H) .. P.
(e) Example 54 -5- [3- (1-Benzoimidazol-2-yl) -l, 15-yl-indazol-5-yl] -1,2,3,4,4a, 8a-hexahydro- [1, 7] Naphthyridine: The title compound was prepared in a 64% yield by deprotection SEM and SES '"of intermediate 54d analogously to 20-procedure used for Example 41. XH NMR (300 JMHz, DMSO-de ) d 13.71 (s, ÍH), 13.00 (s, ÍH), 8.41 (s, .H),; 7.82 (s, ÍH), 7.69 (d, 2H, J = 8.7 Hz), 7.63 (s, 1H) , 7.50, (d, 1H, J = 7.2 Hz), 7.44 (dd, 1H, J - 8.7, 1.5 Hz), 7.16-7.22 (m, 2 H), 6.11 (s, 1H), 3.23 (br s, 2H), 2.55 (t, 2H, J =
f > , - ss¿- ^
A i 222
The title compound was prepared in a 78% yield by means of the SEM deprotection of intermediate 55b in a manner analogous to procedure i used for example 41. H NMR (300 MHz, DMSO-de) d 13.95t < (s, ÍH), 13.04 (s, ÍH), 10.98 (s, ÍH), 9.54 (s, 1H), 9.30 (d, 2H, J * 1.8 Hz), 8.83 (dd, ÍH, J = 4.8, 1.8 Hz), 8.65 (s, ÍH), 8.59 (s, ÍH), 8.45-8.50 (m, 4H), 7.52-7.66 (m, 4H), 7.18 (br s, 2H). Analysis (C29Hi9N70 • 0.5H20) C, H, N. MS (ES) [m + H] / z calculated 482, found 482.
Example 56: N-. { 4- [3- (l-Benzo m? Dazol-2-yl) lg-? Ndazol-5-al] -isoqu? Nolm-8-? L} - acetamide
[Dioxane = Dioxane]
"* < = »223
(a) Intermediate 56a-N- (4-B? Fmf-soquinol? n-8-? l) -acetamide: 8-Am? no-4-bromo-? soqu? nolma (300 mg, 1.35 m ol ), DIEA (0.94 m, 5.38 mmol) and acetic anhydride (255 uL, 2.7 5 'mmol) were stirred in chloroform (20 ml) at reflux temperature for 16 hours. The solution was washed with and # brine, dried (Na 2 SO) and concentrated in vacuo. The residue was stirred in ethanol (6 ml) with HOAc (2 ml) at a temperature of 72 ° C for 20 hours. The ib * solution was either cooled or diluted and diluted with ethyl acetate. The organic compounds were washed with 1 N NaOH and brine, dried (MgSO 4), and concentrated in vacuo. Purification by # chromatography on silica gel (ethyl acetate) gave 232 mg (65%) of intermediate 56a ßn 15 as a white solid. XE NMR (300 MHz, CDCl 3) § 10.31 (s, 1H), 9.47 (s, ÍH), 8.77 (s, 1H), 7.90-7.97 (, 3H), 2.21 (s, 3H). Analysis (CnH9BrN20) C, H, N.
(b) Intermediate substance 56b-27-. { 4-l3- (lH- Benzoi? N? Dazol-2-? L) -1- (2-tpmet? Ls? Lanil-efe? ExXymethyl) -lflA 0? Ndazol-5-? L] -? Soquinol? N -8-? L} Acetamide: The title compound was prepared in an 80% yield from the intermediate Z5a, and the intermediate 56a in a manner similar to the "procedure used for the intermediate 41a.lH 5 NMR (300 MHz, CDC13) d 10.39 (s, ÍH), 9.46 (s, ÍH), 8.76 (s,
2 ÍH), 8.53 (s, ÍH), 8.42 (s, 1H), 7.91 (d, ÍH, J = 7.2 Hz), 7.89 (d, ÍH, J = 7.2 Hz), 7.62-7.72 (m, 3H) , 7.48-7.57 (ra, 3H), 7.24-7.28 (m, ÍH), 5.83 (s, 2H), 3.65 (t, 2H, J - 8.1Hz), 2.35 (s, 3H), 0.95 (t,
(c) Example 56-il) -lfi-indazol-5-yl] -isoquin
The title compound was prepared in a "~ * 4. • - - - yield of 68% by means of the SEM deprotection of "intermediate 56b in a manner analogous to the procedure used for example 41. XH NMR (300 MHz, DMSO-de) d 13.84 (s, 1H) , 13.03 (s, ÍH), 10.34 (s, ÍH), 9.56 (s, 1H), 8.61 (s, ÍH), 8.55 (s, ÍH), 7.82-7.89 (m, 2H), 7.74 (t, 1H , "% ** J = 7.2 Hz), 7.59-7.66 (m, 3H), 7.51 (d, 1H, J = 7.2 f? Z), 7.13-7.21 (m, 2H), 2.25 (s, 3H). Analysis (C25H? 8N60 • 0.4H20) C, H, N. MS (ES) [m + H] / z calculated 419, found 419,
Example 57: N-. { 4- [3- (l-Benzoimidazol-2-yl) lfl-i da2 l-5-% * ^ t jl] -isoquininolin-8-il} benzyl amine
[Dioxane = Dioxane] t
(a) Intermediate 57a-Benzyl- (4- 15-bromo-? soqu? nol? na-8-? l) -amine: 8-Am? no-4-bromo-? soqumol? na (220 mg, 0.99 mmol) and benzaldehyde (110 μl, 1.1 mmol) were stirred in ethanol (15 ml) / HOAc (0.2 ml) at the reflux temperature for 24 hours. The reaction was cooled to a temperature of 0 ° C, and sodium cyanoborohydride (622 mg, 9.9 mmol) was added in portions. After stirring for 1 hour, the reaction was diluted with H2G. and extract with ethyl acetate. The organic compounds were washed with brine, dried (Na 2 SO 4 and concentrated in vacuo.
The title compound was prepared in a < 72% yield by means of the SEM deprotection of id "" intermediate substance 57b analogously to the procedure
used for example 41. H NMR (300 MHz, DMSO-de) $ 13.80 (s, ÍH), 13.01 (s, ÍH), 9.71 (s, 1H), 8.56 (s, ÍH), 8.42 (s, 1H ), 7.71-7.81 (m, 2H), 7.30-7.63 (m, 8H), 7.17- 7.25 (m, 3H), 6.90 (d, ÍH, J = 7.2 Hz), 6.52 (d, ÍH, J- 7.2 Hz), 4.57 (d, 2H, J = 5.4 Hz). Analysis (C3oH22N6 • 0.5 H2Q) C, H, N. MS (ES) [m + H] / z calculated 467, found 467.
10
Example 58: 3- [3- (l-Benzo m-dazol-2-yl) -H-ndazol * -5-l] -4-met l- [3, 3 '] b? P r? Dmil
[Dioxane = Dioxane] 25
? í $?
(a) Intermediate 58a-5-Bromo-4-methyl- [3, 3 '] bipyridinyl: The title compound was prepared in a 54% yield from 3,5-d-bromo-4-met ? lp? r? dihd and 3-pipd? lonic acid in a manner analogous to the procedure * used for intermediate 53a. 1H NMR (300 MHz ,,, CDC13) d 8.67-8.71 (m, 2H), 8.59 (dd, ÍH, J * 2.4, 0.6 Hz), 8.33 (s, ÍH), 7.62-7.66 (m, ÍH), 7.39-7.44 (m, ÍH), 2.35 (m, 3H). Analysis (CnH9BrN2 • 0.1H2O) C, H, N.
(b) Intermediate substance 58b-3- [3- (lff-Benzo? m? dazol-2-yl) -1- (2-trimethylamino? -ethoxymethyl) -Ifl-? ndazol-5-? l] -4-met? L- [3, 3 'Jbípiridinil:
The title compound was prepared in a 37% yield from intermediate 25a and intermediate 58a in a manner analogous to the procedure used for intermediate 41a. H NMR (300 MHz, CDC13) d 10.24 (s, ÍH), 8.68-8.71 (m, 3H), 8.61 * (s, ÍH), 8.47 (s, ÍH), 7.85-7.88 (m, ÍH), 7.70 -7.78 (m, 2H), 7.42-7.53 (m, 3H), 7.26-7.33 (m, 2H), 5.83 (s, 2H), 3.64 (t, 2H, J - 8.1HZ), 2.19 (s, 3H) ), 0.95 (t, 2H, J - 8.1Hz), -0.05 '(s, 9H). 4 -
(c) Example 58 -3- [3- (1-Benzoimidazol-2-yl) -l, -mdazol-5-yl] -4-methyl- [3, 3 '] bipyridyl:
The title compound was prepared in a yield of 74% by means of the deprotection SEM of the intermediate substance 58b analogously to the procedure used for example 41. lE NMR (300 MHz, DMSO-d «) d 13.79 ( s, ÍH), 13.02 (s, ÍH), 8.72 (d, 1H, J -.1.5 Hz), §, 65 (dd, ÍH, J - 4.8, 1.5 Hz), 8.54 (s, ÍH), 8.52 ( s, 1H), 8.48 (s, ÍH), 7.96-8.00 (m, ÍH), 7.78 (d, ÍH, J - 8.7 Hz), 7.6S (d, ÍH, J = 7.5 Hz), 7.49- 7.57 (m, 3H), 7.17-7.23 (m, 2H), 2.16 (s, 3H). Analysis (C25H? 8N6 • 0.6H20) C, H, N. MS (ES) [m + H] / z calculated 403, found 403.
Example 59: (E) -3-. { 5- [3- (LFI-Benzoimidazo > l- til) -lfí-indaiol-5-yl] -4-methyl-pyridin-3-yl} -prop-2-in-l-ol
? je plo 60: (E) -3-. { 5- [3- (1-Benzyl] imidazol-2-yl) -lff-inda-1 -5-iX] -4-methylpyridin-3-yl} -propan-l-ol
[Pipepdme = Piperidma Pypdme = Pyridine Reflux = Reflux Dioxane = Dioxane]
(a) Intermediate 59a-5-Bromo-4- met? l-pyr? dma-3-carbaldehyde: 3,5-D? bromo-4-met? lp? pd? na (3.8 g, 15.1 mmol) s? stirred in dry THF (150 ml) at a temperature of -100 ° C (N2 / ether) in argon. N-Butyllithium (2.5 M) was added dropwise
Hz), 4.29 (q, 2H, J «7.2 Hz), 2.50 (s, 3H), 1.35 (t, 3H, p> = 7.2 Hz). Analysis (CnH12BrN02) C, H, N.
(c) Intermediate substance 59c - (E) -3-. { 5- [3- (1-Benzoimidazol-2-yl) -1- (2-trimethylsilanyl-ethoxymethyl) -lfl-indazol-5-yl] -4-methyl-pyridin-3-yl} ethyl ester of acrylic acid: The title compound was prepared in an 83% yield from intermediate 25a and intermediate 59b in a manner similar to the procedure used for intermediate 41a. iH,
NMR (300 MHz, CDC13) d 10.00 (s, ÍH), 8.74 (s, ÍH), 8.65 (s, ÍH), 8.55 (s, ÍH), 7.99 (d, ÍH, J = 15.9 Hz), 7.83- 7.87 (m, ÍH), 7.71 (d, 1H, J = 8.7 Hz), 7.50-7.53 (m, ÍH), 7.43 (dd, ÍH, J - 8.7, 1.5 Hz), 7.27-7.32 (m, 2H) , 6.50 (d, ÍH, J «15.9 Hz), 5.84 (s, 2H), 4.31 (q, 2H, J = 7.2 Hz), 3.65 (t,
2H, J = 8.1Hz), 2.36 (s, 3H), 1.37 (t, 3H, J - 7.2 Hz), 0.95 (t, 2H, J = 8.1Hz), -0.04 (s, 9H).
(d) Intermediate substance 59d- (E) -3-. { 5- [3- (IHr Benzoimidazol-2-yl) -1- (2-trimethylsilanyl-ethoxymethyl) - x J.fí-? Ndazol-5-yl] -4-met? Lp? Rid? N-3-il } -prop-2-en-l-ol: A solution of intermediate 59c (402 mg, 0.73 mmol) in ether (10 ml) was added dropwise to a stirred suspension of LAH (180 mg, 4.74 mmol) in ether (10 ml) at a temperature of 0 ° C. He let the
-4 > ísS # fef «'' EfCWÍ
reaction for 3 hours while warming it to room temperature. The reaction was tempered with water and? it was extracted with ethyl acetate. The organic compounds were washed with brine, dried over Na 2 SO 4, and concentrated in vacuo. Purification by chromatography on silica gel (50% to 100% ethyl acetate / hexanes) provided 72 mg (19%) of intermediate 59d as a white foam (followed by 186 mg (50%) ) of intermediate '59e) XE NMR (300 MHz, CDC13) d 9.99 (s, ÍH), 8.64 (s, ÍH), 8.63 (S, 1H), 8.45 (s, ÍH), 7.83-7.87 (m , ÍH) - 7.69 (d, ÍH, J = 8.7 Hz), 7.50-7.53 (m, ÍH), 7.43 (dd, ÍH, J = 8.7, 1.5 Hz), 7.26-7.32 (m, 2H), 6.86 ( d, ÍH, J - 15.9 Hz), 6.33-6.41 (m, 1H), 5.84 (s, 2H), 4.42 (br s, 2H), 3.65 (t, 2H, J = 8.1Hz), 2.28 (s, 3H), 1.73 (br s, 1H), 0.95 (t, 2H, J = 8.1Hz), -0.04 (s, 9H).
(e) Intermediate substance 59e - (E) -3-. { 5- [3- (1-Benzoyl? Dazol-2-? L) -1- (2-trimethylaryl-ethoxymethyl) -lfl-mdazol-5-? L] -4-methyl-pyridin-3? l) - propan-1-ol: See the procedure used for the intermediate substance 59d above. XE NMR (300 MHz, CDCl 3) d 10.17 (s, ÍH), 8.63 (s, ÍH), 8.40 (s, 2H), 7.83-7.87 (m, 1H), 7. ^ 68 (d, ÍH, J = 8.7 Hz), 7.49-7.52 (m, ÍH), 7.43 (dd, IB, J - 8.7, 1.5 Hz), 7.26-7.31 (m, 2H), 5.83 (s, 2H), 3.77 (t, 2H,
-"' 2. 3. 4
J = 6.3'Hz), 3.65 (t, 2H, J = 8.1Hz), 2.82 (t, 2H, J - 7.5 Hz), 2.24 (s, 3H), 1.88-1.95 (m, 2H), 1.74 (br s, ÍH), 0.94 (t, 2H, J - 8.1Hz), -0.05 (s, 9H).
(f) Example 59 - (E) -3-. { 5- [3- (1 * -B < Snzoimidazol-2-yl) -lH-indazol-5-yl] -4-methyl-pyridin-3-yl} -prop-2-en-l-ol: The title compound was prepared in a 50% yield by means of the SEM deprotection of intermediate 59d in a manner analogous to the procedure used for example 41. aH NMR (300 MHz , DMSO-de) d 13.78 (s, ÍH), 13.02 (s, ÍH), 8.63 (s, ÍH), 8.43 (s, ÍH), 8.35 (s, ÍH), 7.75 (d, ÍH, J = 8.7 Hz), 7.63 (br. S, 1H), 7.55 (br s, ÍH), 7.46 (dd, ÍH, J - 8.7, 1.5 Hz), 7.20 (br s, 2H), 6.83 (d, ÍH, J - 15.9 Hz), 6.37-6.46 (m, 1H), 4.99 (t, ÍH, J = 5.4 Hz), 4.19 (s, 2H), 2.23 (s, 3H). Analysis (C23H19N5O «0.6 H20) C, H, N. MS (ES) [m + H] / z calculated 382, found 382.
(g) Example 60 - (E) -3-. { 5- [3- (L-, Benzoimidazol-2-yl) -lfl-mdazol-5-yl] -4-methyl-pyridm-3-yl} -propan-1-ol: The title compound was prepared in a 62% yield by means of the SEM deprotection of intermediate 59e in a manner analogous to the procedure used for example 41. XH NMR (300 MHz, DMSO-de ) d 13.77 (s, 1H), 13.02 (s, ÍH), 8.41 (S, ÍH), 8.37 (s,? H),
8. 30 (s, ÍH), 7.73 (d, 1H, J * 8.7 Hz), 7.67 (br s, ÍH), 7.52 (br s, ÍH), 7.44 (dd, ÍH, J = 8.7, 1.5 Hz), 7.19 (br s, -2H), 4.57 (t, ÍH, J - 5.1Hz), 3.49 (q, 2H, J - 6.0 Hz),, 2.74"* y * (t, 2H, J - 7.8 Hz), 2.21 (s, 3H), 1.69-1.79 (m, 2H). ^ í
Analysis (C23H21N5O • 0.5H20) C, H, N. MS (ES) [? FH-H] / z *
calculated 384, found 384.
Example 61: 5- [3- (1-Benzo? M dazol-2-? L) - > lí-ijr > dazol-5-i l * 4-r et? l- [3,4 '] b? p? r? d? n?
(a) Intermediate 61a-3, 5-Dβ-brom-4-et l-pyridine: The title compound was prepared in a yield of 74% by the substitution of iodoethane with iodomethane in the process for the preparation of 3,5-
ít £
**
It was concentrated in vacuo. The on silica gel (75% a
gave 232 mg (60%) of the intermediate substance 61c ^ form of a clear colored oil. 1H NMR (300 MHz, CDC13) d 10.18 (s, ÍH), 8.71-8.75 (m, 3H), 8.57 (s, ÍH), 8.41 (s, ÍH), 7.84-7.87 (m, ÍH), 7.71 ( d, ÍH, J - 8. Hz), 7.48- 7.53 (m, 2H), 7.36 (dd, 2H, J = 4.5, 1.5 Hz), 7.26-7.32 (, 2H), 5.84 (s, 2H), 3.65 (t, 2H, J- 8.1Hz), 2.64 (q, 2H, J -7.5 Hz), 0.94 (t, 2H, J «8.1Hz), 0.77 (t, 3H, J = 7.5 Hz), - 0.04 ( s, 9H).
(d) Example 61-5- [3- (1-Benzoimidazol-2-yl) -lfi-anda2ol-5-? l] -4-et? l [3, 4 '] b? p? r? din? 1: The title compound was prepared in a 61% yield by means of the SEM deprotection of intermediate 61c, analogous to the procedure used for example 41. 1 H NMR (300 MHz, DMSO-de) d 13.79 (s, 1H), 13.02 (s, ÍH), 8.71 (dd, 2H, J = 4.5, 1.5 Hz) , 8.51 (s, 2H), 8.40 (s, ÍH), 7.78 (d, ÍH, J * 8.7 Hz), 7.68 (d, ÍH, J = 7.5 Hz), 7.49-7.56 (m, 4H), 7.14- 7.25 (m, 2H), 2.59 (q, 2H, J - 7.5 Hz), 0.69 (t, 3H, J = 7.5 Hz). TAnállsiS (C26H20N6 • 0.3H20) C, H, N. MS (ES) [m + H] a calculated 417, found 417.
Example 62: 3- [3- (1-Benzooim? Da2ol-2-? L) -lfi-imtazol-5-yl] -4- - *. .., j - * ft 6 methyl- [2, 3 '] bipyridine?
[Sulfur = Sulfur Dioxane = Dioxan Anisol = Anisol]
(a) Intermediate 62a-3- (l-Benzoimidazol-2? l) -5-iodo-l- (4-m tox? -benzyl) -lfl? nda2?: The title compound was prepared in a yield of 59% from intermediate 19d and phenylenediamine in a manner similar to the procedure used for intermediate 7c '. ? E NMR (300 MHz, DMSO-ds) d 13.06 (s, ÍH), 8.91 (s, ÍH), 7.70-7.78 (m, 3H), 7.51 (dd,
239
ÍH, J - 6.3, 2.1Hz), 7.19-7.28 (m, 4H), 6.88, (dd, 2H, J = 6.6, 2.1Hz), 5.72 (s, 2H), 3.69 (s, 3H). Analysis (C22H? 7IN40) C, H, N.
(b) Intermediate 62b-3 * - (lff-Benzoimidazol-2-yl) -l- (4-methoxy-benzyl) -5- (4,5,5-tetramethyl [1, 3, 2] dioxaborolan-2 -il) -lfí-indazol:
The title compound was prepared in a 73% yield from the substance in a manner analogous to the preparation of
'intermediate 19e. XH NMR (300 MHz, DMSO-de) d 13.03 (s, 1H), 8.93 (d, ÍH, J - 4.2 Hz), 7.78-7.84 (m, 2H), 7.73 (dd, ÍH, * J = 8.7, 0.9 Hz), 7.51 (d, ÍH, J = 7.2 Hz), 7.20-7.27 (m, 4H), 6.87 (d, 2H, J «8.7 Hz), 5.74 (s, 2H), 3.68 (s, 3H), 1.34 (s, 12H). Analysis (C28H29BN403) C, H, N.
$ (c) Intermediate 62c-5 '-Bromo- * f-methyl- [2, 3' J bipyridinyl: p. 3, 5-Dibromo-4-met? L-pyridine (2.0 g, 7.8 mmol) and 2-tributyltanamlpyridine (2.4 g, 6.5 mmol) were shaken nn? Oxano (20 ml) in a purged beaker with argon. 0 Tetrakis (triphenylphosphine) -palladium (0) (600 mg, * 0.5 mmol) was added and the reaction was stirred at a temperature of 100 ° C for 80 hours. The solution was concentrated in vacuo and purified by chromatography on silica gel (30% to 50% ethyl acetate / hexanes, two purifications) to
provide 788 mg (49%) of intermediate 62c as a white solid. ? E NMR (300 MHz, CDC13) 8.72-8.75 (m, ÍH), 8.70 (s, ÍH), 8.46 (s, 1H), 7.78-7.84 (m, ÍH), 7.31-7.42 (m, 2H) , 2.42 (s, 3H). Analysis (CuH9BrN2) C, H, N. f (d) Intermediate 62d-3- [3- (lfl * -Benzoimidazol-2-yl) -1- (4-methoxy-benzyl) -lfi-indazol-5- il] -4- ethyl- [2, 3 '] bipyridini1: The title compound was prepared in a 76% yield from intermediate 62b, and intermediate 62c similarly to the "procedure employed for intermediate 61c. XH -NMR (300 MHz, DMSO-d6) d 13.08 (s, ÍH), 8.73 (d, ÍH, J = 4.2 Hz), 8.52-8.57 (m, 3H), 7.92-7.98 (m, 2H), 7.68 -7.72 (m, 2H), 7.58 (dd, ÍH, J - 8.7, 1.5 Hz), 7.51 (d, ÍH, J = 7.2 Hz), 7.43-7.47 (m, ÍH), 7.36 (d, 2H, J = 8.7 Hz), 7.17-7.23 (m, 2H), 6.91 (d, 2H, J = 8.7 Hz), 5.79 (s, 2H), 3.70 (á, 3H), 2.21 (s, 3H). Analysis (C33H26N6O) C, H, N.
(e) Example 62 -3- [3- (1-Benzoimidazol-2-yl) -lfl-ipdazdl-5-yl] -4-met? l- [2, 3 '] bipyridinyl: Intermediate 62d (400 mg, 9.77 mmol) was stirred in a solution of concentrated H2SO4 (1 ml) and anisole (1 * ml) in TFA (8 ml) for 48 hours. The solution was concentrated to a volume of ~ 3 ml in vacuo and then quenched with NaHCO3"pi *. *
»« ~ I i 2 * • h *
Saturated and extracted with ethyl acetate / THF in a ratio of 4: 1. The organic compounds were washed with brine, dried (MgSO 4) and concentrated in vacuo. Purification by chromatography on silica gel 0.% "
NH40H / 6% to 10% MeOH / ethyl acetate) yielded 102 mg
(33%) of the substance of Example 62 in the form of a white solid. XE NMR (300 MHz, DMSO-de) d 13.78 (s, ÍH),
13. 02 (s, 1H), 8.74 (d, ÍH, J = 4.2 Hz), 8.57 (s, 1H), 8.53
(s, ÍH), 7.51 (s, ÍH), 7.93-7.99 (m, ÍH), 7.77 (d, ÍH, J = 8.7 Hz), 7.70 (d, 2H, J = 7.8 Hz), 7.43-7.56 ( m, 3H), 7.20
(br s, 2H), 2.23 (s, 3H). Analysis (C25H? 8N6 • 0.5 H20) C, H,
N. MS (ES) [m + H] / z calculated 403, found 403.
Example 63: l-. { 5- [3- (1-Benzoimidazol-2-yl) -fí-indagol-5-yl 3 ^ 3, 4-dihydro-2-yl [1,7] naphyridin-1-yl} -etanone
•%. 243
(b) Intermediate 63b-1- (5 ~ B-OHOH ~ 3,4-dihydro-2-y [1, 7] naphthyrid? n-1-yl) ethanone: Intermediate 63a (212 mg, 1.0 m ol) ), DIEA (1.4 m, 8.0 mmol) and acetic anhydride (4.0 mraol) were stirred in dry chloroform (10 ml) at a temperature of ',
68 ° C for 40 hours. The solution was washed with saturated NaHCOs and brine, dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on silica gel (70% ethyl acetate / hexanes) provided 242 mg (95%) of the intermediate 63b as a white solid. XH NMR (300 MHz, CDC13) d 8.61 (br s, ÍH), 8.46 (s, ÍH), 3.79 (q, 2H, J = 6.0 Hz), 2.83 (t, 2H, J = 6.9 Hz.}., 2.93 (s, 3H), 2.01-2.08 (m, 2H) Analysis (C1QHnBrN20) C, H, N.
(c) Intermediate substance 63c-1-. { 5- [3- (1-Benzoimidazol-2-yl) -1- (2-trimethylsilanylethyloxymethyl) -lfl-indazol-5-yl] -3,4-dihydro-2-yl] [1,7] naphthyridin-1-yl } - ethanone: - s The title compound was prepared in an 83% yield from intermediate 25a and intermediate 63c in a manner similar to the procedure used for intermediate 61c aH NMR (300 MHz, CDC13) d 10.06 (s, ÍH), 8.68 (s, ÍH), 8.55 (br s, ÍH), 8.42 (s, ÍH), 7.84-7.87 (m, ÍH), 7.71 (d, ÍH, J - 8.7 Hz), 7.50-7.53 (m, ÍH), 7.46 (dd, ÍH, J = 8.7, 1.5 Hz),
7. 2? -7.32 (m, 2H), 5.84 (s, 2H), 3.84 (t, 2H, J - 6.6 Hz), 3.64 (t, 2H, J = 8.1Hz), 2.70 (t, 2H, J - 6.6 -Hz), 2.36 (S, 3H), 1.87-1.93 (m, 2H), 0.94 (t, 2H, J = 8.1Hz), -0.04 (S, 9H). Analysis (C3oH34Ne02Si «0.5 H20) C, H, N.
(d) Example 63-1- (5- [3- (1-Benzimidazol-2-yl) -lfl-indazol-5-yl] -3,4-dihydro-2-yl [1, 7] naphthyridin-1 - il.} - ethanone: The title compound was prepared in a 65% yield by means of the SEM deprotection of the intermediate 63c in a manner analogous to the procedure used for example 41. 1 H NMR (300 MHz, DMSO -de) d 13.77 (s, ÍH), 13.02 (s, ÍH), 8.78 (s, ÍH), 8.46 (br s, ÍH), 8.27 (s, ÍH), 7.75 (d, 1H, J = 8.7 Hz ), 7.67 (br. S, ÍH), '' 7.49 (dd, 2H, J = 5.7, 1.5 Hz), 7.20 (br s, 2H), 3.74 (t, 2H, J = 6.3 Hz), 2.63 (t , 2H, J - 6.3 Hz), 2.27 (s, 3H), *
1. 79-1.85 (m, 2H). Analysis (C24H20NeO) C, H, N. MS (ES) [m + H] / z calculated 409, found 409.
Ejepplo 64: 5- [3- (lH-Benzoimidazol-2-yl) -lH-indazol ^ -5 * - il] -4-methyl-nicotinamide
Chromatography on silica (ethyl 5: 1 to 10: 1 hexanes-acetate and then with 100% ethyl acetate) yielded 236 mg (9%) of the 64a amide. Rf = 0.09 (50% ethyl acetate in hexanes); XH NMR (300 MHz, CDC13) d 8.70 (bs, ÍH), 8.54 (bs, 1H), 5.98 (bs, ÍH), 5.93 (bs, ÍH). (LCMS: M + 215).
(b) Intermediate substance 64b-5- [3- < L-Benzoim? dazol-2-yl) -1- (2-trimethylsilylethylethoxymethyl) -lfl-indazol-5-yl] -4-methyl-nicotinamide: The title compound was prepared in a 75% yield from of intermediate 25a and intermediate 64a in a manner similar to the procedure used for intermediate 61c. 1H NMR (300 MHz, CDC13) d 10.18 (s, ÍH), 8.66 (s, ÍH), 8.64 (s, 1H), 8.59 (s, ÍH), 7.82-7.86 (m, ÍH), 7.70 ( d, 1H, J = 8.4 Hz), 7.48-7.52 (m, ÍH), 7.42 (dd, ÍH, J «8.4, 1.5 Hz), 7.26-7.31 (m, 2H), 6.13 (br s, ÍH), 5.91 (br s, ÍH), 5.83 (s, 2H), 3. * 64 (t, 2H, J «8.1Hz), 2.40 (s, 3H), 0.94 (t, 2H, J - 8.1Hz), - 0.04 (s, 9H).
(c) Example 64-5- [3- (1-Benzo [mu] -dazol-2-yl) -lfl-indazol-5-yl] -4-methylnicotinamide: The title compound was prepared in a yield of 77% by means of the SEM deprotection of the intermediate substance 64b analogously to the procedure used for example 41. XH NMR (300 MHz, DMSO-de) d
13. 80 (s, 1H), 13.03 (s, ÍH), 8.54 (s, 1H), ß.50 (s, 1H), "f '8.45 (s, 1H), 8.05 (s, ÍH), 7.76 (d) , 1H, J * 8.7 Hz), 7.68 (br, s, 2H), 7.44-7.52 (m, 2H), 7.16-7.22 (m, 2H), 2.29 s,. 'R 3H) Analysis (C2iHi6N60 • 0.55 H20) C, H, N. MS (ES) [m + Ji] / z; calculated 369, found 369.
Example 65: 3- (1-Benzoimidazol-2-yl) '-5- [5- (1-methyl-4-yl) -4-methyl-1-pyridin-3-yl) -lfi-indazole 1?
65a 65b
(a) Intermediate 65a-3-Bromo-4-methyl-5-lfl-imidazole-4? -pyr? dma: To a stirred suspension of tosylmethyl isocyanide (1.02 g, 5.25 mmol) and 3- bromo-4-met l-5-formyl pyridine (1.0 g, 5 mmol) in 5 ral of dry ethanol was added finely powdered NaCN (25 mg, 0.5 mmol) to a
*. ,, x 248
temperature of 25 ° C. After 30 minutes, the reaction was concentrated in an oil. The resulting oil was added to a saturated solution of ammonia in dry methanol in a sealed tube and heated to 100 ° C for 24 - '/ hours. Cooling and concentration followed by chromatography on silica (10: 1 ethyl acetate-hexanps) provided 167 mg (14%) of intermediate 65a as a white solid. XE NMR (300 MHz, DMSO-d6) 12.45 (bs, ÍH), 8.71 (s, 1H), 8.55 (s, ÍH), 7.83 (S / ÍH), '"7.52 (s, 1H), 2.56 (s) , 3H).
(b) Intermediate 65b-3-Bromo-4-methyl-5- [1- (2-trimethylsilanyl-ethoxymethyl) -lfi-imidazol-4-yl] -pyridine: Intermediate 65a was protected with SEM in a yield 45% in a manner analogous to the procedure used for intermediate 49a. 1H NMR (300 MHz, CDC13) d 8.67 (s, ÍH), 8.60 (s, 1H), 7.70 (s, ÍH), 7.21 (d, ÍH, J - 1.2 Hz), 5.33 (s, 2H), 3.56 (t, 2H, J = 8.1Hz), 2.58 (s, 3H), 0.94 (t, 2H, J = 8.1Hz), 0.00 (s, 9H). Analysis (C? 5H22BrN3OSÍ) C, H, N.
(c) Intermediate 65s-3- (1-J2-imidazol-2-yl) -5-. { 5- [1- (2-Trimethyl-silyl-α-toxymethyl) -lfi-imidazol-4-yl] -4-methyl-pyridin-3-yl} -1- (2-trimethylsilanyl-ethoxymethyl) -lfi-indazole:
,? ^ -,. 249 f The title compound was prepared in an 83% yield from intermediate 2 & amp; and intermediate 65b in a manner similar to the procedure employed for intermediate 61c. 1H NMR (300 MHz, CDC13) d 10.09 (s, 1H), 8.85 (s, ÍH), 7.70 (S, ÍH), 8.50 (s, ÍH), 7.84-7.88 (m, ÍH), 7.68-7.74 ( m, 2H), 7.47-7.52 (m, 2H), 7.26-7.31 (m, 3H), 5.84 (s, 2H), 5.36 ($ | 2H), 3.55-3.68 (m, 4H), 2.41 (s, 3H), 0.92-0.98 (m, 4H), -0.01 (s, 9H), -0.05 (s, 9H).
(d) Example 65 -3- (1-Benzoimidazol-2-yl) -5- [5- (1-yl-imidazol-4-yl) -4-met? lp? ridin-3? l] -lfl-indazole :
> The title compound was prepared in a 43% yield by means of the SEM deprotection of the intermediate 65c in a manner analogous to the procedure used for example 41. XH NMR (300 MHz, DMS0-d6) d 13.78 (s, ), 13.02 (s, ÍH), 12.38 (s, ÍH), 8.83 (s, 1H), 8.47 (s, ÍH), 8.35 (s, ÍH), 7.83 (d, ÍH, J - 0.9 Hz), 7.76 (d, ÍH, J = 8.4 Hz), 8.69 (d, 1H, J = 7.5 Hz), 7.47-7.51 (ra, 3H), 7.16-7.22 (m, 2H), 2.37 (s, 3H). Analysis (C23H17N7 • 2 «5 * 'H20) C, H, N. MS (ES) [m + H] / z calculated 392, found 392.
Example 66: 4- [3- (4, 5, 6, 7-Tetrah? Dro-lfíj »bew &oimidago3.« - 2- jl) -lfí-mdazol-4 -? L] isoquinoline
(b) Intermediate 66b-4- [3- (4, 5,6,7-, 1-tetrahydro-1-benzyl-2-yl-2-yl-2-yl) -1- (2-tnmethylsilane-ethoxymethyl) -lfi -mda2? l-5-yl] -isoqumolma: The title compound was prepared in 75% yield from intermediate 6 a and. and acid? soqumolm-4-boron? co (EP 976747) similarly to the procedure used for intermediate 7d1, XH NMR (300 MHz, CDC13) d 9.57 (br s, ÍH), 9.28 (s, ÍH), 8.67 (s, ÍH), 8.58 (s, ÍH), 8.04-8.08 (m, 1H), 7.85-7.89 (s, 1H), 7.57-7.70 (m, 4H), 5.80 (s, 2H), 3.63 ( t, 2H, J - 8.1Hz), 2.7 (br s, 4 H), 1.86 (br s, 4 H), 0.96 (t, 2 H, J = 8.1 Hz) * - '0.03 (s, 9 H).
(c) Example 66-4- [3- (, 5,6,7-? ehydro-l-benzyl-2-yl-2-? l) -lfl-nda2? l-5-yl] -isoquinoline: The title compound was prepared in 64% yield by means of the SEM deprotection of intermediate 66b in a manner analogous to the procedure used for Example 41. X H NMR (300 MHz, DMSO-de) d 13.31 (s, ), 12.25 (s, ÍH), 9.36 (s, ÍH), 8.49 (s, 1H), 8.43 (s, ÍH), 8.24 (d, 1H, J = 7.8 Hz), 7.69-7.85 (m, 4H) , 7.53 (dd, 1H, J - 8.7, 1.8 Hz), 2.50 (br s, 4H), 1.73 (br s, 4H). Analysis (C23H19N5 • 0.2H20) C, H, N. MS (ES) [m + H] / z Calculated 366, found 366.
F"
Example 67: 4- [3- (4-Met? L-5-f in l-l-ymidazole-2-? L) - > lfí- '? ndazol-5-3. soqumol na
[Benzene = Benzene Reflux = Anisol Reflux = Anisole]
(a) Intermediate substance 67a-5-Iodo-l- (4-methoxy-benzyl) -3- (4-met? l-5-phen? l-lf? -m? dazol-2-? l) -lfi mdazole: The title compound was prepared from intermediate 19d and 1-phen? ll, 2-propanedione in a manner similar to the procedure used for intermediate 66a. XH NMR (300 MHz, CDC13) d 9.87 (br s, 0.5 H), "9.71 (br s, 0.5 H), 8.98 (br s, 0.5 H), 8.92 (br s, 0.5 H), 0 7.84 (d) , 1H, J = 7.2 Hz), 7.61 (dd, ÍH, J = 8.7, 1.5 Hz), 7.44-7.53 £ m, 3H), 7.31 (d, ÍH, J = 7.5 Hz), 7.11 (app d, 3H , J = 8.7 Hz), 6.81 (dd, 2H, J - 6.6, 1.8 Hz), 5.49 (s, 2H), 3.77 (s, 3H), 2.55 (s, 3H) Analysis (C25H2IN4?) C, H , N. 5
(b) Intermediate substance 67b-4- [1- (4-MefcF? i-benzyl) * S- (4-methyl-5-phenyl-1-yl-imidazol-2-yl) -% N-indazol-5-yl ] -isoquinoline: The title compound was prepared in a 75% yield from intermediate 67a and isoquinolm-4-boron acid co (EP 976747) analogously to the procedure used for intermediate 7d '. XH NMR (300 MHz, CDC13) d 9.97 (br s, 0.5 H), 9.85 (br S, 0.5 H), 9.28 (s, HI), 8.76 (br s, 0.5 H), 8.70 (br s, 0.5 H) ), 8.59 (s, 1H), 8.03-8.10 (m, ÍH), 7.90 (br s, 1H), 7.75 (br s, ÍH), 7.37-7.68 (m, 8H), 7.20-7.26 (m, 2H) ), 6.86 (dd, 2H, J = 6.6, 1.5 Hz), 5.60 (s, 2H), 3.78 (s, 3H), 2.54 (br s, 1.5H), 2.49 (br s, 1.5H).
(c) Example 67-4- [3- (4-Methyl-5-phenyl-1-yl-imidazol-2-yl) -lfl-indazol-5-yl] -isoquinoline: The title compound was prepared in a yield of 15% by means of the PMB protection of intermediate 67b in a manner analogous to the procedure used for example 62. XH NMR (300 MHz, DMSO-de) d 12.67 (s, ÍH), 13.02 (s, ÍH) , 9.38 (s, ÍH), 8.57 (s, ÍH), 8.53 (s, 1H), 8.25 (d, ÍH, J = 7.5 Hz), 7.66-7.91 (m, 6H), 7.57 (dd, ÍH, J - 8.7, 1.5 Hz), 7.30-7.33 (m, 2H), 7.15-7.18 (m, ÍH), 2.50 (s, 3H). Analysis (C 26 H 19 N • 0.5 H 20) C, H, N. S (ES) [m + H] / z calculated 402, found 402.
faith
• * 254
E em lo- 68: D methyl-. { 2- [5 * i £ ¡«g¡ ^ t -E., 4 '] bip ridinil-5- 1, i
il) -lfí-indazol-3-yl] -lfí- "ber? zoimidazol-4-A ^ - 'itethyl] -amjftjt
(a) Intermediate 68a- (2- [5-Iodo-l- (4-ethoxy-benzyl) -lfl-ndazol-3-yl] -lfi-benzoim-dazol-4-ylmethyl} -methanol: The title compound was prepared in a 40% yield from intermediate 19d and intermediate 23b in a manner similar to the procedure used for intermediate 7c.
NMR (300 MHz, DMSO-de) d 13 8.91 (s, ÍH), 7.64-7.77 (m, 1.5 Hz), 7.18-7.27 (m, 4H), (s, ÍH), 5.71 (s, ÍH), 5.14
5. 7 Hz), 4.86 (d, ÍH, J = 5.7 Hz), 3.69 (s, 3H) 1.
(b) Intermediate substance 68b -. { 2- [5-Iodo * l- * 4-toxy-benzyl] -lfl-indazol-3-yl] -lfi-benzoimidazol-4-yl-ethyl} -dimethylamine: • Intermediate 68a (2.5 g, 4.9 ramol) and -DIEA (1.38 m, 10 ramol) were stirred in THF (90 ml) at a temperature of 0 ° C. Methanesulfonyl chloride (0.76 g) was added. m, 9.8 mmol), and the reaction was stirred for 2.5 hours at a temperature of 0 ° C. Dimethylamine was bubbled through the solution for 1 minute and the reaction was stirred for 2 hours while warming room temperature. The solution was warmed with H20 and extracted with ethyl acetate. The organic compounds were washed with saturated NaHC 3 3 and brine, dried (Na 2 SO 4) and concentrated in vacuo. Purification by chromatography on * and on silica gel (0.2% NH40H / 3% MeOH / ethylpV '*' acetate gave 2.56 g (97%) of intermediate 68b "as a white foam. XH NMR (300 MHz, CDCl 3) S 9.07 (d, ÍH, J = 0.9 Hz), 7.80 (d, ÍH, J - 7.8 Hz), 7.63 (dd, 1H, J = 8.7, 1.5 Hz), 7.07-7.25 (m, 5H), 6.85 (dd, H,
t.
J = 6.6, 1.8 Hz), 5.61 (s, 2H), 3.77 (app s, 5H), 2.33 (s, 6H).
(c) Intermediate substance 68c -. { 2- [l- (4- *. * Methoxy-benzyl) -5- (4, 4, 5,5-tetramethyl- [1, 3, 2] dioxaborolan-2? L) -lfl-ndazol-3? L] -lfl-benzoimidazole-i, 4-1-methyl-dimethyl- amine: The title compound was prepared in a 62% yield from the intermediate substance * ß8b similar to the method used for the preparation of the intermediate substance 19e. XH NMR (300 MHz, CDC13) d 9.11 (s, », * ÍH), 7.82 (dd, 2H, J = 8.4, 0.9 Hz), 7.35 (dd, 1H, J» 8.4, 0.9 Hz), 7.16-7.21 (m, 4H), 6.85 (dd, 2H, J = 6.9, 1.8 H), 5.64 (s, 2H), 3.80 (br s, 2H), 3.76 (s, 3H), 2.35 (s, 6H) , 1.37 (s, 12H).
15 (d) Intermediate substance 68d - Dimet? L-. { 2- [5- > (4-methyl- [3,4 '] bip? Rid? Nil-5-yl) -1- (4-methoxy-benzyl) -l-yl-indazol-3-yl] -lfi-benzoimidazol-4-yl-met ? l} -amine: The title compound was prepared in an 85% yield from intermediate 68c 0 and intermediate 53a in a manner similar to the procedure used for intermediate 61c. 1H «MR (300 MHz, CDC13) d 8.69-8.75 (m, 4H), 8.57 (s, ÍH), 8.43 (s, ÍH), 7.75 (d, ÍH, J = 8.1Hz), 7.46 (d, ÍH) , J = 8.7 Hz), r 7.34-7.40 (m, 3H), 7.25-7.28 (m, ÍH), 7.19 (t, ÍH, J = 7.6
X¿2'k
(a) Intermediate 69a- [3- (5-Bromo-4-met? lp? r? dm-3-? l) -phenyl] -methanol: The title compound was prepared in a 79% rebirth from of 3, 5-d? bromo-4-met? l? r? d? na and 3 (hydroxymethyl) -feml-boronic acid in a manner similar to the procedure used for intermediate 53a. H NMR (300 MHz, CDC13) d 8.62 (s, ÍH), 8.22 (s, 1H), 7.42-7.46 (m, 2H), 7.29 (s, ÍH), 7.16-7.20 (m, 1H), 4.76 ( d, 2H, * J = 5.7 Hz), 2.48 (t, ÍH, J = 5.7 Hz), 2.32 (s, 3H). Analysis (C ^ 3H12BrNO «0.2 H20) C, H, N.
(b) Intermediate 69b - (3- { 5- [3- (l-Benzo? m? dazol-2-? l) -1- (4-methox? -benzyl) -lfl-mdazol-5- ll] -4-met? lp? r? dm-3-? l.}. - phenyl) -methanol:
The title compound was prepared in an 83% yield from intermediate substance 62b and intermediate 69a in a similar manner to the procedure used for intermediate 61c. 1H NMR (300 MHz, CDC13) d 10.39 (s, ÍH), 8.69 (s, ÍH), 8.45 (s, ÍH), 8.36 (s, ÍH), 7.83-7.87 (m, ÍH), 7.36-7.49 ( m, 7H), 7.22-7.31 (m, 4H), 6.84 (d, 2H, J = 8.7 Hz), 5.60 (s, 2H), 4.79 (s, 2H), 3.76 (s, 3H), 2.51 (br s, ÍH), 2.11 (s, 3H).
(c) Example 69- (3-. {5- [3- (1-Ben-2'-imidazol-2-yl) -lfl-indazol-5-yl] -4-methyl-pyridin-3-yl} .alpha.-methanol: The title compound was prepared in a 41% yield by means of PMB deprotection of intermediate substance 69b analogously to the procedure used for Example 62. 1H NMR (300 MHz, DMSO-d6 ) d 13.79 (s, ÍH), 13.02 (s, ÍH), 849 (d, 2H, J - 6.3 Hz), 8.41 (s, ÍH), 7.76 (d, ÍH, J = 8.7 Hz), 7.34-7.69 (m, 7H), 7.19-7.22 (m, 2H), 5.25 (br s, 1H), 4.58 (s, 2H), 2.15 (s, 3H). Analysis (C27H21N502 • 1 .2H20) C, H, N. MS (ES) [m + H] / z calculated 432, found 432.
Example 70: N- [2- (5-Isoquinolin-4-yl-1-yl-in & azol-3-yl) -3 H-benzo-imidazol-5-yl] methanesulfonamide-y *, '*
• m
[Anisol = Anisol]
0 (a) Intermediate substance 70a - N-. { 2- [5- Isoquinol? N-4-? L-l- (4-methoxy-benzyl) -lfl-mdazol-3-yl] -3f-benzo? M? Dazol-5-? L} -methanesulfonamide: The title compound was prepared in an 89% yield from the intermediate, Ißf * and N- (3,4-d? ammophen? l) methanesulfonamide (See Rajappa et al., Indian J. Chem. Sect. B, 19, 7, 1980, 533-535), d "d similar to the procedure used for intermediate 7c '. XH NMR (300 MHz, MeOD-d4) d 9.26 (s, ÍH) > 8.63 (s, ÍH), 8.49 (s, ÍH), 8.20 (d, ÍH, J - 7.8 Hz), 7.96 0 (d, 1H, J = 7.8 Hz), 7.72-7.81 (m, 3H), 7.58- 7.63 (m, 3H), 7.35 (d, 2H, J = 8.7 Hz), 7.16 (br s, HI), 6.89 (d, 2H, J * > 8.7 Hz), 5.76 (s, 2H), 3.75 ( s, 3H), 2.93 (s, 3H). Y. (b) EXAMPLE 70 N- [2- (5-Isoquinol-n-4-l-liy-indazol-3-yl) -3-f-benzo-m-dazol-5-l] -methanesulfonamide: 5
% -n -. ^^
t The title compound was prepared in a renßffiußnio á < 448% by PMB deprotection of the intermediate 70a analogously to the emulated procedure for example 62. 'H NMR (300 MHz, DMSO- <) d 1383 (s, ÍH), 1304 (s, ÍH) .954 (br s, ÍH), 940 (s.1H), 860 (s, 1H), i 55 X ís. ÍH), 827 (d, 1H, J = 87 Hz), 772-788 (m, 4H), 763 (dd, ÍH, J = 87.15 Hz), 754 (br s, ÍH), 746 $ ,. ÍH), 707 (d, 1H, J = 78 Hz) .291 (s, 3H) Analysis
• 105 H20) C, H, N, S MS (ES) lm + H] / z calculated 455, found 455
Example 71: N-. { 2- [5- (4-met l- [3,4 'Jb? Pr? D ru.l-5-il rlfr-nda2ol-3-? L) -3f-benzo midazole-5- l] -me tanosuif onamide
[Sulfur = Sulfur Anisol = Anisol "
(a) Intermediate 71a -1- (4-Met? x? -benzyl) -5- (4-methyl- [3,4 '] b? p? r? dm? l-5-? l) - lfí-indazol -3-carbaldehído:
*? * 262 \ S "The title compound was prepared by yielding 76% from the intermediate 19e ^ and the intermediate substance 53a in a manner similar to the * * - procedure used for the intermediate 610 »lH 5 ÍJMR (300 MHz, CDC13) d 10.28 (s, ÍH), 8.73 (dd, 2H, J =. 1.5 Hz), 8.49 (s, ÍH), 8.43 (s, ÍH), 8.31 (s, ÍH), 7.53 (d, ÍH, J - 8.7 Hz), 7.40 (dd, ÍH, J = 8.7, 1.5 Hz), 7.26-7.34 (m, 4H), 6.89 (d, 2H, J - 8.7 Hz), 5.67 (s, 2H), 3.79 (s, 3H), 2.15 (s, 3H). Analysis (C27H22N402 • 0.25 H20) C, H,. '
0 (b) Intermediate substance 71b - 2? -. { 2- [5- (4-ethyl- [3,4 '] bipyr? Dinyl-5-yl) -1- (4-methoxy-benzyl) -I-yl-indazol-3-yl) -3-yl-benzoimida-2-yl-5- il] -methanesulfonamide: The title compound was prepared in a 96% yield from intermediate 71a 5 and hh (3, -diam? nophenyl) methanesulfonaraide in a manner similar to the procedure used for intermediate 7c '. 1 H NMR (300 MHz, MeOD-d 4) d 8.66 (dd, 2 H, J = 4.5, 1.5 Hz), ^ .52 k 1 .-, *
ÍS, 2H), 8.39 (s, ÍH), 7.73 (d, ÍH, J = 8.7 Hz), 7.47-7, .65 (m, 5H), 7.35 (d, 2H, J = 8.7 Hz), 7.17 ( br s, ÍH), 6.86 (d, 2H, J = 8.7 Hz), 5.72 (s, 2H), 3.73 (s, 3H), 2.94 (s, 3tí) ', * «
2. 24 (s, 3H).
(C) Example 71 - N-. { 2- [5- (4-met? L-3, 4 /] bipyridinyl-5-yl) -lfl-indazol-3-yl) -3? -benzoimidazol-5-yl] -methanesulfonamide:
! - **? : tp, 263 x The title compound was prepared in a yield of 35% by means of the PMB deprotection of the intermediate 71b in a manner analogous to the procedure used for example 62.? 'E NMR (300 MHz, DMSO-c) δ 13.79 (s, 1H), 13.02 (s, ÍH), 9.56 (s, 1H), 8.70 (d, 2H,. - 5.7 Hz), 8.54 (s, 1H ), 8.47 (d, 2H, J - 7.8 Hz), 7.78 (d, ÍH, J * 8.7 Hz), 7.49-7.58 (m, 5H), 7.10 (d, 1H, J *? '. 7, Hz) , 2.93 (s, 3H), 2.17 (s, 3H). Analysis (C2sH21N702S • 1.45H20) C, H, N, S. MS (ES) [m + H] / z calculated 496, found fe. S '., T 10 Example 72:. { 5- [3- (1-Benzo? M? Dazol-2-yl) -lfi-mda2? L * $ -Il] -4-met l-p? R? Din-3- l} -methanol * *
(a) Intermediate 72a - (5-Brom * -4-met? l-pindm-3? l) -methanol:
ff »" '' 264 > ** 4 Intermediate 59a (1.5 g, 7.5 mmol) was stirred in MeOH at a temperature of 0 ° C, Sodium borohydride (850 mg, 22.5 ramol) was added and The reaction was stirred for 1 hour, the solution was diluted with ethyl acetate and the organics were washed with H 2 O and brine, dried (MgSO 4) and concentrated in vacuo, purification by chromatography on silica gel. % to 100% ethyl acetate / hexanes) yielded 1.39> g-e (92%) of intermediate 72a as a white solid XH NMR (300 MHz, CDC13) d 8.59 (s, 1H ),, 8.38 .., ** (s, ÍH), 8.43 (s, 1H), 4.75 (d, 1H, J = 5.4 Hz), 2.45 4 (s, 3H), 2.37 (t, ÍH, J = 5.4 Hz).
(b) Intermediate substance 72b-. { 5- [3- (1-Benzo? M? Dazol-2-yl) -1- (4-methox? -benz? L) -lfl-indazol-5-yl] -4-met? Lp? Ridin-3 -? l} -methanol: The title compound was prepared in a *** 92% yield from intermediate 62b and intermediate 72a in a manner similar to the procedure used for intermediate 61c. 1H 'NMR (300 MHz, CDC13) d 10.48 (s, ÍH), 8.62 (s, ÍH), 8.48 (s, 1H), 8.42 (s, ÍH), 7.83 (br s, ÍH), 7.45 (d, 2H, J = 8.7 Hz), 7.21-7.32 (m, 5H), 6.83 (d, 2H, J - 8.7 Hz), 5.60, (d, 2H, J = 4.5 Hz), 4.80 (s, 2H), 3.76 (s, 3H), 2.25 (s, 3H), 1.94 (br s, ÍH).
* T X 'A.ISJ? SM = J rr * • '* .rt: *** i
r *? » 265
(c) Example 72 -. { 5- [3- (1-Benzoxm? Dazol-2-yl) -l-? Nda2? L-5-? L] -4-met? L-p? R? Dm-3-? L} -methanol: The title compound was prepared in u? *, yield of 59% by means of PMB deprotection of intermediate 72b analogously to the procedure used for example 62. XH NMR (300 MHz, DMSO-dg) d *? 13.78 (s, ÍH), 13.01 (s, Í 8.39 (s, ÍH), 7.75 (dd, ÍH,
"7.2 Hz), 7.50 (d, ÍH, J = 7.2 Hz), 7.44 (dd, ÍH, J = 8.4,
0 1.5 Hz), 7.15-7.23 (m, 2H), 5.29 (t, ÍH, J = 5.4 Hz), 4.64 (d, 2H, J = 5.4 Hz), 2.22 (s, 3H). Analysis (C2? H? 7N50 • 1.25H20) C, H, N. MS (ES) [m + H] / z calculated 356, found 356.
Example 73: { 5- [3- (lfí-Benzo? M? Dazol-2-? L) -lfífcinda2? J. »- 5-5 íl] -4 -met? Lp? R? D? N -3? L-met ? l} -d? met l-amma * i
(a) Example 73 -. { 5- [3- (lfl-Ben # o? M? Dazol-2-yl) -lfí-ndazol-5-? L] -4 -met? Lp? R? D? N -3? -methyl } -dim til-amma:
IX 268 »intermediate 59a. XH NMR (300 MHz, CDC13) d 8.50 (s, 1HJ, 8.22 (s, 1H), 2.36 (s, 3H), 2.30 (s, 3H), *. * 4 (b) Intermediate substance 75b- 3- 4 | 2- ^^ * J Benzo? Midazole-2-? L) -5- (4, 5-d? Met? Lp? Idin-3-? L) -1- (4- * methoxy-benzyl) - 1-mdazole: 1 The title compound was prepared in a 79% yield from intermediate 62b and intermediate 75a in a similar manner to > procedure used for intermediate 61c. XH 10 NMR (300 MHz, CDC13) d 10.66 (s, ÍH), 8.64 (s, ÍH), 8.40 (s, * 1H), 8.36 (s, ÍH), 7.81-7.85 (m, ÍH), 7.41- 7.49 (m, 2H), 7.Í8-7.27 (m, 5H), 6.81 (d, 2H, J = 4.5 Hz), 5.57 (s, 2H), 3.74 (s, 3H), 2.31 (s, 3H) , 2.16 (s, 3H). (c) Example 75-3- (l-Benzo-madazole-2-? l) -5- (4,5- * l * i't-? d? met? lp? r? din? 3-? l ) -Ifl-mdazole: p The title compound was prepared at a rx * yield of 37% by means of PMB deprotection of the "F * intermediate 75b in a manner similar to Example 62. 1H" NMR (300 MHz, DMSO -de) d 13.76 (s, 1H), 13.02 (s, ÍH), 842 20 (S, ÍH), 8.38 (s, ÍH), 8.31 (s, 1H), 7.74 (dd, 1H, J = 8.4, 0.6Hz), 7.51-7.69 (m, 2H), 7.44 (dd, 1H, J = 8.7, 1.8 Hz), # * 7.17-7.22 (m, 2H) 2.33 (s, 3H), 2.18 (s, 3H) . Analysis (C2? H17N5 # 1.0
269
gjerft lo 76: 3- [3- (lfí-Benzo? m? dazol-2-jl) -lfí-ifidazol-5-? J] -4-
[Anisol = Anisole] (a) Intermediate 76a-3- [3- (l-Benzo? M? Da2? L-2-? L) -1- (4-methox? -benz? L) -lfl-mdazole -5-yl] -4-m-l-qu? Nol? Na: The title compound was prepared in an 86% yield from intermediate 62b and 3-bromo-4-met? Lqumol? Na ( see K on et al., Synthesis, 1976, 249) in a manner similar to the procedure used for intermediate 61c. X NMR (300 MHz, CDC13) d 10.24 (s, ÍH), 8.94 (s, 1H), 8.78 (s, ÍH), 8.25 (dd, ÍH, J = 7.8, **., 0.3Hz), 8.14 ( dd, ÍH, J = 7.8, 0.3 Hz), 7.75-7.88 (m, 2H), 7.64-7.70 (m, ÍH), 7.45-7.57 (m, 3H), 7.27-7.35 (m, 4H), 6.91 ( d, 2H, J = 6.9Hz), 5.68 (s, 2H), 3.82 (s, 3H), 2.70 (s, 3H). Analysis (C32H20N5O • 0.15 H20) C, H, N.
2 * 270
(b) Example 76- 3- [3- (l-Benzoimidazol-2-yl) -lfl-mdazol-5-yl] -4-methyl-quinoline: The title compound was prepared in * a yield of 72% by medium of PMB deprotection of intermediate 76a in a manner similar to the procedure used for example 62. lE NMR (300 MHz, DMS0-dfi) d 13.81 (s, ÍH), 13.06 (s, ÍH), 8.86 (s, ÍH), 8.55 (s, ÍH), «.23 (d, ÍH, J = 7.8 Hz), 8.09 (d, 1H, J = 7.2 Hz), 7.68-7.84 (m, 3H), 7.55-7.59 (m , 3H), 7.17-7.23 (m, 2H), 2.66 (s, 3H). Analysis (C2H? 7N5 • 0.8 H20) C, H, N. MS (ES) Im + H] / z calculated 376, found 376.
Example 77: 5- [3- (1-Benzoimidazol-2-yl) -lfl-jpdazpl-5-yl] -4-m t? L-pi £ Jdin-3-ol
i
NaOMe OMF MeOH 180 ° C, CO, «Cetone 654C 8 ^ / ^ O ffl (61%) N (40%) N 77» 77b n ß
[Acétone = Acetone Anisol = Anisole] (a) Intermediate 77a-5-Bromo-4-me il-p? R? Dm-3-ol: 3,5-D? Bromo-4-met? Lp? R? d (Na (2.42 g, 9.64 mmol) and sodium methoxide (3.12 g, 57.8 mmol) were stirred in a mixture of DMF (8 ml) and MeOH (2 ml) in a sealed tube at 180 ° C for 24 hours. The reaction was either cooled or concentrated in vacuo. Purification by chromatography on silica gel (100% ethyl acetate) gave 1.10 g (61 *) of the intermediate 77a as a white solid. H NMR (300 MHZ, DMSO-ds) d 10.31 (s, 1H), 8.12 (s, ÍH),, 8.04 (s, ÍH), 2.21 (s, 3H). Analysis (C6H6BrNO) C, H, N. (b) Intermediate 77b-3-Bromo-5- (4-svethoxy-benzoyloxy) -4-met? L-p? R? D? Na:
Intermediate 77a (1.0 g, 5.3 mmol.), Tetramethylammonium iodide (107 mg, 0.53 mmol) and potassium carbonate (1.47 g, 10.6 mmol) were stirred in acetone (30 mL). p-Methoxybenzyl (1.08 ml, 7.98% * 5 mmol) and the reaction was stirred at 55 ° C for 8 hours.The solution was diluted with ethyl acetate.The organic compounds were washed with H20 and brine, dried (MgSO 4) and concentrated in vacuo Purification by chromatography on silica gel (25% acetate 10 afforded 648 mg (40%) of the substance form of a white solid XH NMR '- 8.33 (s, ÍH) , 8.16 (s, ÍH), 7.34 (d, 2H,
, í. (d, 2H, J = 8.7 Hz), 5.08 (s, 2H), 3.83 (s, 3H), 2.34 (s,: • 3H). Analysis (C? 4H? 4BrN02) C, H, N. v * fc .. 15"(c) Intermediate substance 77c- 5- [3- (14- * '* *
Ben2oimida2ol-2-? L) -1- (4-methoxy-benzyl) -lfl-indazol-5-yl] -4-methyl-pyrid? N-3-ol: The title compound was prepared in an 89% from intermediate 62b. '* / * 4 20 and intermediate 77b, similar to; procedure used for intermediate 61c. XH MMR (300 MHz, CDCI3) d 10.17 (s, ÍH), 8.64 (s, ÍH), 8.29 (s, 1H), 8.25 (s, ÍH), 7.81-7.86 (m, 1H),
P
274"" -4- (a > Example 78-. {5- [3- (1-Benzimddazole-2-? Ljt. * Ii? -? Ndazol-5-yl] -4-methyl-p ? nd? n-3-? l-methyl-isoprop? l-am? nat The title compound was prepared in a 28% solution from Example 72 onwards.
with a procedure similar to the preparation of intermediate 68b. XH NMR (300 MHz, DMSO-dg) d 13.76 (s, 1H), 13.01 (s, 1H), 7.74 (d, 1H,
(d, ÍH, J * = 7.2Hz), 7.43 (dd, ÍH, J = 8.7, 1.5Hz), 7.15-7.25 Ír i (m, 2H), 3.79 (s, 2H), 2.80-2.86 (m, ÍH), 2.27 (s, 3H), 1.07 (d, 6H, J = 6.6Hz). Analysis (C24H24N6 • 0.7H20) C, H, N. M (ES) [m + HJ / z calculated 397, found 397.
Example 79: (5-Isoquinol-n-4-? L-l-yldazol-3-? L-methylepo-p-rrol-1-yl-amine
«- [Toluene = Toluene] K - * - i j Oa (aV Intermediate substance 79a-5-Isoqu? Nolm-4-yl- via
1- (2-tr? Met? Lsilan? L-ethox? Met? L) -lfl-ndazole-3-carbaldehyde: The title compound was prepared in a manner similar to the preparation of the intermediate lif.
replacing by a SWL protection (see intermediate 3a) the PMB protection of the substance int rpted á "-19c .. XH NMR (300 MHz, CDC13) d 10.30 (s, 1H), 9.30 (s, Ifi),. *% 8.54 (s, 1H), 8.48 (s, 1H), 8.08 (dd, ÍH, J = 6.6, 2.4Hz) '/ * * 7.86 (dd, 1H, J = 6.6, 0.6Hz), 7.81 (dd, ÍH, J «8.7, 0.9Hz), 7.64-7.70 (m, 3H), 5.91 (s, 2H), 3.66 (t, 2H," J = 8.4Hz), 0.97 (t, 2H, J = 8.4Hz) , -0.02 (s, 9H). (b) Intermediate 79b- [S-Isoqüin lift-4-yl-l- (2-trimethylsilane-ethoxymethyl) -lJf-i »da2ol-3-yl-ethylene] -pyrrol-1-yl-amine: Intermediate 79a (400 mg, 0.99 ramol) and 1-aminopyrrole (98 rag, 1.2 mmol) were stirred with p-toluenesulfonic acid (10 mg) in toluene (6 ml) at 80 ° C for 2 hours. The solution was concentrated in vacuo and purified by chromatography on silica gel (50% ethyl acetate / hexanes) to give 410 mcf (89%) of the intermediate 79b as a yellow oil.? E NMR ( 300 MHz, CDCI3) d 9.31 (s, ÍH), 8.77 (s, ÍH), 8.58-8.60 (m, 2H), 8.09 (dd, ÍH, J = 7.3, 0.9Hz), 7.92 (d, ÍH, J = 7.8Hz), 7.76 (dd, 1H, J = 8.7, 0.9Hz), 7.63-7.70 (m, 3H), 7.19 (t, 2H, J = 2.4 z), 6.26 if "(t, 2H, J = 2.4Hz), 5.85 (s, 2H), 3.66 (t, 2H, J = 8.4Hz), 0.97 (t, 2H, J = 8.4Hz), -0.02 (s, 9H).
(c) Example 79- (5-Isoquinolin-4-yl-1-yl-indazol-33-yl-methylene) -pyrrole-1-yl-amma: The title compound was prepared in a 68% yield by of the SEM checkout of the
Intermediate substance 79b similar to the procedure used for example 41. XH NMR (300 MHz, DMS0-d #) d 13.82 (s, ÍH), 9.38 (s, ÍH), 9.09 (s, ÍH), 8.52 (S , ÍH), 8.41 (s, ÍH), 8.24 (dd, ÍH, J = 7.2, 1.5Hz), 7.71-7.85 (m / 4H), 7.61 (dd, ÍH, J = 8.4, 1.5Hz), 7.46 ( t, 2H, J »2.4Z), 6.15 (t, 2H, J = 2.4Hz). Analysis (C2? H15N5) C, H, N. MS (ES) [m + H] / z calculated 338, found 338. r *
Example 80: 2-f5- (5-Etylamino-Nomethyl-4-methyl-pyridin-3-yl) * lJ: - indazol-3-yl] - H-benzoimidazole-4-methylamide methylamide
(b) Intermediate intermediate 80b-5-Bromo-4-methyl-pyridin-3-yl-methyl) -ethyl-ethyl-ethyl ester of carbáraic acid: The intermediate 80a (850 mg, 3.7 branch) 5 was stirred in a THF solution (80 ml) and 1 N NaOH (10 ml). Di-tert-butyl dicarbonate (1.09 g, 5 mmol) was added and the reaction was stirred for 2 hours at room temperature, the solution was diluted with ethyl acetate.The organics were washed with H20 and brine. dried (MgSO 4) and concentrated in vacuo Purification by chromatography on silica gel (33% ethyl acetate / hexanes) gave 760 mg (62%) fe of the intermediate 80b as a clear oil XH NMR (300 MHz, CDC13) d 8.60 (s, ÍH),., 8.24 (s, ÍH), 4.49 (s, 2H), 3.18 (bs, 2H), 2.39 (s, 3JÍ), '' * 1.47 (s , 9H), 1.05 (t, 3H, J = 7.2 Hz)., (C) Intermediate substance Oc- Ethyl- [5- (3-butyl-phenyl-n-nazol-5-yl) -4-methyl-p ? ddin-3-yl-methyl] ethyl ester of carbamic acid: The title compound was prepared in an 85% yield from intermediate 19ie, * and intermediate 80b in a similar manner to the procedure used for intermediate 61c. * XH * NMR (300 MHz, CDC13) d 10.27 (s, ÍH), 8.38 (s, 1H), 8.35 (s-, ÍH), 8.23 (s, ÍH), 7.49 (dd, ÍH, J = 8.7, 0.6Hz) , 7.26-7.51
• *
[Sulfur = Anisol Sulfur = Anisole] (a) Intermediate 81a-3-Methalosulfanyl-2-nitro-phenylamine: 3-Chloro-2-n-tro-anamma (1.0 g, 5.8 mmol) and carbonate of Potassium (880 mg, 6.4 mmol) was stirred in dry DMF (15 ml) in a sealable tube at 0 ° C. Metanetiol was bubbled through the solution for 4 minutes. The tube was sealed and the reaction was stirred at 122 ° C for 16 hours. The cooled reaction was diluted with H20 and extracted with ethyl acetate. The organic compounds were washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on silica gel (33% • < * - * ethyl acetate / hexanes) provided 950 mg (89%) of the intermediate substance 81a as a bright red-orange solid. "H NMR (300 MHz, CDC13) d 7.21 (t,
A. »? Í ~ 282 'and ÍH, J = 8.1Hz), 6.55 (d, 2H, J = 8.1Hz), 5.93 (bs, 2H), 2.42. (s, 3H). Analysis (C7H8N202S) C, H, N, S, * (b) Intermediate 81b-3-Methylsuifanyl-1-f, 1-behzeno-l, 2-diamine: f The title compound was prepared in a 96% yield from intermediate 81a in a manner similar to the hydrogenation process * - < v f 'developed for the intermediate substance 9a'. 1 H NMR (300 MHz, CDC13) d 6.93-6.97 (m, HH), 6.63-6.70 (m, 2H), 3.71 fbs, 0 4H), 2.36 (s, 3H). Analysis (C7H? 0N2S) C, H, N, S. (c) Intermediate 81c- Ethyl-. { 5- [1- (4-Ethoxy-benzyl) -3- (4-methylsulfanyl-1-yl-benzoimidazol-2-yl) -I-yl-indazol * -5-yl] -4-methyl-pyridin-3-yl-methyl } dimethyl ethyl carbamic acid ester: The title compound was prepared in an 80% yield from intermediate 81b and intermediate 80c in a manner similar to the procedure used for intermediate 7s'. XH NMR (300 MHz, CDCl 3) d 10.15 (s, 0.6H), 10.12 (s, 0. H), ft 8.64 (s, 0.4H), 8.59 (s, 0.6H), 8.47 (s, ÍH), 8.37 (s, 1H), 7.72 (d, 0.6H, J = 7.5 Hz), 7.45 (t, ÍH, J = 7.2 Hz), 7.19- '7.34 (m, 5H), 7.10 (d, 0.4H, J = 7.5 Hz), 6.83-6.89 (m, $ f) t, - 5.65 (s, 1.2H), 5.61 (s, 0.8H), 4.55 (bs, 2H), 3.78"(s, 1.8H), 3.77 (s, 1.2H), 3.26 (bs, 2H), 2.67 (s, 1.2H), 2. Sl
* £ * "'
(s, 1.8H), 2.24 (s, 1.2H), 2.22 (s, 1.8H), 1.49 (s, 9H) V X and **
1. 12 (t, 3H, J = 6.9 Hz). (d) Example 81- Et? l-4-. { met? l-5- [3- (4-, t. * 4 methylsulfamyl-1-benzo-m? dazal-2-? l) -lfl-mdazol-5? l] -p? pdm-3? l-met? l} -amine: The title compound was prepared in a & amp; amp; yield of 25% by means of PMB deprotection of the * (i •, - intermediate substance 81c in a manner similar to the procedure used for example 62. 1H NMR (300 MHz, DMSO-d <; f) 13.78 (s, ÍH), 13.10 (s, ÍH), 8.48 (S, 1H), 8.44 (s, ÍH), 8.39 (s, 1H), 7.75 (d, ÍH, J = 8.7 Hz), 7.44 (d, 1H, J * 8.7, 1.8 Hz), 7.30 (d, 1H, J - 7.8 Hz), 7.19 (t, ÍH, J * 7.8 rf Hz), 6.99 (d, 1H, J = 7.2 Hz) , 3.82 (s, 2H), 2.66 (q, 2H, J j. • = 7.2 Hz), 2.56 (s, 3H), 2.28 (s, 3H), 1.08 (t, 3H, J »7.2 * £ Hz) . Analysis (C24H24N6S • 1.5H20) C, H, N, S. MS (83 [m + H] / z calculated 429, found 429.
1"
Example 82: N-. { 2- [5- (5-Et? Lam? Nomet? L-4-roetjlrtir? D? N-3-il) -
* "£ -. 284 *
[Sulfur = Anisol Sulfur = Anisole] (a) Intermediate substance 'ß2a- 2J 2,3-dian Í < "* faith .1) -trace acetate: The title compound was prepared in a 98% yield from N- (2-ammo-3-n-tro-phenyl) -acetamide (See Harvey et al., J. Chem. Soc. Perk. Trans. 1, 1988, 1939-1944) similar to the hydrogenation of the intermediate substance 9a '. 1 H NMR (300 MHz, CDC13) d 9.04 (a, ÍH), 6.35-6.49 (m, 3H), 4.38 (bs, 4H), 2.00 (s, 3H). (b) Intermediate substance 82b- { 5- [3- (4-Acet? lam? no-lfl-benzoim? dazol- 2-? L) -1- (4-methox? -benz? L) - fí -
indazol-5-? 1] -4-methyl-p? r? d n -3? -methyl} ethyl ester of carbamic acid: The title compound was prepared in 65% yield from intermediate 82a and intermediate 80c in a manner similar to the procedure used for intermediate 7c 'lH NMR (300 MHz, CDC13) d 12.35 (bs, 1H), 10.80 (bs, ÍH), 7.90-8.85 (m, 4H), 6.76-7.46 (m, 8H), 5.60 (bs, 2H), 4.51 (bs) , 2H), 3.78 (s, 3H), 3.61 (bs, 2H), 3.19 (bs, 3H), 1.74 (bs, 12H), 1.18 (bs, 3H). MS (ES) [m + H] / z calculated 660, found 660.
i? p
$? '
(c) Example 82- N- (2- [5- (5-Etylaminomethyl-4-yl] et? l-pyridin-3-yl) -lfl-indazol-3? l] -lfi-benzo3.m Dazol-4-yl.) Acetamide: The title compound was prepared in wñ 6% yield by means of PMB deprotection of intermediate * 82b in a manner similar to the procedure used for example 62. XE NMR (300 MHz, MeOD-d4) d 8. 64 '(s, ÍH), 8.58 (s, ÍH), 8.45 (s, ÍH), 7.82 (d, 1H, J *, 8.4Hz), 7.57 (d, ÍH, J = 7.2Hz), 7.50 (d, 2H, J = 7.2Hz),
10 7.34 (t, 1H, J = 8.4Hz), 4.44 (s, 2H), 3.27 (q, 2H, J * 7.5Hz), 2.43 (s, 3H), 2.22 (s, 3H), 1.41 (t, 3H, J = 7.5Hz). MS (ES) [m + H] / z calculated 440, found 440.
Example 83: 5- (2,6-D? Fluorophenyl) -3-f n l-lfl-indazole
• * • k
5 83
-tm .. =
18b
H2, Pd / C EtOAc * 99%
85 84
With a synthetic method similar to that used for 5 intermediate substance 18c, the hydrogenation of 5-n? Tro-3- (2-p? Rrol? L) -1 H -mdazole 18b 'on 10% palladium in *
carbon afforded 5-ammo-3- (2-pyrrolidol) -Iff-indazole 84 (99%) in the form of a beige solid: lE NMR (DMSO-d6) d 6.13 (def, 1H, J = 2.4, 2.6 Hz), 6.49 (dd, ÍH, J = 1.5, 2.4 0 Hz), 6.76 (dd, ÍH, J = 1.5, 2.6 Hz), 6.79 (dd, ÍH, J = 2.1, 8.9 Hz), 7.03 (d, ÍH, J = 2.1 Hz), 7.22 (d, 1H, J = 8.9 Hz), 11.16 (s, ÍH), 12.45 (s, 1H). Analysis (C? .Hx0N4 »0.2 ethyl acetate) C, H, N.
* »--'-. , 5
The title compound was prepared in an 81% yield from Example 72 and isobutylamines with a procedure similar to the preparation of intermediate 68b. -H NMR (300 MHz, DMSO-de) d 13.77 (s, ÍH), 13.02 (s, ÍH), 8.50 (s, ÍH), 8.42 (s, 1H), 8.37 (s, ÍH), 7.74 (d, ÍH, J = 8.7Hz), 7.68 (d, 1H, J * 7.5Hz), 7.50 V. (d, ÍH, J = 7.5Hz), 7.43 (dd, ÍH, ^ 8.7,1.5Hz), 7.14-7.24 * (m, 2H), 3.85 (s, 2H), 2.49 (bs, 2H), 2.27 (s, 3H), 1 * 73- f .'i 1.79 (m, ÍH), 0.90 (d, 6H, J = 6.6Hz). Analysis (C2SH26N6 * 0.3 H20) C, H, N. MS (ES) [m + H] / z calculated 411, found yf 411.
Ejefnplp 88? . { 5- [3- (lfl »Benzo? M? Dazol-2 ~ jl) -Üffi-indazol-S-il] - * 4-met l-pj¿, id? N-3-il-met l} -benz l-amine
(a) Example 88-. { 5- [3- (1-Benzo [mu] midazole-2? -1) -1? E »mdazol-5? 1] -4-met? L-p? Pdm-3? -methyl} -bengyl-amine The title compound was prepared in a yield of 73% from example 72 and benzylamine in a manner similar to intermediate 68b. XH NMR (300 MHz, DMS0-d6) d 13.77 (s, ÍH), 13.02 (s, ÍH), 8.51 (s, ÍH) "- 8.42 (s, ÍH), 8.38 (s, ÍH), 7.74 (d , 1H, J * 8.7 Hz), 7.6 # (d, 1H, J = 7.5 Hz), 7.50 (d, ÍH, J = 7.5 Hz) », 7.16-7.44 (m, 8H), 3.90 (bs, 4H) , 2.23 (s, 3H). Analysis (C28H2N6 • 1.2H20) C, H, N. MS (ES) [m + H] / z calculated 445, found 445.
Example 89: 2- ( { 5- [3- (lfí-Ben2? M? Da2 l-2-? L) -lfí-m aa £ l * - l] -4 - ?? et lp? r? d? n-3-? l-met l.}. -am? no-ethanol
(a) In n nal substance) -dial flow:
A solution of 2, 3-d? Met? L-7-n? Thromdol (Acros Organics, 13.55 g, 71.24 mmol) in diechloromethane (1.0 L) was cooled to an internal temperature of -60 ° C and
a greenish yellow. Argon was bubbled through the solution for one hour, causing the color change to yellow. Dimethylsulfide (10.5 rol, »)
142. 5 mmol) and stirring continued at -60 ° C for 1.5. s hours. After warming to room temperature, the solution was concentrated in vacuo to ~ 200 ml, washed with water (2 x 50 ml), dried over magnesium sulfate, filtered, concentrated and purified by gel * chromatography. of silica (50 to 100% ethyl acetate efn hexanes), which yielded compound 90a (11.85 g, *
75%) in the form of an orange solid. Rf = 0.36
(75% ethyl acetate / hexanes); XH NMR (DMSO-d6) d 2.02
(s, 3H), 2.52 (s, 3H), 7.52 (t, ÍH, J = 7.9 Hz), 8.00
(dd 1H, J = 7.9, 1.5 Hz), 8.05 (dd, ÍH, J = 8.1, 1.5
Hz), 10. 32 (s, 1H). Analisis (C? OH? 0N2O4 • 0 .4 H20) C, H, N.
(b) Intermediate 9Qb-l- (2 -! &fnino-3-nitro-j enyl) -ethanon: Concentrated hydrochloric acid (40 ml) was added to a solution of 90a (4.00 g, 18.0 mmol) in absolute ethanol (80 ml) and water (40 ml). The mixture was heated to reflux
(internal temperature of 87 ° C) for 1 hour. After cooling to room temperature, a saturated aqueous solution of sodium bicarbonate was added to bring the pH to 8. The solution was extracted with ethyl acetate (2 x 200 * ml). The combined organic extracts were dried magnesium sulfate sulfate, filtered, concentrated and purified by chromatography on silica gel (20 to 70% ethyl acetate in hexanes) to give compound 90b (2.67 g, 82%) as of a yellow solid. Rf = 0.45 (50% ethyl acetate / hexanes); XH NMR (DMSOefe >? D, 2.62 (s, 3H), 6.74 (t, ÍH, J = 8.1 Hz), 8.31 (m 2H), 8.85 (br s, 2H) Analysis (C8H8N203) C, H, N. (c) Intermediate 90c-l- (2,3-Diamino-pheny1) -ethanone: With a synthetic method similar to the synthesis of 9a, the hydrogenation of 90b (2.00 g, 11.1 mmol) in ethanol provided Compound 90c (1.54 g, 92%) in the form of bright yellow crystals Rl = O.34 (50% ethyl acetate / hexanes); X NMR (DMSO-d6 d '2.47 (s, 3H), 4.75 (br s, 2H), 6.40 (dd, ÍH, J «7.5,
'
*
295
8. 1 Hz), 6.69 (dd, 1H, J = 7.5, 1.3 Hz), 6.79 (br s, 2H), 7.10 (dd, ÍH, J = 8.1, 1.3 Hz). Analysis (CßHioNjO) C, H, N. (d) Intermediate substance 90d - l-. { 3*. { 5- Isoquinol? N-4-? Ll- (4-methox? -benz? L) -lfí-mda2? L -3? L] -lfí ~ * ben2om? Da2? L-4-? L) -ethanone : In a manner similar to the 19hr synthesis, aldehyde 19f (2.02 g, 5.13 mmol) and diam 90c (771 mg, 5.13 mmol) were condensed in the presence of sulfur to provide 90d (1.83 g, 68%) as a bright yellow solid. Rf = 0.19 (75% 4-ethyl acetate / exanos); XH NMR (DMSO-d6) [Some * • * peaks were doubled due to the isome izaoion 'tautomeric] d 2.72 and 2.87 (2 brs, 3H as a whole), # ^ "3.71 (s, 3H), 5.85 (s) , 2H), 6.93 (d, 2H, J = 8.7 Ha), 7.34 (m, 3H), 7.75 (m, 5H), 8.07 (ra, 2H), 8.25 (d, ÍH, J * 7.5 Hz), 8.56 and 8.80 (2 br, 2H as a whole), ft.38, (s, ÍH), 11.83 (s, ÍH), 13.53 (s, ÍH). (e) Intermediate substance 90e - (l- { 2 - [5- ", 'Isoquinolin-4-? II- (4-methox? -benz? L) -lfl-? Ndazol-3? L] -lfi-benzoam? Dazol-4-íl} -ethyl) -methyl-amine: A solution of methylamine in methanol (2.0 M, 3.02 mL, 6.04 mmol) was added to the ketone 90d (527.8 mg, 1.01 mmol) at room temperature, followed by hydrochloric acid (4.0 mL). in dioxane, 0.504 ml, 2.02 mmol),
^ m ta ol (6.0 ml) and sodium cycloborohydride (38.0 mg, 0.605 mmol). The suspension was stirred at RT 4 * > Environment for 23 hours, but nirif ^ 'tj • > The reaction was carried out by TLC analysis, anhydrous THF (10 ml) was added to increase the solubility and the stirring was continued for 70 hours.The mixture was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. Organic phase was dried over magnesium sulfateit was filtered, concentrated and purified by chromatography on silica gel (1: 20: 200 B0H - aqueous: tanol: d? chloromethane), which yielded compound 90e (275.0 rag, 51%) as a foam yellow. Rf = 0.09 (1: 20: 400 aqueous NH 4 OH: ethanol: dichloromethane); ? E NMR (CD30D) d 1.53 (d, 3H, J = 6.8 Hz), 2.24 (s, 3H), 3.75 (s, 3H), 4.28 (q, ÍH, J = 6 * 8 Hz), 5.45 (s, ÍH), 5.77 (s, 2H), 6.89 (d, 2H, J «= 8.7 'Hz), 7.22 (m, 2H), 7.34 (d, 2H, J = 8.7 Hz), 7.52 (d , ÍH, J = 7.9 Hz), 7.61 (dd, 1H, J = 8.7, 1.5 JÍZ), 7.76 (m, 3H), 7.99 (d, ÍH, J = 8.3 Hz), 8.20 (dd, ÍH, J = 7.2, 0 1.7 Hz), 8.48 (s, ÍH), 8.70 (s, ÍH), 9.27 (s, 1H). * Analysis (C34H3oN60 »1.0 H20) C, H, N. 'i and ^ (f) Example 90 -. { 1- [2- (5-Isoqui-olin ~ 4-? L-lf? -4-? Ndazol-3-? L) -lfi-benzo? M? Dazol-4 ~ l] -ethyl} - * netil-am? na: A solution of 90e (179.7 mg, 0.334 mmol), * 5 trifluoromethanesulfonic acid (0.84 ml) and acid
i 297
trifluoroacetic (3.34 ml) was stirred at 50 ° C for 2 hours. The solution was then added dropwise to a rapidly stirred mixture of concentrated aqueous NH40H (10 ml) and ethyl acetate (30 ml). Extraction and purification similar to that of Example 33, provided the compound * 90 * in the form of a whitish solid * * (140.9 mg). Although this material appeared pure by HPLC and XH NMR analysis, the analysis of elements revealed significant impurities. The impure material was dissolved in ethyl acetate (50 ml) and washed with water (10 ml), saturated aqueous sodium bicarbonate solution (10 ml) and saturated aqueous sodium chloride solution (10 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated to give compound 90 (49.4 mg, 35%) as a white solid: XH NMR (CD3OD) d 1.71 (d, 3H, J = 6.8 Hz), 2.45 (s, 3H), 4.66 (q, 1H, J = 7.0 Hz), 7.24 (d, 1H, J *, • 7.5 Hz), 7.32 (t, ÍH, J = 7.7 Hz) , 7.61 (dd, ÍH, J * 7.9, 1.0 Hz), 7.67 (dd, ÍH, J = 8.5, 1.5 Hz), 7.82 (m, 2T 3H), 8.03 (d, ÍH, J = 8.3 Hz), 8.24 (d, 1H, J «7.5 Hz), 8.53 (s, ÍH), 8.71 (s, ÍH), 9.30 (s, ÍH) Analysis Yes (C26H22N6'0.4 CH2C12) C, H, N.
after 20 minutes with the addition of ethylenediaminetetraacetic acid (EDTA) up to 250 mM. The phosphorylated substrate was then captured on a nitrocellulose or phosphocellulose membrane using a 96-well filament manifold and the unincorporated radioactivity was removed%. by repeated washing with 0.85% phosphoric acid. Radioactivity was quantified by exposing the dried membranes to an optical scanner with phosphorus storage techniques (Phosphorimager). The apparent values of K ± were measured by assays of the enzymatic activity in the presence of P different concentrations of inhibitory compounds and r subtraction of background radioactivity measured in the absence of the enzyme. The inhibition data were entered into an equation for competitive inhibition using the Kaleidagraph application (Synergy Software) or entered into an equation for competitive inhibition for strong bonds using the KmeTic software (BioKm, Ltd.).
Inhibition of kinase activity of the retinffelastoma kinase CDK4 / Cyclamen D A complex of human CDK4 and cyclin D3, or a complex of human CDK4 and (1-264) cyclma D3 genetically truncated, was purified using traditional chromatographic biochemical techniques with insect cells what
# * •
were co-infected with the corresponding baculovirus expression vectors (See for example, Meijer and Kim, "Chemical Inhibitors of Cyclin-Dependent Kinases," Metho? ls in Enzymol,., vol.283 (1997), pp. 113-128 .). The enzyme complex (5 or 50 nM) was tested with 0.3-0.5 μg of purified recombinant protein fragment of retinoblastoma (Rb) as a substrate. The Rb engineering fragment (residues 386-928 of the native retinoblastoma protein, 62.3 kDa) contains the majority of the phosphorylation sites found in the native 106-kDa protein, and also an indicator of histidine residues to facilitate , purification. ' The phosphorylated substrate Rb was captured by microfiltration on a nitrocellulose membrane and quantified using a phosphorimager as described above. For the measurement of strong ligation inhibitors, the concentration of the enzyme complex was decreased to 5 nM, and the duration of the test was extended to 60 minutes, during which the time-dependent formation of the product was linear.
Inhibition of the kinase activity of CDK2 / Cyclin A gibenblase A CDK2 was purified using published methodology (Rosenblatt et al., "Purification and Crystallization of Human Cyclin-dependent Kinase 2," J. Mol. Biol. , vol 230, 1993, pp. 1317-1319) from cells
** < • .303
of insects infected with baculovirus expression vectors. Cyclin A was purified from *, J E. coli cells expressing recombinant cyclin A of full length, a truncated cyclin A construct was generated by limited proteolysis and purified as previously described (Jeffrey et al., "Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex,"
Nature, vol. 376 (July 27, 1995), p. 313-320). A complex of CDK2 and proteolyzed cyclin A was prepared and purified by gel filtration. The substrate for this erisa, I * J was the same Rb substrate fragment used for the / sac of CDK4 and the CDK2 / cyclin A and r CDK4 / cyclin D3 assay methodology was essentially the same, except that CDK2 was present in values of 150 nM or 5 nM. The values of Kx were measured as described above. > - The stimulation of cell proliferation by growth factors, such as VEGF and others, depends on the induction of autophosphorylation of each of the tyrosine kinases of their respective receptors. Therefore, the ability of an inhibitor of * ¿. , «Protem-qumasa to stop the cell proliferation induced by these growth factors is directly correlated with its ability to block the autophosphorylation of the receptor. For m dir ^
*? < * 304
inhibitory activity of protein kinase of 1 $ 4ÉÍ - ». compounds, the following constructions were used ..
Construction for the VEGF-R2 test This construction determines the capacity of * tt > - • test compound to inhibit dß activity. the tyrosine kinase. A construction (VEGF-R2? 50) of the domain,. Cytosolic receptor 2 of the human endothelial vascular growth factor (VEGF-R2) with absence of the 50 central residues of the 68 residues of the kinase insertion domain, was expressed in a baculovirus / cell system of > •; * insect. Of the 1356 full-length residues VEGF-R2, VEGF-R2? 50 contains residues 806-939 and 990-1171, as well as a point mutation (E990V) within the domain and insertion of the kinase relative to VEGF-R2 of wild type. The autophosphorylation of the purified construct was carried out by incubation of the enzyme at a concentration of I *. μM in the presence of 3 mM ATP and 40 mM MgCl2 in Hepes 100 jraM, *, ", - pH 7.5, containing 5% glycerol and 5 mM DTT, at 4 ° C for 2 hours After autophosphorylation, it is demonstrated that construction possesses essentially catalytic activity - equivalent to the construction of the wild-type autophosphorylated kinase domain (See Parast et al., Biochemistry, 37, 16788-16801 (1998).
- - £ *. *
Construction for the ens, of QHK1 The full length human CHK1 (FL-CHK1) with His and C terminal indicators was expressed using the baculovirus / insect cell system. It contains 6 histidine residues (6 x His indicator) in the C terminal of the human CHKl of amino acid 476. The protein was purified by standard chromatographic techniques.
10 VEGF-R2 assay Coupled spectrophotometric assay (FLVK-P) The production of ADP from ATP that encapsulated the phosphoryl transfer was coupled to the oxidation of NADH using phosphoenolpyruvate (PEP) and a system having p-pyruvate kinase (PK) and lactic dehydrogenase (LDH). The oxidation of NADH was monitored by monitoring the decrease in absorbance at 340 nm (e34o = 6.22 cm "1 mM" 1) using a Beckman DU 650 spectrophotometer. The conditions "of the assay for the phosphorylated compound VEGF-R2? 50
2 & (indicated as FLVK-P in the tables below) were the. following: 1 mM PEP; NADH 250 μM; 50 units of LDH / i ^ l; 2 * PK / ml units; 5 mM DTT; poly (E4Y?) 5.1 mM; ATP 1 mM f
"Í '^ 25 mM MgCl2 in 200 mM Hepes, pH 7.5. The df-assay conditions for the non-phosphorylated compound VEGF-R2? 50 (indicated
25 as FLVK in the tables) were the following: PEP1 mM;
t
NADH 250 μM; 50 units of LDH / mL; 20 units of PK / mL; 5 mM DTT; poly (E4Y?) 20 mM; 3 mM ATP; MgCl260 pM and 2 aM MnCl2 in 200 mM Hepes, pH 7.5. The assays were started with 5 to 40 nM enzyme. The Kx values were determined by measuring the enzymatic activity in the presence of varied conditions of the test compounds. The data was r- * analyzed using the Enzyme Kinetic and Kaleidagraph software.
ELISA assay The formation of phosphogastrin was monitored using biotinylated gastrin peptide (1-17) as a substrate. The "*" biotinylated phosphogastrin was immobilized using 96-well microtiter plates coated with streptavidite, followed by detection using anti-phosphotyrosine antibodies conjugated with horseradish peroxidase The activity of horseradish peroxidase was monitored using p-salt of 2, 2 '-azmo-di- [3-ethylbenzathiazoline sulfonate (6)] (ABTS) .'Typical assay solutions contain: 2 μM biotinylated gastrin peptide, 5 mM DTT, 20 μM ATP, MgCl226 μg, and M Cl2 2 mM in 200 mM Hepes, pH 7.5 The assay was started with 0.8 nM phosphorylated VEGF-R2 50. The activity of horseradish peroxidase was evaluated using 10 mM ABTS The reaction of horseradish peroxidase was stopped the * acid addition (H2S04), followed by the absorbance reading at 405 nm.The Kx values were determined by
"í
the measurement of the enzymatic activity in the presence of variable concentrations of the test compounds. The data were analyzed using the software Enzyme Kínetíc and ¡i t X Kaleidagraph.
CHKl assay The production of ADP from ATP that accompanies •.
The transfer of phosphoryl to the synthetic peptide substrate Syntide-2 (PLARTLSVAGLPGKK) was coupled to the oxidation of NADH using phosphoenolpyruvate (PEP) through the action of pyruvate kinase (PK) and lactic dehydrogemase (LDH). Oxidation of NADH was monitored by monitoring the decrease in absorbance at 340 nm (€ 340 = 6.22 cm "1 mM" 1) using a HP8432 spectrophotometer Typical reaction solutions contained: 4 mN PEP, NADH 0.15 mM, 28 units of LDH / ml, 16 units of PK / ml, 3 mM DTT, 0.125 mM Syntide-2, 0.15 mM ATP, 25 mM MgCl2 in 50 mM TRIS, pH 7.5 and 400 mM NaCl. 10 nM of FL-CHK1 The Ki values were determined by measuring the initial enzymatic activity in the presence of varying concentrations of the test compounds.The * data were analyzed using the Enzyme Kínetic and Kaleidagraph software.
• ste.
* 308
Inhibition of the phosphorylated FGF receptor and LCK tyrosine kinase activity The cloning, expression and purification of the tyrosine kinase dointin cytosolic FGFR1 (amino acids 436 5 766) containing three substituted amino acids (L457V, 488A «and C584S) was conducted as previously described ', (Mohammadi, M., Schlessinger, J., &Hubbard, SR (199 * 6) • * Cell 86, 577-587). This domain was expressed in Sf9 insect cells using a baculovirus expression vector, and the protein was purified using standard * ß techniques. LCK tyrosine kinase was expressed in insect cells - cpmo deletion of N terminals beginning at amino acid * 223 until the end of the protein at amino acid 509. The N-terminus of the protein also had two substitutions of 15 amino acids, P223M and C 224D. The kinases were purified using conventional chromatographic methods. The tyrosine kinase activity was measured using a coupled continuous spectrophotometric assay, in which the production of phosphorylated substrate poly (Glu, T? 4; 1) and 0 'ADP is coupled to the transfer of a phosphoenolpyruvate phosphate to ADP, catalyzed by pyruvate kinase, with the generation of pyruvate and the regeneration of ATP. The production of pyruvate in turn is coupled with the reduction of pyruvate to form lactate, catalyzed by lactic 5-dehydrogenase, with the concomitant conversion of
i *** $ • -3í $ 8W
NADH to NAD +. The loss of NADH is monitored by measuring the absorbance at 340 nm (see for example ^ Technikova-Dobrova et al., "Spectrophotometric determination of functional characteristics of protein.
csupled enzymatic assay, "FEBS Letters, vol 292 (1991)," pp. 69-72) Enzyme activity was measured in the presence of 200 mM HEPES (pH 7.5), 2 mM phosphoenolpyruvate, 0.3 mM NADH, 20 mM MgCl2, 100 μM ATP, 5 mM DTT, poly JGlu, Tir) 4: 1, 5.1 or 25 mM for the P-FGF or P-LCK assays, respectively, and 15 units / ml of each of pyruvate kinase and lactic dehydrogenase. The phosphorylated kinase of the phosphorylated FGF receptor was present in 100 nM and the kinase phosphorylated LCK in 50 nM. The tests were carried out under conditions of initial proportions at 37 ° C and the proportions were corrected according to the measurements of background proportions in the absence of the enzyme. The percentage of inhibition was calculated in relation to the enzyme? control assayed in the presence of 2% (v / v) DMSO. The
results are shown in Table 1.
Coupled spectrophotometric assay (FAK) Tyrosine kinase assays were monitored using a Beckman DU 650 spectrophotometer. The ADP production was coupled to the oxidation of NADH using phosphoenolpyruvate (PEP) by the action of the
* á H Í 310
pyruvate qumasa (PK) and lactic dehydrogenase (LDH). The oxidation of NADH was monitored by following the lafß: decrease in absorbance at 340 nm (e34c = 6-22 cm "1 mM"). Typical reaction solutions contain: 1 mM PEP, 250 μM NA H, 50 LDH units / ml, 20 PK units / ml, DTT 5,. tm mM, in 200 mM Hepes, pH 7.5 and vanablef concentrations of poly
of cdFGFRl. The results of the tests carried out with the compounds, which include the specific examples described above, are indicated below in Table I. Except where otherwise indicated in a particular line, the units and tests used are as indicated in Applicable column of the table.
Table I: Kx with kinases
* x c 311
1t. «? * 'P tea
i
> .
* •
saw"
*
(
Note: NT = not tested f
Inhibition of cell growth: assessment of cytotoxicity Inhibition of cell growth is iftidio * f. using the tetrazoyl salt assay, which is based on the ability of viable cells to reduce 3- (4,5-d? met? lt? azol-2-? l) -2, 5- [2H] -bromide from diphenyltetranolium (MTT) to formazan (Mossman, Journal of Immunological Methods, vol 65 (1983), pp. 55-58). The product formazan purple insoluble in water was then detected spectrophotometrically. The HCT 116 cell line was incubated - ^ in 96-well plates. The cells were placed in pI Gas in the appropriate medium at a volume of 135 μl / well in the McCoy 5A Medium. The plates were incubated for four hours before adding the inhibitor compounds. Different concentrations of compounds were added *. ** i * ^ • inhibitors in 0.5% (v / v) of dimethyl? Ulphoxide 6.5 'μl / well) and the cells were incubated at 37 ° C (5% C02) > for four to six days (depending on the cell type). At the end *, of the incubation, MTT was added to a concent ^ afdi? N *? final 0.2 mg / ml and the cells were incubated for 4. «. • * more hours at 37 ° c After the centrifugation of the, '< 4 plates and the removal of the medium, the absorbance of the forraazan (solubilized in dimethylsulfoxide) was measured at 540 nm. The concentration of the inhibitor compound causing 50% of the growth inhibition was determined from the
linear portion of a semilogarithmic graph of%? -inhibitor concentration as a function of the -percentage "of inhibition. All results were compared with r * control cells treated only with dimethylsulfoxide 0.5% (v / v).
Table II
X
- 321 4 * s
incorporates a suitable dosage unit form pax'a • administration by injection.
Oral Composition To prepare a pharmaceutical composition for oral administration, 100 mg of a compound or fß '' Formula I or II is mixed with 750 mg of lactose. The mixture is incorporated into an oral dosage unit, such as capsules of A »hard gelatin, suitable for oral administration. * It should be understood that the foregoing description is of an exemplary and explanatory nature, and prefers to illustrate the invention and its preferential materializations. Therefore, the scope of the invention must be understood in its definition, not by the previous description, but by the following claims and equivalent sug.
It is noted that in relation to this date, the best known method for the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects or products to which the
• same refers.
Claims (1)
- '323"wherein R 4 is H or a lower alkyl, and X is an alkyl, aryl, heteroaryl, carbocycle or substituted on substituted heterocycle, or the pharmaceutically acceptable salt of a compound of Formula I, or a pharmaceutically active prodrug or metabolite of a compound of Formula I, or a pharmaceutically metabolite salt. 2. A computer acceptable, a prodrug, or active according to claim 1, characterized in that: Ri is X «^ v ** > , where R4 is hydrogen; or where Y is CH or N and R3 is H, or an alkyl group, I. aryl, carbocycle, hetero 25 or a pharmaceutically acceptable salt, pharmaceutically active prodrug or metabolite, or a pharmaceutically acceptable salt of a prodrug or metabolite. 32 » of R is H or a lower alkyl, and X is a substituted or unsubstituted heteroaryl, carbocycle or heterocycle; or a pharmaceutically acceptable salt of, ün -f * compound of Formula I; a prodrug or a pharmaceutically active metabolite of a compound of Formula I, or a pharmaceutically acceptable salt of a prodrug or metabolite; and a pharmaceutically acceptable carrier. 5. A method of treatment of diseases; 0 or disorders mediated by the inhibition of a complex of Xt¿ 4 * 'kinase, which includes the administration to the patient that requires it *, a cell cycle control agent *. selected from the group consisting of a compound - \ where R 4 is H or a lower alkyl, and X is a alkyl, aryl, heteroaryl, carbocycle or heterocycle cl group; substituted or unsubstituted; and R2 is an alkyl, apl, heteroaryl, carbocycle or heterocycle group, substituted or unsubstituted, or where R 4 is H or a lower alkyl, and X is a substituted or unsubstituted, substituted or unsubstituted heteroaryl group; or a pharmaceutically acceptable salt of a compound of Formula I; a prodrug or a pharmaceutically active metabolite of a compound of Formula I, or a pharmaceutically acceptable salt of a prodrug or metabolite. 6. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound represented by Formula I: -fr. 'replaced; or -C (0) -R 10 where > ? or is: H; an optionally substituted alkyl, aryl, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, or OR100 or NR100R110, wherein R100 and R110 are each independently H or a ~ 1 alkyl, alkenyl group , alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, - and optionally substituted, R 2 is H or alkyl; R7 and R8 are each independently H or a replaced; where R1, R4, R5, R6 and R7 are each H, Rs is unsubstituted phenyl; or a pharmaceutically acceptable salt, prodrug, active metabolite or solvate of the compound. 10. A method according to Claim 1, wherein the protein kinase receptor is a CDK, 10 VEGF or CHK1 complex. 11. A pharmaceutical composition, which Wherein Ri is hydrogen or an alkyl, aryl ", 4 * heteroaryl, carbocycle or heterocycle, substituted or unsubstituted group, or v * where R 4 is H or a lower alkyl, and X is an alkyl, aryl, heteroaryl, carbocycle or heterocycle group, "substituted or unsubstituted R 2 is a group or substituted heterocycle H > where R 4 is H or a lower alkyl, and X is an aryl, heteroaryl, carbocycle or heterocycle group, substituted or unsubstituted; or X 'a pharmaceutically acceptable salt of a compound of Formula I; a prodrug or a pharmaceutically active 1% metabolite of a compound of Formula 1, or uncontrolled, which includes administering to the patient that requires a therapeutically effective amount of a compound represented by Formula I: 25 -. 25 - * J «J«? • tí »• i,; * where Ri is hydrogen or an alkyl, aryl, * i? teteroaryl, carbocycle or heterocycle, substituted or substituted group, or W * > where R 4 is H or a lower alkyl, and X is an aryl, heteroaryl, carbocycle or heterocycle, substituted or substituted nd group; or a pharmaceutically acceptable salt of a compound of Formula I; a prodrug or a pharmaceutically active metabolite of a compound of Formula I, or pharmaceutically active of a compound of Formula II or 4 ^ iina pharmaceutically acceptable salt of the prodrug "or imetabolite. 14. A pharmaceutically acceptable compound, a pharmaceutically acceptable salt, a prodrug, or metabolite 10 active according to claim 13, characterized in that R'i is claim 13, characterized in that R'2 is a group - 19, A compound in accordance with. the claim 13, characterized in that R '2 is a group' * $ "x 25 substituted or unsubstituted of the formula V-s 20. A compound according to claim 12, characterized in that it has the structure: or a pharmaceutically acceptable salt thereof. 21. A compound according to claim 15, characterized in that the agent that inhibits PARP is 22 A compound selected from the group consisting of ** ¡S * ^ 25 ** ^ g 25 »%, *** ' 25 5 25"#V 25 'F? Vtii 9- X 349 S « , * Or a pharmaceutically acceptable salt thereof, a prodrug or a pharmaceutically active metabolite, or a pharmaceutically acceptable salt or X + prodrug of a prodrug or an inetabolite 23. A pharmaceutical composition for the treatment of a disease associated with cell proliferation. uncontrolled comprising: i) a compound as claimed in the * Claim 13 or a pharmaceutically acceptable salt, prodrug or metabolite p pharmaceutically active or a pharmaceutically acceptable salt of a metabolite? prodigal, and 25 ii. a pharmaceutically acceptable carrier. * S i > Y*? 24. A method of disorder associated with uncontrollable, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Claim 13, or a pharmaceutically acceptable salt of a compound of Formula-II; or a prodrug, or metab < A pharmaceutically active marker of a compound of Formula II, or a pharmaceutically acceptable salt of the prodrug or metabolite. 25. A compound according to claim 1, characterized in that Ri is ^ S * "where R'2 is * 25 ? ~ 4 5
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17648400P | 2000-01-18 | 2000-01-18 | |
PCT/US2001/001477 WO2001053268A2 (en) | 2000-01-18 | 2001-01-18 | Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02007058A true MXPA02007058A (en) | 2003-01-28 |
Family
ID=22644536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02007058A MXPA02007058A (en) | 2000-01-18 | 2001-01-18 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation. |
Country Status (39)
Country | Link |
---|---|
US (4) | US6555539B2 (en) |
EP (1) | EP1250326A2 (en) |
JP (1) | JP2003520273A (en) |
KR (1) | KR20020073505A (en) |
CN (1) | CN1394205A (en) |
AP (1) | AP1609A (en) |
AR (1) | AR032438A1 (en) |
AU (1) | AU785013B2 (en) |
BG (1) | BG107011A (en) |
BR (1) | BR0107783A (en) |
CA (1) | CA2388885A1 (en) |
CO (1) | CO5280070A1 (en) |
CR (1) | CR6630A (en) |
DO (1) | DOP2001000120A (en) |
DZ (1) | DZ3301A1 (en) |
EA (1) | EA200200768A1 (en) |
EE (1) | EE200200398A (en) |
GE (1) | GEP20043363B (en) |
GT (1) | GT200100009A (en) |
HN (1) | HN2001000007A (en) |
HR (1) | HRP20020675A2 (en) |
HU (1) | HUP0203965A3 (en) |
IL (1) | IL150730A0 (en) |
IS (1) | IS6474A (en) |
MA (1) | MA27589A1 (en) |
MX (1) | MXPA02007058A (en) |
MY (1) | MY136604A (en) |
NO (1) | NO20022117L (en) |
NZ (1) | NZ518531A (en) |
OA (1) | OA12160A (en) |
PA (1) | PA8509901A1 (en) |
PE (1) | PE20011334A1 (en) |
PL (1) | PL357590A1 (en) |
SK (1) | SK10052002A3 (en) |
SV (1) | SV2002000293A (en) |
UA (1) | UA75880C2 (en) |
WO (1) | WO2001053268A2 (en) |
YU (1) | YU54202A (en) |
ZA (1) | ZA200203040B (en) |
Families Citing this family (196)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150921A1 (en) * | 1996-02-09 | 2002-10-17 | Francis Barany | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
CZ301750B6 (en) | 1999-12-24 | 2010-06-09 | Aventis Pharma Limited | Bicyclic pyrrole derivative, its use in the preparation of a medicament, pharmaceutical composition in which the derivative is comprised and for use in therapy |
YU54202A (en) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
WO2002016348A1 (en) * | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
ES2302106T3 (en) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | PROCEDURE FOR PREPARATION OF BENCIMIDAZOL-2-IL QUINOLINE DERIVATIVES. |
DE10046029A1 (en) | 2000-09-18 | 2002-03-28 | Bayer Ag | indazoles |
US6982274B2 (en) | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
US7642278B2 (en) | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
EP1401831A1 (en) | 2001-07-03 | 2004-03-31 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
FR2827861B1 (en) | 2001-07-27 | 2004-04-02 | Aventis Pharma Sa | DERIVATIVES OF INDAZOLES OR INDOLES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY |
US20040077702A1 (en) * | 2001-09-14 | 2004-04-22 | Wen-Mei Fu | Treatment of nuerodegenerative diseases |
EP1432416B1 (en) | 2001-09-26 | 2011-01-19 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
JP4637481B2 (en) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 2-phenylbenzimidazole and imidazo- [4,5] -pyridine as CDS1 / CHK2 inhibitors and adjuvants for chemotherapy or radiotherapy in cancer treatment |
FR2831536A1 (en) * | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS KDR INHIBITORS |
FR2831537B1 (en) * | 2001-10-26 | 2008-02-29 | Aventis Pharma Sa | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF |
IL161576A0 (en) * | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
US6867320B2 (en) * | 2002-02-21 | 2005-03-15 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivatives and use thereof |
NZ535349A (en) * | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
FR2836914B1 (en) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
US20050119278A1 (en) * | 2002-05-16 | 2005-06-02 | Che-Ming Teng | Anti-angiogenesis methods |
MXPA04011851A (en) * | 2002-05-30 | 2005-03-31 | Celgene Corp | Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes. |
IL164209A0 (en) * | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
JP2004075673A (en) * | 2002-06-19 | 2004-03-11 | Mitsubishi Chemicals Corp | Compound and organic electroluminescent element using the same |
GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
EP1582211A1 (en) * | 2002-12-03 | 2005-10-05 | Kyowa Hakko Kogyo Co., Ltd. | Jnk inhibitor |
EA008501B1 (en) | 2002-12-19 | 2007-06-29 | Пфайзер Инк. | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
BRPI0407618A (en) * | 2003-02-21 | 2006-02-21 | Pfizer | cycloalkyl-substituted amino thiazole derivatives containing n and pharmaceutical compositions for inhibiting cell proliferation and methods for their use |
DE602004029145D1 (en) | 2003-02-27 | 2010-10-28 | Palau Pharma Sa | Pyrazolopyridine DERIVATIVES |
ES2214150B1 (en) * | 2003-02-27 | 2005-12-01 | J. URIACH & CIA S.A. | "NEW DERIVATIVES OF PIRAZOLOPIRIDINAS". |
DE602004006852D1 (en) | 2003-04-17 | 2007-07-19 | Janssen Pharmaceutica Nv | 2-PHENYL-BENZIMIDAZOLE AND 2-PHENYL-IMIDAZO-4,5'-PYRIDINE DERIVATIVES AS CHECKPOINT-KINASE-CDS1 (CHK2) INHIBITOR FOR THE TREATMENT OF CANCER |
FR2854159B1 (en) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | NOVEL INDOLE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS KDR INHIBITORS |
US7015233B2 (en) | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
ITRM20030355A1 (en) * | 2003-07-18 | 2005-01-19 | Sigma Tau Ind Farmaceuti | COMPOUNDS OF CYTOTOXIC ACTIVITIES COMBRETASTATINE DERIVATIVES. |
KR101204247B1 (en) | 2003-07-22 | 2012-11-22 | 아스텍스 테라퓨틱스 리미티드 | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases cdk and glycogen synthase kinase-3 gsk-3 modulators |
CA2518951A1 (en) * | 2003-07-30 | 2005-02-10 | Kyowa Hakko Kogyo Co., Ltd. | Protein kinase inhibitors |
EP1652842B1 (en) * | 2003-07-30 | 2012-04-11 | Kyowa Hakko Kirin Co., Ltd. | Indazole derivatives |
US7008953B2 (en) * | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7511145B2 (en) * | 2003-08-01 | 2009-03-31 | Genelabs Technologies, Inc. | Bicyclic heteroaryl derivatives |
US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
WO2005014554A1 (en) * | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
EP1660427A4 (en) | 2003-08-14 | 2006-12-20 | Asahi Kasei Pharma Corp | Substituted arylalkanoic acid derivative and use thereof |
JP2005089457A (en) * | 2003-09-03 | 2005-04-07 | Yung Shin Pharmaceutical Industry Co Ltd | Pharmaceutical composition for promoting bone growth or inhibiting bone resorption |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
MY144339A (en) * | 2003-09-08 | 2011-08-29 | Aventis Pharma Inc | Thienopyrazoles |
TWI344961B (en) * | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
BRPI0416266A (en) * | 2003-11-06 | 2007-01-09 | Celgene Corp | method for treating, preventing and / or controlling an asbestos-related disease or disorder in a patient |
EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
US20060179711A1 (en) * | 2003-11-17 | 2006-08-17 | Aerogrow International, Inc. | Devices and methods for growing plants |
EP2065383A1 (en) | 2003-11-19 | 2009-06-03 | Signal Pharmaceuticals, Inc. | Indazole compounds and methods of use thereof as protein kinase inhibitors |
US7488817B2 (en) * | 2004-02-02 | 2009-02-10 | The Trustees Of The University Of Pennsylvania | Metal complex protein kinase inhibitors |
WO2005094823A1 (en) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Flt-3 INHIBITOR |
BRPI0509580A (en) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | signal transduction inhibitor combinations |
GB0409080D0 (en) * | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
AU2005266494B2 (en) * | 2004-07-27 | 2009-09-10 | Novartis Ag | Inhibitors of Hsp90 |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
FR2876584B1 (en) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | USE OF KENPAULLONE FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS |
US20060116519A1 (en) * | 2004-11-17 | 2006-06-01 | Agouron Pharmaceuticals, Inc. | Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester |
WO2006054143A1 (en) * | 2004-11-17 | 2006-05-26 | Pfizer Inc. | Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
CA2588558A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Jnk inhibitors for treatment of cns injury |
AU2005321091B2 (en) | 2004-12-30 | 2012-04-12 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases |
US20080161251A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
JP5475235B2 (en) | 2005-01-21 | 2014-04-16 | アステックス・セラピューティクス・リミテッド | Pharmaceutical compounds |
CA2596527C (en) | 2005-01-27 | 2013-02-12 | Kyowa Hakko Kogyo Co., Ltd. | Igf-1r inhibitors |
GT200600042A (en) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | BIS ARILO AND HETEROARILO COMPOUNDS REPLACED AS SELECTIVE ANTAGONISTS OF 5HT2A |
US20070004777A1 (en) * | 2005-03-23 | 2007-01-04 | Bhagwat Shripad S | Methods for treating or preventing acute myelogenous leukemia |
PT1869020E (en) | 2005-03-29 | 2010-12-23 | Icos Corp | Heteroaryl urea derivatives useful for inhibiting chk1 |
JP2008540345A (en) * | 2005-04-29 | 2008-11-20 | セルジーン・コーポレーション | Solid form of 1- (5- (1H-1,2,4-triazol-5-yl) (1H-indazol-3-yl))-3- (2-piperidylethoxy) benzene |
ATE530533T1 (en) | 2005-05-17 | 2011-11-15 | Novartis Ag | METHOD FOR SYNTHESIS OF HETEROCYCLIC COMPOUNDS |
WO2006130673A1 (en) | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
US7470787B2 (en) | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
PT1957074E (en) | 2005-11-29 | 2014-06-25 | Novartis Ag | Formulations of quinolinones |
KR20070077468A (en) * | 2006-01-23 | 2007-07-26 | 크리스탈지노믹스(주) | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
AU2007213452A1 (en) * | 2006-02-10 | 2007-08-16 | Biomarin Iga Limited | Treatment of Duchenne muscular dystrophy |
JP2009530337A (en) * | 2006-03-23 | 2009-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Substituted indazole derivatives, process for producing the same, and use thereof as a drug |
CN101484427A (en) | 2006-06-30 | 2009-07-15 | 协和发酵麒麟株式会社 | Abl kinase inhibitor |
US20090209537A1 (en) * | 2006-06-30 | 2009-08-20 | Kyowa Hakko Kirin Co., Ltd. | Aurora inhibitors |
JPWO2008020606A1 (en) * | 2006-08-16 | 2010-01-07 | 協和発酵キリン株式会社 | Angiogenesis inhibitor |
CA2661898A1 (en) * | 2006-08-25 | 2008-02-28 | Abbott Laboratories | Indazole derivatives that inhibit trpv1 and uses thereof |
CL2007002617A1 (en) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO. |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
JP2010513557A (en) * | 2006-12-20 | 2010-04-30 | アボット・ラボラトリーズ | N- (5,6,7,8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as TRPV1 vanilloid receptor antagonists for the treatment of pain |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
WO2008106594A2 (en) * | 2007-02-28 | 2008-09-04 | The Arizona Board Of Regents, On Behalf Of The University Of Arizona | Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis |
CN101622015A (en) | 2007-03-05 | 2010-01-06 | 协和发酵麒麟株式会社 | Pharmaceutical composition |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
CN101790526A (en) * | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 5-heteroaryl substituted indazoles as kinase inhibitors |
EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
EP2323989A4 (en) * | 2008-03-20 | 2011-06-22 | Abbott Lab | Methods for making central nervous system agents that are trpv1 antagonists |
KR101269393B1 (en) | 2008-04-28 | 2013-05-29 | 아사히 가세이 파마 가부시키가이샤 | Phenylpropionic acid derivative and use thereof |
US8106039B2 (en) * | 2008-04-30 | 2012-01-31 | The Trustees Of The University Of Pennsylvania | Metal complex phosphatidyl-inositol-3-kinase inhibitors |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
ES2465971T3 (en) | 2009-04-06 | 2014-06-09 | University Health Network | Kinase inhibitors and method to treat cancer with them |
ES2553827T3 (en) | 2009-05-01 | 2015-12-14 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
JP2013501792A (en) * | 2009-08-10 | 2013-01-17 | サミュメッド リミテッド ライアビリティ カンパニー | Indazole and its therapeutic use as WNT / B-catenin signaling pathway inhibitor |
DK2987487T3 (en) * | 2009-08-10 | 2020-12-07 | Samumed Llc | INDAZOLINE INHIBITORS OF THE WNT SIGNAL ROAD AND ITS THERAPEUTIC USES |
UY33001A (en) | 2009-11-06 | 2011-05-31 | Boehringer Ingelheim Int | ARYL AND HETEROARILCARBONYL HIVAHYDROINDENOPIRIDINE AND OCTAHYDROBENZOQUINOLINE DERIVATIVES |
CA2986631C (en) | 2009-12-21 | 2020-06-02 | Samumed, Llc | 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof |
TWI516262B (en) | 2010-04-06 | 2016-01-11 | 健康網路大學 | Kinase inhibitors and method of treating cancer with same |
WO2012020725A1 (en) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Heterocyclic derivative having npy y5 receptor antagonism |
ES2879314T3 (en) | 2010-08-18 | 2021-11-22 | Biosplice Therapeutics Inc | Dketones and hydroxyketones as activators of the catenin signaling pathway |
TWI537258B (en) | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline |
CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
WO2012129338A1 (en) | 2011-03-22 | 2012-09-27 | Amgen Inc. | Azole compounds as pim inhibitors |
JP2014509660A (en) * | 2011-04-01 | 2014-04-21 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | Substituted 3- (1H-benzo {d} imidazol-2-yl) -1H-indazole analogs as inhibitors of PDK1 kinase |
BR112014006127A2 (en) | 2011-09-14 | 2017-04-04 | Samumed Llc | indazol-3-carboxamides and their use as inhibitors of the wnt / b-catenin signaling pathway |
WO2013063321A1 (en) | 2011-10-25 | 2013-05-02 | The General Hospital Corporation | Wnt/b-catenin inhibitors and methods of use |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
CN104271133B (en) | 2012-05-04 | 2017-10-13 | 萨穆梅德有限公司 | 1H pyrazolos [3,4 b] pyridine and its treatment use |
WO2014041518A1 (en) * | 2012-09-14 | 2014-03-20 | Glenmark Pharmaceuticals S.A. | Thienopyrrole derivatives as itk inhibitors |
EP2943198B1 (en) | 2013-01-08 | 2019-07-17 | Samumed, LLC | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
CN104370889A (en) * | 2013-01-24 | 2015-02-25 | 韩冰 | Intraocular tension reducing compound and preparation method and use thereof |
JP6401189B2 (en) | 2013-02-22 | 2018-10-03 | サミュメッド リミテッド ライアビリティ カンパニー | Γ-diketones as activators of Wnt / β-catenin signaling pathway |
WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134776A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9440952B2 (en) | 2013-03-04 | 2016-09-13 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
CN109528721B (en) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | Combination therapy |
EP3027605B1 (en) | 2013-07-31 | 2017-11-08 | Council of Scientific & Industrial Research | Novel indazole compounds and a process for the preparation thereof |
KR102195494B1 (en) | 2013-10-18 | 2020-12-28 | 유니버시티 헬스 네트워크 | Treatment for pancreatic cancer |
CN106687454B8 (en) | 2014-07-24 | 2019-08-30 | 贝达医药公司 | 2H- indazole derivative and its medical application as cell cycle protein dependent kinase (CDK) inhibitor |
EP3206686B1 (en) | 2014-08-20 | 2019-10-09 | Samumed, LLC | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
CN107922349B (en) * | 2015-08-07 | 2021-05-07 | 哈尔滨珍宝制药有限公司 | Vinyl compounds as FGFR and VEGFR inhibitors |
WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
JP6832946B2 (en) | 2015-11-17 | 2021-02-24 | アエリエ ファーマシューティカルズ インコーポレイテッド | How to prepare kinase inhibitors and their intermediates |
AR108325A1 (en) | 2016-04-27 | 2018-08-08 | Samumed Llc | ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME |
AR108326A1 (en) | 2016-04-27 | 2018-08-08 | Samumed Llc | ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME |
CN109476660B (en) | 2016-06-01 | 2023-04-04 | 拜斯丽治疗有限公司 | Preparation method of N- (5- (3- (7- (3-fluorophenyl) -3H-imidazo [4,5-C ] pyridine-2-yl) -1H-indazol-5-yl) pyridine-3-yl) -3-methylbutyramide |
US11078192B2 (en) | 2016-07-05 | 2021-08-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
EP3506890A1 (en) | 2016-08-31 | 2019-07-10 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
CA3041291A1 (en) * | 2016-10-21 | 2018-04-26 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
US10758523B2 (en) | 2016-11-07 | 2020-09-01 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
SG11201908179UA (en) | 2017-03-31 | 2019-10-30 | Aerie Pharmaceuticals Inc | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6-(6-membered heteroaryl & aryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
US10413537B2 (en) | 2017-10-27 | 2019-09-17 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof |
US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
JP7293560B2 (en) | 2017-12-29 | 2023-06-20 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | Aromatic vinyl or aromatic ethyl derivative, its production method, intermediate, drug composition and use |
BR112020017087A2 (en) | 2018-02-23 | 2020-12-22 | Samumed, Llc | INDAZOL-3-CARBOXAMIDES REPLACED 5-HETEROARILLA AND PREPARATION AND USE OF THE SAME |
US10759799B2 (en) | 2018-06-15 | 2020-09-01 | Samumed, Llc | Indazole containing macrocycles and therapeutic uses thereof |
WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
WO2020150545A1 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway |
WO2021088859A1 (en) * | 2019-11-06 | 2021-05-14 | 暨南大学 | Indazole compound, pharmaceutical composition of same, and applications thereof |
WO2021125229A1 (en) * | 2019-12-17 | 2021-06-24 | 富士フイルム株式会社 | Indazole compound or salt thereof, and pharmaceutical composition |
WO2021121420A1 (en) * | 2019-12-20 | 2021-06-24 | 江苏凯迪恩医药科技有限公司 | Benzopyrazole compound and intermediate, preparation method, and application thereof |
WO2021168341A1 (en) | 2020-02-21 | 2021-08-26 | Samumed, Llc | Solid forms of 1-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-dimethylmethanamine |
CN112724134B (en) * | 2021-01-14 | 2022-04-01 | 复旦大学 | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy |
WO2023240138A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole containing macrocycles and their use |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1376600A (en) | 1971-02-15 | 1974-12-04 | Agfa Gevaert | Photographic developer compositions |
CH575397A5 (en) | 1971-11-09 | 1976-05-14 | Basf Ag | |
US3994890A (en) * | 1974-01-31 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | 1-Aminoalkyl, 3-phenyl indazoles |
FR2265739B1 (en) | 1974-03-29 | 1976-12-17 | Ugine Kuhlmann | |
JPS5615287A (en) | 1979-07-16 | 1981-02-14 | Chugai Pharmaceut Co Ltd | Pyrazoloindazole derivative and its preparation |
EP0104029B1 (en) | 1982-09-17 | 1988-08-24 | Kudelski S.A. | Control system for an electric motor |
JPS59228248A (en) | 1983-06-08 | 1984-12-21 | Konishiroku Photo Ind Co Ltd | Posi-posi silver halide photosensitive material |
JPS604184A (en) * | 1983-06-23 | 1985-01-10 | Chugai Pharmaceut Co Ltd | Pyrazoloindazole derivative |
JPH083564B2 (en) | 1986-07-25 | 1996-01-17 | 三菱化学株式会社 | Polarizing film |
DE3842091A1 (en) * | 1987-12-14 | 1989-07-13 | Fuji Photo Film Co Ltd | IMAGING PROCESS |
EP0477436B1 (en) | 1990-09-24 | 1995-12-13 | Agfa-Gevaert N.V. | Roomlight handleable UV sensitive direct positive silver halide photographic material |
US5208248A (en) * | 1991-01-11 | 1993-05-04 | Merck Sharpe & Dohme, Ltd. | Indazole-substituted five-membered heteroaromatic compounds |
EP0494774A1 (en) | 1991-01-11 | 1992-07-15 | MERCK SHARP & DOHME LTD. | Indazole-substituted fivemembered heteroaromatic compounds |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
AU5704594A (en) | 1992-12-18 | 1994-07-19 | Wellcome Foundation Limited, The | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
DE69532817T2 (en) | 1994-11-10 | 2005-01-13 | Millenium Pharmaceuticals, Inc., Cambridge | USE OF PYRAZOLE COMPOUNDS FOR THE TREATMENT OF GLOMERULONEPHRITIS, CANCER, ATHEROSCLEROSIS OR RESTENOSIS |
ZA951822B (en) * | 1994-12-23 | 1996-09-26 | Glaxo Group Ltd | Chemical compounds |
KR19980701879A (en) | 1995-02-02 | 1998-06-25 | 피터 기딩스 | Indole derivatives as 5-hydroxytryptamine receptor antagonists |
AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
US6495526B2 (en) | 1996-01-23 | 2002-12-17 | Gpc Biotech, Inc. | Inhibitors of cell-cycle progression and uses related thereto |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
US5821243A (en) | 1996-07-22 | 1998-10-13 | Viropharma Incorporated | Compounds compositions and methods for treating influenza |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
WO1998033798A2 (en) | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
AU6230098A (en) | 1997-02-27 | 1998-09-18 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
JP2001518094A (en) | 1997-03-31 | 2001-10-09 | デュポン ファーマシューティカルズ カンパニー | Indazole-cyclic ureas useful as HIV protease inhibitors |
CA2294244A1 (en) | 1997-07-12 | 1999-01-21 | Cancer Research Campaign Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
GB9716324D0 (en) | 1997-08-01 | 1997-10-08 | Mead Corp | Packaging machine and method of carton set up |
FR2767475A1 (en) | 1997-08-25 | 1999-02-26 | Oreal | Oxidation hair dyes |
FR2767827A1 (en) | 1997-09-03 | 1999-02-26 | Adir | NOVEL INDOLE AND INDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
DE19744026A1 (en) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazole derivatives, their preparation and their use in medicinal products |
AU9691198A (en) * | 1997-10-06 | 1999-04-27 | Basf Aktiengesellschaft | Indeno{1,2-c}-, naphtho{1,2-c}- and benzo{6,7}cyclohepta{1,2-c}pyrazole derivatives |
BR9815200A (en) | 1997-10-27 | 2001-10-16 | Agouron Pharma | Compound, pharmaceutical composition and method of treating a disease or disorder mediated by the inhibition of cdk4 or a cdk4 / cyclin complex |
IL135900A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeuticaly active compounds |
NZ503995A (en) | 1997-11-04 | 2003-02-28 | Pfizer Prod Inc | Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors |
US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
HUP0100931A3 (en) | 1998-02-26 | 2002-08-28 | Aventis Pharma Inc | 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
EA003603B1 (en) | 1998-02-27 | 2003-06-26 | Пфайзер Продактс Инк. | N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia |
JP4665239B2 (en) | 1998-04-21 | 2011-04-06 | アゲンニクス アーゲー | 5-Aminoindeno [1,2-c] pyrazol-4-ones as anticancer and antiproliferative agents |
YU54202A (en) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
EP1545515A1 (en) * | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
-
2000
- 2000-01-18 YU YU54202A patent/YU54202A/en unknown
-
2001
- 2001-01-17 MY MYPI20010207A patent/MY136604A/en unknown
- 2001-01-17 DO DO2001000120A patent/DOP2001000120A/en unknown
- 2001-01-17 PE PE2001000043A patent/PE20011334A1/en not_active Application Discontinuation
- 2001-01-18 HN HN2001000007A patent/HN2001000007A/en unknown
- 2001-01-18 AU AU29539/01A patent/AU785013B2/en not_active Ceased
- 2001-01-18 EA EA200200768A patent/EA200200768A1/en unknown
- 2001-01-18 WO PCT/US2001/001477 patent/WO2001053268A2/en active IP Right Grant
- 2001-01-18 BR BR0107783-0A patent/BR0107783A/en not_active IP Right Cessation
- 2001-01-18 PL PL01357590A patent/PL357590A1/en not_active Application Discontinuation
- 2001-01-18 MX MXPA02007058A patent/MXPA02007058A/en active IP Right Grant
- 2001-01-18 OA OA1200200212A patent/OA12160A/en unknown
- 2001-01-18 AP APAP/P/2002/002564A patent/AP1609A/en active
- 2001-01-18 KR KR1020027009194A patent/KR20020073505A/en active IP Right Grant
- 2001-01-18 JP JP2001553270A patent/JP2003520273A/en not_active Abandoned
- 2001-01-18 HU HU0203965A patent/HUP0203965A3/en unknown
- 2001-01-18 EP EP01942620A patent/EP1250326A2/en not_active Withdrawn
- 2001-01-18 DZ DZ013301A patent/DZ3301A1/en active
- 2001-01-18 GT GT200100009A patent/GT200100009A/en unknown
- 2001-01-18 CA CA002388885A patent/CA2388885A1/en not_active Abandoned
- 2001-01-18 GE GE4848A patent/GEP20043363B/en unknown
- 2001-01-18 SK SK1005-2002A patent/SK10052002A3/en not_active Application Discontinuation
- 2001-01-18 IL IL15073001A patent/IL150730A0/en unknown
- 2001-01-18 AR ARP010100234A patent/AR032438A1/en unknown
- 2001-01-18 UA UA2002086633A patent/UA75880C2/en unknown
- 2001-01-18 CN CN01803552A patent/CN1394205A/en active Pending
- 2001-01-18 US US09/761,656 patent/US6555539B2/en not_active Expired - Fee Related
- 2001-01-18 NZ NZ518531A patent/NZ518531A/en unknown
- 2001-01-18 EE EEP200200398A patent/EE200200398A/en unknown
- 2001-01-18 PA PA20018509901A patent/PA8509901A1/en unknown
- 2001-01-18 CO CO01003496A patent/CO5280070A1/en not_active Application Discontinuation
- 2001-01-22 SV SV2001000293A patent/SV2002000293A/en not_active Application Discontinuation
-
2002
- 2002-04-17 ZA ZA200203040A patent/ZA200203040B/en unknown
- 2002-04-25 CR CR6630A patent/CR6630A/en not_active Application Discontinuation
- 2002-05-03 NO NO20022117A patent/NO20022117L/en unknown
- 2002-07-16 IS IS6474A patent/IS6474A/en unknown
- 2002-08-16 MA MA26785A patent/MA27589A1/en unknown
- 2002-08-16 HR HRP20020675 patent/HRP20020675A2/en not_active Application Discontinuation
- 2002-08-16 BG BG107011A patent/BG107011A/en unknown
- 2002-11-08 US US10/291,158 patent/US6919461B2/en not_active Expired - Fee Related
-
2005
- 2005-04-22 US US11/112,423 patent/US7232912B2/en not_active Expired - Fee Related
-
2006
- 2006-01-10 US US11/329,303 patent/US20060111322A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02007058A (en) | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation. | |
US6462069B2 (en) | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | |
JP4762543B2 (en) | Indazole carboxamide derivatives, processes for their preparation and use as CDK1, CDK2 and CDK4 inhibitors | |
AU777701B2 (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
CN102993084B (en) | Alkynyl derivatives as modulators of metabotropic glutamate receptors | |
EP2468729A1 (en) | Novel indazole derivative | |
KR20020015333A (en) | Diaminothiazoles and their use for inhibiting protein kinases | |
WO2005094805A1 (en) | Imine derivative and amide derivative | |
WO2005090328A1 (en) | Heterocyclic compound and use thereof | |
CN105073742A (en) | Flap modulators | |
US6566363B2 (en) | Pyrazole-thiazole compounds, pharmaceutical compositions containing them | |
JPH10291988A (en) | Heterocyclic compound | |
EP4023640A1 (en) | Phenylimidazole compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |